Index to Volume 48 - Cancer Research · thylpsoralen, 2015 Aneuploidy sequential development...
Transcript of Index to Volume 48 - Cancer Research · thylpsoralen, 2015 Aneuploidy sequential development...
Index to Volume 48
Subject Index
Abclscm virus-infected promonocytic leukemia cells
viral oncogene expression, 1702Accessory cells
T helper cells andtumor-specific CTL generation, 1422
A-431 cellsAh receptor analysis, 2388isolation and characterization
epidermal growth factor, stimulation,2377
Acetaldophosphamideleukemic progenitor cell effects
bone marrow purging, 339Acetone
-inducible cytochrome P-450benzene metabolism, liver micro-
somes, 53872-Acetylaminofluorene
carcinogenesispremalignant hepatic nodules, DNA
adducts, 5270depletion of adenosine diphosphate-ribo-
syl transferasc in rat liver, 3581Acidification: see pHAcidosis
effect on cytotoxicityplatinum complexes, 2342
Acivicindipyridamole and
biochemical assessment, 5591inhibited nucleoside salvage, Phase I
clinical trial, 5585Aclacinomycin
enhanced activity of peritoneal cellsrespiratory burst, 3440
Acodazole hydrochloridePhase I trial
pharmacokinetics, cardiotoxicity, 44234'-(<>-Acridinylamino )nii'thanesulfon-Af-an-
isididcmethotrexate and
metabolic interaction, 5106Acrolein
enhancement of murine immune responses, 41
pathobiological effectshuman bronchial epithelial cells, 1717
Actinpolymerization in HL-60 cells, 6721
Actinomycin Dquantification by ELISA
ff-D-galactosidase label, 4843Adenine nucleotides
poly(ADP-ribose) metabolism alterationhyperthermia, 4233
Adenocarcinomabladder
epidemiological characteristics, 3853c-myc and c-fos differential expression
familial polyposis coli, 4855cervical
monoclonal antibody, immunodi-agnostic potential, 6565
coloniec-myc expression, recurrence and sur
vival, 1350DNA lesions, leucovorin-5-fluoropyr-
imidine, 4153effect, voluntary exercise, 7079glyceraldehyde-3-phosphate dehydro-
genase gene expression, 6354growth inhibition, methotrexate or 5-
fluorodeoxyuridine, 3319localization, radiolabeled monoclonal
antibodies, 4324mitoxantrone, Phase I study, 5874monoclonal antibody binding, cell sur
face antigen, 6573mono-, di-, and tri-O-acetylated sialic
acids, 483plasminogen activator profiles, 4520platelet-aggregating factor, mono
clonal antibodies, 6411pulmonary metastasis, mechanism of
inhibition, 3728restoration of differentiation, polyeth
ylene glycol, 2498xenografts, folate pools, 3062
colorectalcathepsin B-like proteinase, 6855serum, natural killer cell activity, 2596
endometrialheterogeneity, progesterone receptor
distribution, 1889gastric
xenograft growth, a-difluoromethylor-nithine, 3265
humanprostaglandin biosynthesis, 4770
interferon interactionshalogenated pyrimidine antimetabo-
lites, 4868lung
expression of a-amylase, 3292( rM•¿�ganglioside residue disrimination,
monoclonal antibodies, 6154incidence by histológica!type, popula
tion-based registry, 6580risk factors, personal and family his
tory, 7279significance, K-ras activation, 5730thromboxane biosynthesis, 2674
mammarycell growth, semisolid clonogenic me
dium, 3995-deazaaminopterin, 5-alkyl deriva
tives, 5686differential expression, WDNM1 gene,
5203insulin effects, phosphatidylinositol ki-
nase, 6727insulin receptor kinase, diabetes and
sex steroids, 3742lymphatic metastasis, soybean agglu-
tinin binding cells, 1451overgrowth of primary tumors, genetic
evidence, 6109photosensitization, plasma membrane
enzymes, 3360suppression, genetic factor, 2204suppressor lymphokine production, T-
cells, 943ovarian
aromatization, testosterone, 6491characterization and properties, 6166effect, sodium butyrate, 6161
mitoxantrone, Phase I study, 5874pancreatic
glyceraldehyde-3-phosphate dehydro-genase gene expression, 6354
prostaticmetastatic potential, cell mol ¡litv.
4312renal
anticarcinoma activity, rhodamine123,2061
salivary glandras p21, cAMP levels, 2898
sporadic amplification of HER2/neuprotooncogene, 1517
uterine cervixhuman papillomavirus types, 993
Adenocarcinoma cellshuman salivary
growth inhibition, normal human lìbroblasts, 2819
Adenoma cellsgrowth of neoplastic thyroid cells
epidermal growth factor receptor,3652
Adenosine dialdehydeinhibitory effect
neuroblastoma growth, 5933Adenosine diphosphate-ribosyl transferase
depletion in liverexposure, ./V-2-acetylaminofluorene,
3581inhibitors
enhanced cytotoxicity, 6-thioguanine,5650
Adenosine 3':5'-monophosphate, cyclic
cellular proliferation and ras p21salivary gland adenocarcinoma, 2898
-dependent protein kinasesphorbol ester effect, teratocarcinoma
cells, 3993postconfluence growth arrest
lOT'/i fibroblasts, 1874site-selective analogues
cancer control, 1642vasoactive intestinal peptide receptors
breast cancer cells, 5079Adenosine triphosphatase
P-glycoproteinsmuitidrug resistance, K562/ADM
cells, 4926Adenosine triphosphate
anthracycline cardiotoxicity model, 5222flavone acetic acid-induced modulation
tumor physiology, NMR spectroscopy,4749
leukemia 1,1210 cell linesresistance, ribonucleotide reducÃasein
hibitors, 8395-Adenosylmethionine
formation in liverchronic feeding, Di.-ethionine, 4464
properties of LI210 resistant cellsa-difluoromethylornithine, 2678
Adi-novirus-12human bronchial epithelial cells
T-antigen transformation, 1904selective cytotoxicity
phospholipids, diacylglycerols, 578Adenoviruses
7401
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
DNA amplificationcellular genotoxic stress, 3123
typeSmethyl methanesulfonate effect, libro
blast cells, 3050Adenylate cyclase
cellular processingvasoactive intestinal peptide, 6201
tumorigenicityS49 wild-type and eye" lymphoma,
641Adhesion
laminin-dependent and laminili inde
pendentsulfatides, melanoma cells, 3367
Adjuvantsactive specific immunotherapy
melanoma. Phase I trial, 5883contribution of medicine
primary treatment, breast cancer, 2314Adrenal cortex
strong expressionM, 170,000-180,000 P-glycoprotein,
4611Adrenal glands
regulation of mammary tumorigenesis,3801, 3808
Adriuimi-in: see also Doxorubicinantitumor activity of MX2
murine tumor cells, 6653cardiotoxicity
free radical formation, 4766doxycycline in combination chemother
apyleukemia, 6686
enhancement of antitumor activitypolymethacrylate nanospheres, U937
cells, 1835flow cytometric localization
isolation of viable cells, 5742glutathione contents
human and rodent tumor cells, cellcycle phases, 3661
increased levels in hepatic implantscarcinoma from regional infusion,
4584intrinsic drug resistance
possible link, detoxification mechanism, 3025
iron andreappraisal of association, 5645
liposome-encapsulated Adriamycin oralterations, murine host defense func
tions, 130multifactorial resistance
P388 leukemia, 3595potentiation of cytotoxicity
dipyridamole, HeLa and sarcoma 180cells, 1208
recurrent tumor sensitivityrat model, mammary tumors, 4549
resistance and sensitivitymetallothionein induction, prostatic
carcinoma, 4503-resistant cells
85-kDa protein, 7082vinculin phosphorylation. protein ki-
nase C role in HL-60 cells, 3324therapy effect
monocyte activation, liposome-encapsulated immunomodulators, 5256
tolerance in Chinese hamster ovary cellsantioxidant defenses, glutathione,
4493
Aflatoxinphotoactivated
DNA strand scission, apurinic sites,3070
Aflatoxin B,adduction of active genes, 7146-dichloride DNA adducts
structural characterization, calf thymus DNA, 5391
DNA binding and glutathione conjugation
effects, butylated hydroxyanisole, 2688effect on glucocorticoid receptors
tyrosine aminotransferase, Reuberhepatoma cells, 5188
immunological detection of adductsin vivo formation, 6328
influence on duck liversduck hepatitis B virus infection, 1559
Agingdistribution of Wilms' tumor, 1653
DNA replication in hepatocytesunscheduled DNA synthesis, 1618
growth of Sinclair swine melanoma,1708
Aircarbon dioxide mixture or
pH mollificai ion. hydralazine and glucose, 1543
Albumindifferential regulation of «,-fetoprotein
hepatocyte hybrids, 6371embryonic liver epithelial cell lines, 4909lack of
marker of preneoplastic hepatocytes,albumin-positive liver, 387
Alcoholbreast cancer epidemiology, 5615comparative epidemiology of cancer
United States, Italy, 7285consumption
risk of breast cancer, 2284drinking and smoking
oral and pharyngeal cancer, 3282esophageal carcinoma, 3843
Aldehyde dehydrogenasecytosolic
characterization, LI210 cells, 2963deficient carboxyphosphamide excretion
cyclophosphamide administration,cancer patients, 5167
role in survival of progenitorsmurine blast cell colonies, 4-hydrope-
roxycyclophosphamide, 1223tumor-associated
gene expression, hepatoma, 7009Alkaline phosphatase
uptake of WR-2721 derivativestransported form of drug, 3634
WR-2721radioprotection of cells, 3641
Alkylating agentsantitumor effects of pentoxifylline
thiotepa, human cancer cells, 4375chemosensitization by misonidazole,
3528chemotherapy of medulloblastoma cell
linestransplantable xenografts, 4189
cytotoxicityinduction, sister chromatid exchange,
3100m-diamminedichloroplatinum(Il) and
gene expression, Escherichia coli, 4823
effect of doseclinical correlation, 6417
ethacrynic acid and piriprostcytotoxicity effect, 3622
point mutation of ras protooncogenesacute nonlymphocytic leukemia, 1812
(f-propiolactoneH-ras oncogene activation, mouse car
cinoma, 556protection of Ehrlich ascites tumor cells
nitrogen mustard, 5-jV^V-dimethylami-loride, 2454
06-Alkyldeoxyguanosinedetection by "P-postlabeling
nucleotide Chromatographie analysis,2156
Alkylglycerolsactivation of macrophages
cancerous tissues, 604406-Alkylguanine-DNA alkyltransferase
inactivationnitrosourea potentiation, leukemic
cells, 1521regeneration in lymphocytes
nitrosourea exposure, 5368secondary leukemia. 3084
Alkyl lysophospholipidmodification of cell surface carbohy
dratesinvasive behavior, 977
reduction of epidermal growth factorbinding
breast cancer cell lines, 6033Aluminum:nickel alloy
decontamination and disposalosoureas, related A'-nitroso compounds,
522Alveolar nodules
hyperplastictransplantation, gland-free fat pads,
3197Alveolar type II cells
origin of papillary lung tumorsA'-nitrosoethylurea-induced, 148
Amino acidsbranched chain
pan-literal nutrition, Yoshida sarcoma,2698
4-c/i-hydroxy-L-prolinegrowth sensitivity, transformed rodent
cell lines, 24839-Aminoacridines
DNA damage and cell kill, 8607-Aminoactinomycin D
activation of B-cellseliminatili structure, flow cytometry,
67084-Aminobiphenyl
cigarette-induced bladder cancereffects of timing, tobacco type, 3849
DNA adductsimmunochemical quantitation, 6336
6-Aminohexanoic acidinduction of differentiation
HL-60 cells, 36137a-(4'-Amino)phenylthio-4-androstene-
3,17-dioneeffect on mammary carcinoma, 6808
Aminopterin8-deaza analogues
cytotoxicity, polyglutamate formation,1481
1-Aminopyrene1-nitropyrene derivatives and
7402
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
carcinogenic activities, 4256Ammonium acetate
effects on colon carcinogenesisA'-methyl-Ar'-nitro-/V-nitrosoguani-
dine-induced, 3035Amonafide
limited sampling modelspharmacokinetics, 4127
AmsacrineDNA damage and cell kill
9-aminoacridines, 860production of protein-associated DNA
breaksLI210 cells, PZE, 1404
resistance of noncycling cells, 310Amsacrine analogues
Phase I trial of CI-921, 6593a-Amy lase
expression in human lung cancers, 3292Anchorage independence
cancer suppressor genegenetic assessment, hamster cells, 46
requirement for transformationtumor promoter exposure, 7126
Anchorage-independent growthcomparison of growth requirements
monolayer and soft agarose, colon carcinoma, 2469
reversible inductionepidermal keratinocytes, 1566
Androgenaromatization of testosterone
ovarian epithelial tumor cells, 6491conjugate content in breast cyst fluid
epidermal growth factor, 5860-dependent Shionogi carcinoma
early phases of regression, geneexpression, 6309
estrogen-stimulated hormone receptorprofiles
prostatic carcinoma, 3077-independent prostate carcinoma
testosterone, 5a-dihydrotestosterone,609
-responsive and -unresponsive cellsautocrine growth factor, paracrine
mechanism, 4904testosterone effect on B16 melanoma
imidazole-induced tyrosinase expression, 3586
AnemiaFanconi's
repair of DNA damage, 4,5',8-trime-
thylpsoralen, 2015Aneuploidy
sequential development•¿�y-glutamyltransferase,skin papillo-
mas, 3253Anorexia
cancertumor necrosis factor as mediator,
4567Anthracycline
cardiotoxicity modeladenosine triphosphate/protein ratios,
5222hemin-induced cell protection
hemopoietic cells, 3566morpholinyl
selective inhibition, ribosomal genetranscription, 4101
partial reversal of doxorubicin resistanceforskolin, murine sarcoma S180 var
iants, 539
second-generationinteraction with polynucleotides, 6962
Anthroneschrysarobin
epidermal polyamine levels, DNA synthesis, 6390
Anthropometrybreast cancer risk assessments, 5363
Antiantibodytumor targeting
human colonie tumor xenografts, 2005Antibodies: see also specific type
antiidiotypicmonoclonal antibody, carcinoem-
bryonic antigen, 4002anti tumor
diffusion and binding, spheroids, 4032methotrexate conjugate, nature of
linkage, 3330Andes trogens
growth inhibitionbreast cancer, 6819
regulation of growth and invasivenessMCF-7 cells, 6764
tamoxifen and hydroxytamoxifenv.v.estradici effects, normal breast
cells, 7193Antifolates
interactions, 2421lipophilic
trimetrexate transport, lymphoblastoidcells, 6986
Antileukemia agentseffects on nuclear matrix-bound DNA
replicationCCRF-CEM leukemia cells, 1850
Antineoplastic agentsplatinum(rhodamine-l 23)2
m-diamminedichloroplatinum(II),squameHIScell carcinoma, 5101
Antiobesity drugsnovel dehydroepiandrosterone analogues
enhanced biological activity, reducedside effects, 4817
Antioxidant enzymesxeroderma pigmentosum fibroblasts,
2132Ant ¡tumoractivity
Adriamycinpolymethacrylate nanospheres, U937
cells, 1835antibody-dependent cellular cytotoxicity
LAK cells, 1173augmented effect of interleukin-la
indomethacin, 584COS 16949A
hormone-dependent and -independenttumors, 834
m-diamminedichloroplatinum(II) andanalogues
myelotoxic concentrations, 3135deglycosylated ricin A-chain immunotox-
inshindered disulfide linkages, 6396
enhancement of l-hexylcarbamoyl-5-fluorouracil
hyperthermia, Ehrlich ascites tumor,3977
FK973, 1166interleukin 2
interferons, syngeneic murine tumors,260
tumor necrosis lac tor ri, 4011LAK cell generation from blood
glioblastoma patients, 6069quinocarmycin
leukemia, lymphoma cell lines, 6029ricin A chain-containing immunotoxins
clinical trial evaluation, CD 19 andCD22 antigens, 2610
saporin immunotoxinshepatotoxicity, 7072
somatostatin analoguesoncological applications, 6977
12-O-tetradecanoylphorbol-13-acetateoleanane-type triterpenoid compounds,
5210Antitumor agents
FK973DNA cross-linking, LI210 cells, 5172
MX2murine tumor cells, 6653
polyamine metabolismneoplastic growth, chemotherapy, 759
testing ofsnail neurons, side-effects, 7184
Antitumor drugsditercalinium
loss, mitochondria! DNA, 4982quinone
resistance, L5178Y murine lympho-blasts, 1727
AphidicolinDNA repair as mechanism of acquired
resistancecisplatin, ovarian cancer, 5713
1-/3-D-ArabinofuranosyIcytosineclinical pharmacology
effect of tetrahydrouridine, 13372',2'-difluorodeoxycytidine and
comparison, toxicity, 4024doxycycline in combination chemother
apyleukemia, 6686
effects of incorporation on elongationDNA polymerase 0, 1494
flow cytometric localizationisolation of viable cells, 5742
5-hydroxymethyl-2'-deoxyuridine
promyelocytic leukemia cells, 3117influence of lipid conjugates
growth and metastasis, Lewis lung carcinoma, 826
in vivo pharmacodynamicssynergy, m-diamminedichloropla-
tinum(II), 117metabolic activation
bromodeoxyuridine enhancement, HL-60 cells, 517
modulation of arabinonucleoside metabolism
arabinosylnucleotides, 329vincristine and methotrexate combina
tionacute lymphoblastic leukemia, 351
L-Arabinoseresistance test with Salmonella typhimu-
riumprimary tool, carcinogen screening,
907Arabinosyl-5-azacytidine
preclinical pharmacologynonhuman primates, 4294
9-/3-D-Arabinosylguaninemodulation of antibody response
natural killer cell activity, purine mi -cleoside analogues, 4799
Arabinosylnucleoside
7403
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
modulation of metabolismhuman leukemia cells, 329
Arachidonic acidenhanced activity of peritoneal cells
aclacinomycin, respiratory burst, 3440evidence for thromboxane biosynthesis
lung adenocarcinomas, 2674linoleic acid and
thymidine incorporation, hepatoma,3106
metabolite releasebryostatins and phorbol esters, C3H
10T'/2 cells, 3702
profiles of prostaglandin biosynthesisnormal lung and tumor tissue, lung
cancer patients, 3140A roma tase
antitumor effects of CGS 16949Ahormone-dependent and -independent
tumors, 834inhibitor
effects on mammary carcinoma, 6808ovarian epithelial tumor cells, 6491
Arylamines¿V-hydroxyderivatives
DNA repair, urinary bladder epithelialcells, 4227
Aryl hydrocarbon hydroxylasel/i receptor analysis
A43I squamous cell carcinoma, 2388mono- and bifunctional enzyme inducers
in liver, 4776Asbestiform minerals
induction of ornithine decarboxylase activity
trachea! epithelial cells, 709Asbestos
diet and mesotheliomacase-control study in Louisiana, 2911
-induced mesotheliomaschromosomal translocations, specific
breakpoints, 6455occupational risk factors
laryngeal cancer, Texas Gulf Coast,1960
Ascitesfibrin-fibronectin degradation
ovarian carcinoma, 3507hepatoma cells
factor with antiinvasive potential fromrat liver, 3760
pantropic killer cellsadoptive immunotherapy, OK-432,
4163predictive value
in vitro clonogenic assays, 5447Ascitic fluid
growth factorovarian cancer, 1066
pleural effusions andinterleukin 2-inducible killer cells,
6321i.-Ascorbic acid
amplification of second-stage bladdercarcinogenesis
promotion by NaHCOi, 6317Aspartate carbantoyltransferase
A'-(phosphoacetyl)-i--aspartate biochemistry, 4441
Aspirinrisk of colorectal cancer, 4399
Assaysaffinity chromatography
target proteins, Bowman-Birk protease
inhibitor, 1798antibodies against 7-methyldeoxyguano-
sine, 5065benzo(a)pyrene
anticarinogen detection, natural products, 6257
bromodeoxyuridine/DNAmethotrexate effects, LI210 cells,
4288bromodeoxyuridine labeling method
analysis, chromosomal DNA replication pattern, 219
capillary human tumor clonogenic celloptimization, characterization, 715
chemotherapeutic drug sensitivitycolon carcinomas, monolayer culture,
3236clonogenic
growth requirements, acute lympho-blastic leukemia cells, 5901
prediction, response to tumors, 5447purging regimens, mice, 3394vital cell counting and, 5722
comparative light microscopic, ultra-structural, and immunohistochemi-cal
alveolar type II cell origin, papillarylung tumors, 148
dextran-coated charcoalSAMBA 200 analysis of estrogen re
ceptors, breast carcinoma, 1578differential hybridization analysis
fibronectin messenger RNA, prostaticcancer, 2042
differential responsiveness of breast cancer cells
growth factors, 17/3-estradiol, 4083DNA precipitation and alkali unwinding,
6444dual label fluorescence technique
monoclonal antibody-drug conjugates,6211
ELISAactinomycin D quantification, /3-D-ga-
lactosidase label, 4843extracellular matrix invasion
protein gels, 6933fluorescence-detected antibody binding
tumorigenicity, murine lymphomas,270
genotoxicity of jV-nitroso compoundshepatocytes, 4144
immunoassayshuman chorionic gonadotropin, detec
tion of antigens in urine, 1361immunoenzymatic
cathepsin D, breast cancer cytosols,462
limited sampling modelsaim mat ule pharmacokinetics, 4127
Luria-Delbruck fluctuation analysispitfalls and practice, 1060
microculture tetrazoliumfeasibility of drug screening, panels of
human tumor cell lines, 589monoclonal antibodies as immunotoxins,
1119multiparametric (SAMBA)
anti-Ki67, breast carcinoma, 4368new medium-term bioassays
development of, carcinogens, 5051"P-postlabeling and nucleotide Chro
matographiedetection of ¿T'-alkylguanosine,2156
purification and characterization of P-52normal and preneoplastic liver nod
ules, 2805quantitative studies
tumor transplant ahi Iit) in mice, 6510quantitative transplantation
spontaneous tumors, C3H mouse,4525
repair of i^-methylguanineoligodeoxynucleotides, 1184
semisolid clonogenic mediumgrowth, mammary adenocarcinoma
cells, 399soft-agar clonogenic
tumor cell viability, inoculum density,3944
soluble tetrazolium/formazanevaluation of, human and other tumor
cell lines, 4827tumor-associated galactosyltransferase
isozyme II, 5325, 5335tumorigenicity
activated ras genes, human melanomas, 950
two-dimensional gel electrophoreticanalysis
Friend erythroleukemia cells, 1110visual grading system
metastatic potential, cell motility,4312
Astrocytomatreatment-induced changes in sensitivity
multiclonal tumor mixture model,2749
Ataxia-telangiectasia cellscancer in homozygotes and hétérozy
gotes of patients in Britain, 2929heterogeneity in chromosome damage
repair rates, bleomycin, 276impaired glutathione biosynthesis, 5374
Australiacancer in migrants, 751
Autoanti bodiesantigen expression
paraneoplastic dorsal root gangliono-pathy, small cell lung carcinoma,430
Autocrine growth factorandrogen-responsive and -unresponsive
cellsparacrine mechanism, 4904
pre-B-cell stimulating activitymalignant pre-B-cell lines, 6438
regulation of epidermal growth factor receptor
1,25-dihydroxyvitamin D.i, breast cancer cells, 2734
response of lung carcinoma cell line,4976
transferrin-likeT-lymphoma cells, normal prolifera
tion, 3425Autocrine growth inhibitor
transforming growth factor-|8ER-negative breast cancer cells, 3898
AutoradiographyM, 97,000 to 250,000 protein antigen
concentrations, melanoma, 54755-Azacytidine
therapy by directing differentiation, 19965-Aza-2 '-deoxycytidine
phenotypic changes in neoplastic cells,2440
Azoxymethane
7404
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
aberrant crypts as preneoplastic lesions,6187
-induced colon carcinogenesisdietary eicosapentaenoic acid, effect,
4790a-difluoromethylornithine, growth in
hibition, 6498effects of voluntary exercise, 7079inhibition, dietary ethanol, 3313omega-3 fatty acids, 6642oncogene expression, retroviral-like se
quences, 3964
B
Bacteriamammalian cells and
mutagenicity, CC-106S and analogues,32
significance of floralung métastases,3031
BALB/c 3T3 cellsgap-junctional communication
cell transformation, 3490p32 cDNA clone isolation, 4795uniqueness of spontaneous transformant,
2512Basement membrane
bile duci ular epithelial cell cultures, 6145interaction of intravascular tumor cells
endothelial cells, subendothelial matrix, 4065
invasion by metastatic cellseffects of inhibitors, 3307
B-cellsactivation of
chromatin structure, flow cytometry,6708
chronic lymphocytic leukemiadistribution, doxorubicin metabolites,
5031,25-dihydroxyvitamin D} receptor
modulation, myeloma cell line, 1213pre-
autocrine production, 6438T-cell receptor gene rearrangements
immunoglobulins, Hodgkin's disease,
3591Benoxaprofen
phagocytes andDNA damage, 3094
Benz(a)anthraceneAh receptor analysis
A431 squamous cell carcinoma, 2388Benzene
-inducible cytochrome P-450metabolism, liver microsomes, 5387
metabolitesoxygen radicals, induced DNA dam
age, 4762Benzo(a)pvrene
assay for detection of anticarcinogensnatural products, 6257
-induced skin tumorigenesisprotection, tannic acid, 2361
species differences in DNA adduct formation
dermal fibroblasts, 7132systemic effects
ultraviolet irradiation, 620Benzo(<i)pyrene diol-epoxide
resistance of mitochondria! DNA to inutagenesis
HeLa cells, 4578Benzodiazepine
bindingisoquinoline, glioma imaging, 5837
Benzotriptgastrin antibodies
colon carcinoma, 7179Bile
human4-hydroxy-JV-desmethyltamoxifen me
tabolite, tamoxifen, 2304Bile acids
biliary metabolites of fluoropyrimidines,2010
Bile ductepithelial cells
cultures, extracellular matrix substitutes, 6145
tumor markers CA 19-9 and CA-50carcinoembryonic antigen, pancreatic
neoplasms, 1985Biochanin A
assay for detection of anticarcinogensnatural products, 6257
Biological response modifiersOK-432
adoptive immunotherapy, pantropickiller cells, 4163
Biotechnology productsin cancer therapy, 223
Bis-chloroethylnitrosoureaD,L-buthionine-S,/î-sulfoximineeffect
cytotoxicity, human melanoma cells,19
l,3-Bis(2-chloroethyl)-l-nitrosoureaeffect of thymidine on activity, 4272tumor bioenergetics and histology
nuclear magnetic resonance spectros-copy, 676
yV,/V'-Bis(2-chloro)-/V-nitrosourea
effect of alkylating agent doseclinical correlation, 6417
CM-Bis-neodecanoato-frani-Ä,Ä,-l,2-diaini-nocyclohexaneplatinum(II)
cellular pharmacology, 1300entrapment in multilamellar lipid vesi
cles(•/s-diamminedichloroplatinum(II) cy
totoxicity, 4509Bladder
carcinogenesisNaHCOj promotion, ascorbic acid
amplification, 6317Bladder neoplasms
antitumor effects of pentoxifyllinethiotepa, human cancer cells, 4375
cigarette-inducedeffects of timing, tobacco type, 3849
comparative carcinogenesisnitrosomethylalkylamines, 6648
differential repair of platinum-DNA ad-ducts, 3019
glycosyltransferases, 4427increased levels
fibroblast growth factor-like activity,2083
malignant properties of sublinesactivated c-Ha-ros oncogene, 4993
motor exhaust-related occupations, 1989photodynamic effect
hematoporphyrin derivative, 6115quantitation of DNA adducts
4-aminobiphenyI, 6336relation to cigarette smoking, 4405site-specific analysis of total serum cho
lesterol
incident cancer, National Health andNutrition Examination Survey, 452
transplan tablemetallopurpurin derivatives, photody
namic therapy, 194Blast cells
acute myeloblastic leukemia cellsproduction, growth potentiating fac
tors, 6424effect of 4-hydroperoxycyclophospham-
idehemopoietic progenitors, 1223, 2348
Bleomycinbromodeoxyuridine and
cytotoxicity and DNA strand breaks,tumor cells, 4244
effect on murine tumor cellselevated temperatures, pH values, 615
elimination of T-suppressor activity,6658
heterogeneity in chromosome damageand repair
ataxia-telangiectasia cells, 276hyperthermia and radiation
combination therapy development,6291
phleomycin andinternucleosomal cleavage, yeast, 6837
vincristine and methotrexate combination
acute lymphi»hlasiicleukemia, 351Blood
hyperlipemicthymidine incorporation, hepatoma,
3106LAK cell generation and antitumor ac
tivity in glioblastoma, 6069Blood-brain barrier
delivery of monoclonal antibodies, 4725disruption
methotrexate, rat brain tumors, 694Blood flow
elimination of 5-fluoro-2'-deoxyuridine
in liver, 3561monoclonal antibody uptake
Clouser and renal cell xenografts, 188systemic hemodynamics
galactose injection, 1476tumor
determinants of, 2641measurement, NMR spectroscopy,
3449venous pH and
Walker 256 carcinoma, hyperglycemia,1201
Blood group antigensgene-encoded glycosyltransferases
normal and malignant bladder urothe-lium, 4427
germ cell neoplasms, 5342IgG3 monoclonal antibody
Tn antigen, 4361Le" antigens
comparison between human colon andpancreas, 3834
Lex and Le>
human pancreatic cancer, 475pancreatic cancer cells, 5422related antigens in human urothelium,
4113serum type 1 chain antigens, 3856structural variation of A antigens
normal colon and carcinomas, 181Bloom's syndrome
7405
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
relation to human fibroblast strain46BR, 6343
Bombi-silismall cell lung carcinoma
antagonists, effects on growth, 4783exogenous administration, effects on
growth, 1439-stimulated gastrin
gastric cancer, 2296Bone
metastasismurine model. 6876
-resorbing activityinterleukin-1«,adult I cell leukemia,
4284Bone marrow
5-bromo-2'-deoxyuridine incorporationpharmacodynamics, VX-2 tumors,
6900diethyldithiocarbamate inhibition of tox-
icitycu-diamminedichloroplatinum(II),
5708a-difluoromethylornithine
methylglyoxal bis(guanylhydrazone)and. Phase I study, 1367
DNA cross-linkinginfluence of WR2721, nitrogen mus
tard, 6002growth requirements
acute lymphoblastic leukemia cells,clonogenic assay, 5901
i.-histidinol effect5-fluorouracil metabolism, murine tu
mor system, 6664interleukin 1 secretion
•¿�y-interferon,1,25-dihydroxyvitaminD,, 1740
macrophagescytotoxin release, 7-interferon, 1808
metastasismurine model, 6876
Ph-positive myelocytic leukemiasister chromatid exchange, 745
progenitor cellsprotein synthesis, thermotolerance,
3630radiobiological features, acute lympho
blastic leukemia, 5788purging
clonogenic assays in mice, 3394leukemic progenitor cell effects, acetal-
dophosphamide, 339soybean agglutinin, breast cancer cell
removal, 4573review of hemopoietic growth factors,
5624Bone marrow cells
cytotoxic effects of iodobenzylguanidineneuroblastoma cell lines, 2993
Boronneutron capture therapy
murine melanoma, 6313Bowman-Birk protease inhibitor
potential intracellular target proteinsaffinity chromatography, 1798
Braincytotoxicity of alkylating chemothera-
peutic agentsinduction, sister chromatid exchange,
3100human malignant glioma
two types of receptor, insulin-likegrowth factors, 1233
human neuroblastomaidentification, guanine nucleotide-
binding protein, 2756metastasis
highly pigmented melanoma variant,4897
osmotic blood-brain barrier disruptionmonoclonal antibody delivery, 4725
site-specific metastasismelanoma and fibrosarcoma, 3478
transplantability of tumorsquantitative studies, 6510
Brain neoplasmsadoptive immunotherapy
LAK cells, 2047antiproliferative effect of verapamil,
3617fetal forebrain transplants
iV-nitrosoethylurea induction, oligo-dcndrogliomas, 2871
glioblastoma multiformeselective amplification, epidermal
growth factor receptor, 2711malignant
interleukin 2, LAK cells, 5011pediatrìe
chromosome abnormalities, 175Breast
antiestrogens and, 7193cancer
antiestrogen-induced growth inhibition, 6819
cyst fluidepidermal growth factor, 5860
epithelial cellsgrowth factor and oncogene expres
sion, 7041localization of estrogen receptor, 6517neoplastic tissues
11Pmagnetic resonance profiles, 5112
Breast cancer cellsdegradation of extracellular matrix
cathepsin D, 3688differential responsiveness
growth factors, 17/3-estradiol, 4083effects of steroid hormones
peptide growth factors, c-fos expression, 802
endocytosis and intracellular routingantibody-ricin A chain conjugate, 3822
epidermal growth factor gene expressionregulation by progestins, 4555
estrogen receptor-negativebiological activity, transforming
growth factor-/3, 3898glucose metabolism
magnetic resonance spectroscopy, 870interaction of phenol red
estrogenic and antiestrogenic action,3693
precursor of cathepsin Dmonoclonal antibodies, 3709
proliferation effects of melatonin, 6121regulation of epidermal growth factor re
ceptor1,25-dihydroxyvitamin D.,, 2734
regulation of growth and invasivenessantiestrogens, 6764
removal ofsoybean agglutinin, model for purging
marrow, 4573steroid insensitivity
genetic instability, 4340vasoactive intestinal peptide receptors,
5079VP-16-induced DNA strand breaks
mechanism of action, 5096Breast neoplasms
alcohol consumption and risk, 2284bromine-80m-labeled estrogens
therapy, ER-positive cancers, 899cancer families
susceptibility to neoplasia, 5381cancer in migrants to Australia, 751cathepsin D in cystosols
immunoenzymatic assay, 462c-erbB-2 gene copy number and protein,
1238detection of chromosome aneuploidy
interphase nuclei, 5825detection of mammary serum antigen in
seramonoclonal antibodies, 7060
epidemiology, 5615estrogen-induced potentiation
DNA damage, topoisomerase 11-inter-active antitumor drugs, 297
estrogens as cause of human cancer, 246gross cyst disease
proteases, cyst fluid, 6379growth
Gompertzian model, 7067heterogeneous populations
kinetic and morphometric responses,3276
human breast epithelial cellsphenotypical changes, carcinogens,
2837human-human hybridomas
monoclonal antibodies, 3208insulin-like growth factor
mRNA expression, 6691receptors, 6429
interleukin 2-inducible killer cellsascitic fluid, pleural effusions, 6321
malecase-control study, 1326
metastaticcomparison, CAI5-3 and carcinoem-
bryonic antigen, 4107model for survival, 5565iV-nitrosomethylurea-induced
polyamines, progesterone, 3058plasminogen activators
relation, estrogen and epidermalgrowth factor, 6603
premenopausalendocrinology, tamoxifen, 1026
primary treatmentcontribution of medicine, 2314
progesterone receptor localizationanti-receptor monoclonal antibodies,
6462radioimmunotherapy
monoclonal antibodies, human milkfat globule, 4664
receptors of EGF and insulin-like growthfactor I
relation to steroid receptors, 1343reduction of epidermal growth factor
bindingalkyl-lysophospholipid, 6033
risk assessed by anthropometry, 5363risk factors
Chinese women in Shanghai, 1949synergistic inhibition of growth
cyclic AMP analogues, 1642tissue-type plasminogen activator
7406
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
new prognostic marker, 1348tumor growth
disparate actions, tamoxifen, 812xenografts
metabolism in vivo, 7264Bromine-80m
-labeled estrogenstherapy, ER-positive cancers, 899
radiotoxicityestrogen receptor-directed therapy,
Auger electrons, 5805Bromodeoxyuridine
bleomycin andcytotoxicity and DNA strand breaks,
tumor cells, 4244cell kinetics in human malignancies
flow cytometry, 6238cytokinetic effects of methotrexate
L1210 cells, 4288enhancement of l-/3-r>arabinofuranosyl-
cytosinemetabolic activation, HL-60 cells, 617
labeling methodchromosomal DNA replication pat
tern, 219Schwannian cell differentiation
human neuroblastoma cell lines, 25315-Bromo-2'-deoxyuridine
incorporation into DNAtissue-specific pharmacodynamics,
VX-2 tumors, 6900induction of S-100 protein
neuroblastoma cells, 170Bromosulfopht halcin
-sensitive efflux route for methotrexatevincristine action, LI210 cells, 5995
Bryostatin 1-induced phosphorylation pattern mim
icryphorbol ester, HL-60 cells, 5984
phorbol 12,13-dibutyrate andinhibition of cell-cell communication,
epidermal cells, 447protein kinase C as receptor
phorbol ester tumor promoters, 1Bryostatins
phorbol esters, effects on C3H lOT'/zcells, 3702
Buccal cellsplatinum-DNA adducts
cancer patients, 5597Busulfan
induction of sister chromatid exchangechronic myeloid leukemia, 3435
Butano!cell surface cathepsin B-like activity,
1416extraction of tumor-specific antigens
fibrosarcoma, ultraviolet light-induced,7004
Buthionine sulfoximinecytotoxicity effect and DNA cross-link
ingcytostatic drugs, human melanoma
cells, 19-mediated glutathione depletion
enhanced melphalan cytotoxicity, me-dulloblastoma xenograft, 2764
n-Butyl alcoholtumor antigen characterization
autologous cytotoxic T-cell clone,3892
Butylated hydroxyanisolehepatic aflatoxin B, DNA binding
glutathione conjugation, 2688Butyrate
epidermal growth factor bindingDNA synthesis, hepatocytes, 6560
Cachectintumor necrosis factor as mediator
cancer anorexia, 4567Cachexia
alterations in protein synthesisNovikoff hepatoma, Yoshida sarcoma,
1554body composition changes
improvement, exogenous insulin, 2784branched chain amino acids
parenteral nutrition, Yoshida sarcoma,2698
noncachectic sarcoma patientsaltered leucine metabolism, 1374
whole body protein turnover rateresting energy expenditure, cancer pa
tients, 2590Cadmium
carcinogenesisdose-response, prostate and testes,
4656Caerulein
enhancement of gastric carcinogenesis,6332
Caffeic acidinhibition of TPA-induced tumor promo
tion in mouse skin, 5941Caffeine
breast cancer epidemiology, 5615cytogenetic damage and antineoplastic
effectEhrlich ascites tumor cells, cyclophos-
phamide, 1129influence of consumption
mammary gland development, 2078mammary tumorigenesis
unsaturated fat, 2074Calcitonin
gene-related peptidemolecular forms in human medullary
thyroid carcinoma, 2412transcriptional and posttranscriptional
modulationsodium n-butyrate, medullary thyroid
carcinoma, 2096Calcium
antiproliferative effect of verapamil,3617
behavior of murine epidermal cell linesinitiated and noninitiated skin, 435
-binding proteinpurification, multidrug resistance,
3173biomarkers of increased susceptibility
gastrointestinal neoplasms, cancer prevention, 235
bone-resorbing activityinterleukin-la, adult T-cell leukemia,
4284channels
u>-conotoxin and adenosine, Lambert-Eaton myasthéniesyndrome, 4719
cholesterol sulfate accumulationesophageal epithelial cells, 5289
diet and high risk of stomach cancer inChina, 3518
inhibition of chemotactic peptide-in-duced elevation
phorbol 12-myristate 13-acetate, HL-60 cells, 2707
new growth factor in ascitic fluidovarian cancer. 1066
Phase 1clinical trial of carbetimer, 5353protein kinase C and
alteration, LAK cell activity, 635Calcium eliminati-
genotoxicity of chromâtesmouse embryo cells, 5280
Calmidazolium12-0-tetradecanoylphorbol-l 3-acetate
anddifferentiation modulation, colonie
cancer cells, 6173Calmodulin
antagonistsenhancement of immunotoxin activity
in ovarian and epidermoid carcinoma, 3919
inhibitorsgrowth inhibition, colon adenocarci-
noma, 3319cAMP: see Adenosine 3':5'-monophos-
phate, cyclicCamptothecin
identification of mammalian DNA topo-isomerase I
drug target, 1722-resistant CHO cell mutants, 6404
Canceretiology
rare events as clues, 3544families: see also Cancer family syndrome
susceptibility to neoplasia. 5381head and neck
Clq binding macromolecules, immunecomplexes, 5868
cytotoxicity, natural killer cells, 5017pharmacokinetics. m-diamminedichlo-
roplatinum(Il), 3869migrants to Australia, 751nonrandomness of chromosome aberra
tions, 7120risk associated with
adult stature, 1658Cancer family syndrome
normal ( > chromosomal radiosensitivitycell survival, 2579
twenty-four kindreds. 5358Cancer suppressor genes: see GenesCarbetimer
Phase I clinical trial, 5353Carbogen
breathingfluosol-DA (20%), hypoxia, 3350
Carbohydrate antigen 15-3carcinoembryonic antigen comparison
metastatic breast cancer, 4107Carbohydrate antigen 19-9
CA-50 andpancreatic cancer and benign diseases,
1985comparison of sialylated Le" antigens
colon-rial and pancreatic tissues, 3834DU-PAN-2 and
expression in tumor tissue and serum,pancreatic cancer, 1435
expressiongastrointestinal tumor-associated gly-
coprotein, 1505Carbohydrate antigen 125
tumor marker expressionovarian carcinoma, glucocorticoids,
7407
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
3502Carbohydrate antigens
serum type 1 chain antigens, 3856Carbohydrates
cell surfacemodification and invasive behavior, al-
kyl lysophospholipid, 977metabolizing enzymes
profiles, hepatocellular carcinoma, 467Carboxyphosphamide
deficient urinary excretioncyclophosphamide administration to
cancer patients, 5167Carcinoembryonic antigen
antiidiotype antibodiesmonoclonal antibody, cancer patients,
4002CA 15-3 and
comparison, metastatic breast cancer,4107
CA 19-9 and CA-50tumor markers, pancreatic cancer and
benign diseases, 1985cell surface glycoprotein expression
colorectal carcinoma, 7257chromosomal localization of gene family
differential expression, various tumors,2550
DNA hypomethylationcorrelation, colon carcinoma, 5674
growth potential of human colorectalcarcinomas, 1689
protein secretiontransforming growth factor-/3, colon
carcinoma, 4059radioimmunotherapy
colonie cancer xenografts, 3270radiolocalization
polyclonal and monoclonal antibodies,1823
transcription of genesmalignant and nonmalignant human
tissues, 3153Carcinogenesis
2-acetylaminofluorenepremalignant hepatic nodules, DNA
adducts, 5270adult stature and risk of cancer, 1658antioxidant enzymes
xeroderma pigmentosum fibroblasts,2132
azoxymethane-induced colonieomega-3 fatty acids, 6642
bladderNaHCO, promotion, ascorbic acid
amplification. 6317cadmium
dose-response, prostate and testes,4656
cancer suppressor genegenetic assessment, hamster cells, 46
chemicalcytochrome P-450 enzymes, cancer
chemotherapy, 2946Sudan Ill-induced prevention, mecha
nism, 254systemic effects, ultraviolet irradiation,
620colonie
effects of ammonium acetate and sodium cholate, 3035
effects of voluntary exercise, 7079inhibition by ethanol, azoxymethane,
3313
inorganic selenium, effect of dietaryexcess, 1777
comparativenitrosomethylalkylamines, 6648
earlymucin-associated oncofetal antigen,
1571environmental
cancer prevention, changing concepts,1381
gastriccaerulein enhancement, 6332human model, 3554
human bronchial epithelial cellspathobiological effects, acrolein, 1717T-antigen transformation, 1904
lack of methapyrilene bindingrat liver DNA, 6475
liver and thyroidcytochrome P-450 induction, hydan-
toins, 2492low serum uric acid levels, 2916mammary
induction, effect of exercise, 2720¿V-methyl-jV-nitro-W-nitrosoguanidine
proliferative response, gastric mucosa,5275
molecular mechanismscancer prevention and treatment, 4135
oxygen-free radicals, 3882protein kinase C down-regulation
Ha-ros transfection, C3H 10T'/2 cells,6535
renalinhibition, tamoxifen, 779
resistance to nickel(II) ionscharacterization, mouse cell lines,
6850skin
transcriptional control, keratin geneexpression, 3245
Syrian hamster cheek pouchDNA adduct formation, 7,12-dimeth-
ylbenz(a)anthracene, 2025transforming activity of papillomavirus
isolation, new type, 7164tumor progression in SENCAR mice
papillomas, 7048tumor-promoting activity
teleocidins A and B, 4211two-stage
clonogenic keratinocytes, 6285U.S.-Japan Cooperative Cancer Re
search Program Conference, 6249Carcinogenicity
deuterium-labeled 1,2-dimethylhydra-zine, 2162
hydroxyalkylnitrosaminesF344rats, 1533
oxidation of frans-3,4-dihydrodiol metabolites
7,12-dimethylbenz(a)anthracene, 1227Carcinogens
aberrant cryptspreneoplastic lesions, colon, 6187specificity study, colon, 6183
aflatoxin B, adductioneliminatili, active genes, 7146
4-aminobiphenylquantitation, DNA adducts, 6336
behavior of murine epidermal cell linesinitiated and noninitiated skin, 435
chemicalmitochondria! DNA mutagenesis,
HeLa cells, 4578comparative properties
altered hepatocyte foci, hepatic tumors, 4171
cytogenetic changesneoplastic progression, trachea! epi
thelial cells, 702development
medium-term bioassays, 5051Ar-2-fluorenylacetamide
late target protein, liver, 6745inhibition of 0-propiolactone-induced
neoplasia4-mercaptobenzene, forestomach and
large bowel, 27403-(methylnitrosoamino)propionitrile
DNA cyanoethylation, 6780W-[4-(5-nitro-2-furyl)-2-thiazolyl]form-
amideeffect of peroxidase inhibitors, 304
A'-nitrosomethylbenzylaminediallyl MIItide chemoprevention,
esophageal cancer, 6872phenotypical changes
human breast epithelial cells, 2837polycyclic aromatic hydrocarbon-DNA
adductswhite blood cells of foundry workers,
2288rare events as clues to cancer etiology,
3544rat urinary bladder carcinomas
conversion from low grade to highgrade, 1265
screeningi.-arabinose resistance test, Salmonella
typhimurium, 907selective killing of transformed cells
intercellular communication, therapeutic applications, 3203
sodium bisulfitechromosome transformation, Syrian
hamster cells, 7246transformation
differentiation-induced Mil cells,4389
Carcinomahuman TSP-180 complex
quantitation, normal and tumor tissue,816
radiation-induced injurytumor bed ströma. 2116
Syrian hamster cheek pouchDNA adduct formation, 7,12-dimeth-
ylbenz(o)anthracene, 2025transplan table
loss of M, 78,000 marker, 2265tumor progression in SENCAR mice
initiator dose, papilloma, 7048tumors as caricatures
process of tissue renewal, 1996Carcinoma, adenosquamous
uterine cervixhuman papillomavirus types, 993
Carcinoma, bladderhuman papillomavirus type 16
mild immunodeficiency, 7207Carcinoma, breast
anionic form of glutathione transferasepresence, human tumors and cell lines,
527antagonism of progestin action, 5071cancer family syndrome, 5358c-erbB-2 gene amplification
7408
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
correlation, nodal status and nucleargrading, 1238
effect of alkyhiting agent doseclinical correlation, 6417
epidermal growth factor receptorgene amplification, overexpression,
161infiltrating ductal
genomic status, c-myc status, 199keratins 13 and 16
differential expression, 5831latent transformed growth-inhibiting fac
tor, 418localization of estrogen receptor, 6517milk fat globule membrane-associated
antigenendocytosis, monoclonal antibody,
3188Phase I trial
hexamethylene bisacetamide, 7304restricted specificity for tumor-associated
antigenmonoclonal antibody, 4543
SAMBA analysisanti-Ki67, 4368estrogen receptors, 1578
stremai fibronectin staining patternmetastatic ability, 6227
transformation of mammary epithelialcells
oncogenic retroviruses, 4689Ar,Ar',W-triethylenethiophosphoramide
cyclophosphamide, combination in vitro and in vivo, 94
Carcinoma, cervicalcinnamaldehyde with ró-diamminedi-
chloroplatinum(II), 938oral contraceptives and
case-control study in Chile, 1011papilloma early gene expression
correlation, altered growth properties,3780
papilleimavirus type 16immortalization, exocervical epithelial
cells, 4620transformation, C127 mouse fibro-
blasts, 2505papillomavirus type 18
identification, E6 proteins, 2969immortalization, exocervical epithelial
cells, 4620Carcinoma, colonie
alterations of biological characteristicscolon-derived substrata material, 2825
antibody-mediated killingattached effector cells, 624
cell line markers, 1936cellular processing
vasoactive intestinal peptide, 6201c-myc and c-fos differential expression
familial polyposis coli, 4855comparison of growth requirements
monolayer and soft agarose, 2469cytogenetic and phenotypic analysis
resistance, mitoxantrone, 1882DNA hypomethylation
expression, carcinoembryonic antigen,5674
drug sensitivity assaymonolayer culture, 3236
enhanced cytotoxicitynoncompeting monoclonal antibodies,
6303expression of epidermal growth factor,
137nastrili receptor antagonists
antibodies, 7179gene transcription
carcinoembryonic antigen family, 3153heterogeneous responses
hexamethylene bisacetamide, 5487induction of carcinoembryonic antigen
secretionfibronectin expression, transforming
growth factor-/3, 4059levels of urokinase and its receptor, 3112metastatic
sialoglycoprotein expression, 2353modulation of cytotoxic effect of 5-fluo-
rouracilJV-methylformamide, 6193
orthotopic implantation, 6863recurrence and survival
relationship with c-myc expression,1350
selection of highly metastatic cellssurgical specimens, 1943
structural variationblood group A antigens, 181
transfection with foreign geneinduction, immunogenic tumor var
iants, 2975transforming growth factor-/3-resistant
subclonescharacterization, 7120
Carcinoma, coloréela!expression of cell surface glycoprotein,
7257growth potential
carcinoembryonic antigen, 1689localization
radiolabeled monoclonal antibodies,4324
mucinous variantcell culture, 3751
nerve growth factor receptorschromai in, melanoma cells, 7200
neuroendocrine markers, 4078Phase I trial
hexamethylene bisacetamide, 7304Phase II trial
7-interferon, mAb CO 17-1A, 2568variants of phosphohexose isomerase
isoelectric focusing patterns, 2998Carcinoma, embryonal
effects of dietary retinoidsgrowth and differentiation, 3772
Carcinoma, endometrialhyperplastic and neoplastic endometria
progesterone receptors, 6132modulation of plasminoceli activator ac
tivitygrowth factors, 6384
new hypodiploid human cell lineUM-EC-1, 1864
progesterone receptor structureprotease activity, 1143
reproductive factorsrisk of cancer, uterine corpus, 6217
Carcinoma, epidermoidenhancement of immunotoxin activity,
3919Carcinoma, esophageal
tobacco and alcoholdiet and occupation, 3843
Carcinoma, gastricbinding of gastrinl7, 932expression of epidermal growth factor,
137variants of phosphohexose isomerase
isoelectric focusing patterns, 2998Carcinoma, gastrointestinal
-associated glycoproteinCA 19-9 expression, 1505
phosphohexose isomerase characterization
neuroleukin relationship, 7018Carcinoma, hepatocellular
disulfated glycosphingolipidmonoclonal antibodies, 6769
dolichol kinase and phosphatase, 3418in vitro translation analysis, 2382increased Adriamycin levels
regional infusion, 4584isolation of hepatoma nuclear proteins
monoclonal antibodies, 5495non-A/non-B hepatitis-associated, 7294preneoplastic liver and
carbohydrate-metabolizing enzymes,profiles, 467
prognostic factors, 7314putative premalignant hepatic nodules
DNA adducts, 2-acetylaminofluorene,5270
Carcinoma, lungantibody-mediated killing
attached effector cells, 624autocrine growth factor response, 4976comparison of intrathoracic models,
2880Lewis: see Lewis lung carcinoma tumor
Carcinoma, mammaryeffects of aromatase inhibitor, 6808epithelial-like markers
class I MHC, 7237fibrinogen influx and accumulation
cross-linked fibrin, 1920heat-induced vascular damage
thermosensitivity, 7226medroxyprogesterone acetate effect
proliferation, cell cycle kinetics, 5084metastasis and intercellular communica
tion, 5129miicin like1carcinoma antigen
monoclonal antibodies, 6799phospholipids and phorbol ester binding,
1528spontaneous tumors
quantitative transplantation assays,C3H mouse, 4525
Ar,A",A'"-triethylenethiophosphoramide
cyclophosphamide, combination in vitro and in vivo, 94
tumorigenesisinfluence of caffeine, coffee consump
tion, 2068variants of phosphohexose isomerase
isoelectric focusing patterns, 2998xenotransplanted
effect of retinoids, athymic mice, 3733Carcinoma, medullary thyroid
estrogen receptorhormone responsiveness, 2760
modulation of calcitonin gene expressionsodium n-butyrate, 2096
N-njyc expressionneoplasia, thyroid C-cells, 4073
regulatory peptides, 2412Carcinoma, nasopharyngeal
preserved foodscase-control study in China, 1954
Carcinoma, non-small cell lung
7409
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
flow eytometryprognostic factors for survival, 2923
Carcinoma, ovarianCA 125 tumor marker expression
hormonal regulation, 3S02enhancement of immunotoxin activity,
3919epithelial
aromatization of testosterone, 6491steroid receptors, survival, 6222
fibrin-fibronectin degradation, 3507fibrinogen influx and accumulation
cross-linked fibrin. 1920sensitive and resistant cells
accumulation of m-diamminedichloro-platinum(II), 68
Carcinoma, pancreaticfetal pancreatic protein as marker, 6906loss of M 78,000 marker, 2265
Carcinoma, prostaticandrogen-independent
testosterone, 5«-dihydrotestosterone,609
antiinvasive activity of estramustine,1842
constitutive productionplatelet-derived growth factor, 1930
estrogen-stimulated hormone receptorprofiles, 3077
evaluationcytotoxic activity, diethylstilbestrol,
2867metallothionein induction and deinduc-
tionAdriamycin resistance and sensitivity,
4503partial inhibition of growth
Sandostatin, 4651restricted specificity for tumor-associated
antigenmonoclonal antibody, 4543
variation in tumor yield3,2 '-dimethyl-4-aminobiphenyl, 4629
visual grading systemmetastatic potential, cell motility,
4312Carcinoma, renal cell
activated 11 ra.\ oncogenes, 5251cancer families
susceptibility to neoplasia, 5381clinical and immunological effects
interleukin 2, repetitive weekly cycles,2561
Clouser xenograft andmonoclonal antibody uptake, blood
How, 188cytogenetic analysis
tumor aggressiveness, 28871,25-dihydroxyvitamin D3 receptor
measurement, 2458nonfamilial
ultrastructure, 2890recurrent or metastatic
prognostic factors for survival, 7310transplantation in mice
erythropoietin-induced polycythemia,3430
tumor spread and DNA content, 3165Carcinoma, Shionogi
androgen-responsive and -unresponsivecells
autocrine growth factor, paracrinemechanism, 4904
early phases of regression
gene expression, 6309Carcinoma, small cell lung
antagonism of voltage-gated calciumchannels
w-conotoxin, Lambert-Eaton myasthéniesyndrome, 4719
antigen expressionparaneoplastic dorsal root gangliono-
pathy, 430combined modality treatment
thymosin fraction V, 1663<7Vili:iinmiili-difilli)ropl;ilinn nil II) ac
quired resistance, 6803distinct sublines, 2544effects of bombesin on growth, 1439erA/4-related sequence coding
deleted gene, 682membrane sialoglycoprotein
lgG2a antibody, 4318specificity of monoclonal antibody, 7319
Carcinoma, squamous cellactivation of ornithine decarboxylase ac
tivityguanosine triphosphate, 1252
l/i receptor analysis, 2388biosynthesis and secretion of laminin
keratinocytes, 5193m-diamminedichloroplatinum(II) resist
anceeffect, hyperthermia, 5101
epidemiological characteristics, 3853esophageal
cross-contamination, DNA fingerprintanalysis, 5660
GM: ganglioside residue discriminationmonoclonal antibodies, 6154
head and necktwo new cell lines, 2858
larynxoccupational risk factors, Texas Gulf
Coast, 1960lung
incidence by histológica!type, population-based registry, 6580
mechanism of H-ras oncogene activation, 556
pharmacokineticsm-diamminedichloroplatinum(II),
3869spontaneous tumors
quantitative transplantation assays,C3H mouse, 4525
tumor transplantabilityquantitative studies in mice, 6510
Carcinoma, transitional cellpapillary and nodular
relationship, human urinary bladder,2299
polyamine synthesis and interconversionresponse to blockade, normal and ma
lignant urothelium, 357Carcinoma, urothelial
blood group-related antigens, 4113conversion from low grade to high grade,
1265Carcinoma-associated antigen
mucin-likemonoclonal antibodies, 6799
Carcinoma cellscytotrophoblasts and
epidermal growth factor, receptor synthesis, 1105
endocytosis and intracellular routingantibody-ricin A chain conjugate, 3822
growth of neoplastic thyroid cellsepidermal growth factor receptor,
3652second generation monoclonal antibodies
radioimmunolocalization of xeno-grafts, 4597
tumor-associated glycoprotein 72 antigen, 4588
Cardiopulmonary toxicityinterleukin 2
continuous vs. bolus infusion in sheep,2221
Cardiotoxicityacodazole hydrochloride
Phase I trial, 4423Adriamycin-induced
free radical formation, 4766anthracycline model
adenosine triphosphate/protein ratios,5222
0-Carotenediet and high risk of stomach cancer
case-control study in China, 3518dietary
cancer of the prostate, Japan, 1331risk factors for lung adenocarcinoma
personal and family history, 7279Carrageenan
importance of Lyt-2* T-cells
tumor rejection, 4834Castanospermine
inhibition of tumor growthv-/ms-induced, 1091
Catalaseeffect on Adriamycin tolerance
Chinese hamster ovary cells, 4493peroxisomal /^-oxidation mRNAs
rat tissues, 5316xeroderma pigmentosum fibroblasts
antioxidant enzymes, 2132Catechol
yV-methyl-iV'-nitro-A'-nitrosoguanidinestomach carcinogenesis, phenolic an-
tioxidants, 5310Catechol analogues
cytotoxicity against malignant melanomastructure-activity relationships, 5178
Cathepsin B-like activity
cell surface, murine melanomas and 11brosarcomas, 1416
-like proteinasebiochemical study, colon cancer, 6855
Cathepsin Dbreast cancer cytosols
immunoenzymatic assay, 462carbohydrate moiety
increased mannose-6-phosphate, human hepatoma, 362
degradation of extracellular matrixbreast cancer cells, 3688
M, 52,0000 precursormonoclonal antibodies, breast cancer
cells, 3709CC-1065 analogues
mutagenicitymammalian cells and bacteria, 32
U-71,184 and otherscell survival and cycle, Chinese ham
ster ovary cells, 109C-cells
thyroidneoplasia, N-myc expression, 4073
CCRF-CEM cells
7410
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
resistanceimpaired polyglutamylation of metho-
trexate, 2149Cell-cell communication
contrasting duration of inhibitionepidermal cells, phorbol 12,13-dibutyr-
ate and bryostatin 1, 447Cell culture
bile ductular epithelial cells, 6145comparison of monolayer and soft aga-
rosegrowth requirements, colon carci
noma, 2469DNA fingerprint analysis
cross-contamination, squamous cellcarcinoma, 5660
enhancement of LAK cell cytolysisincreased yields to cancer patients,
5696growth in apar
tumor cell viability, inoculum density,3944
markers of colonie cell lines, 1936vital cell counting r.v.clonogenic assay,
5722Cell cycle
assessment of durationsister chromatid exchanges, somatic
and spermatogonial cells, 5953cell growth response
interleukin 1 binding correlation, 5455cell survival and
U-71,184, CHO cells, 109changes in glycosphingolipids
differentiation, squamous SQCC/Y1cells, 2121
changes in maturing III .-60 cellsretinoic acid, 5989
cytokinetic effects of methotrexateL1210 cells, 4288
deferoxamine effectshematopoietic progenitor cells, 3571
m-diamminedichloroplatinum(II)-in-duced cytotoxicity
mechanism of, 4484early G, phase
proliferation-associated antigen, 1244effects of /V-methylformamide
glutathione status, lymphoma cells,3389
inhibitory effects of prostaglandin \HL-60 cells, 2813
isolation of viable cellsdrug-treated cultures, 5742
kineticsmedroxyprogesterone acetate, mam
mary carcinoma, 5084normal G2 chromosomal radiosensitivity
cancer family syndrome, 2579phorbol ester-induced (•delay
time lapse photography, HeLa cells,1759
premature chromosome condensationnuclear fragmentation, CHO cells,
6478progression
m-diamminedichloroplatinum(II),CHO cells, 6703
proliferation-dependent regulationDNA topoisomerase II, cultured hu
man cells, 3230radiosensitivity
normal human fibroblasts, 4535resistance of noncycling cells to amsa-
crine, 310ribonucleotide reducÃaseM l subunit
proliferation, differentiation, 5151transient exposure to hydroxyurea
DNA replication, Syrian hamster cells,6298
various phasesglutathione, human and rodent tumor
cells, 3661Cell density
regulatory effectsgrowth factor binding, 4266
Cell morphologyloss of metastatic responsiveness
B16 melanoma adhesive cell variant,1258
Cell motilityvisual grading system
metastatic potential, 4312Cells: see specific type of cellCepharanthine
lysosomal function, 1307Cerebrospinal fluid
penetration of active metabolitescyclophosphamide and ifosfamide,
2113Cervical neoplasms
analysis of human papillomavirus sequences, 324
human chorionic gonadotropinnew marker, 1356
papillomavirus types 16 and 18 DNAimmortalization, exocervical epithelial
cells, 4620transforming activity of papillomavirus
isolation of a new type, 7164CGS 16949A
antitumor effectshormone-dependent and -independent
tumors, 834Chemoembolization
collagenm-diamminedichloroplatinum(II),
liver and kidney, 2446Chemoimmunothcrapy
interleukin 2 continuous administrationtransplantation antigen, cyclophospha
mide, 101Chemoprevention
assay for detection of anticarcinogensnatural products, 6257
iV-nitrosomethylbenzylamine-inducedesophageal cancer
diallyl sulfide, 6872Chemosensitization
misonidazoleenhancement of melphalan activity,
3528Chemotactic activity
endothelial cell-derived interleukin 1tumor cells, 7041
Chemotactic peptideactin polymerization in HL-60 cells,
6721-induced elevation of intracellular cal
ciuminhibition in HL-60 cells, phorbol es
ter, 2707Chemotherapy
bifunctional alkylating agentsmedulloblastoma, transplantable xeno-
grafts, 4189breast cancer growth
Gompertzian model, 7067
cell kinetics in human malignanciesbromodeoxyuridine, flow cytometry,
6238combination
doxycycline, leukemia, 6686combined modality treatment
thymosin fraction V, small cell lungcancer, 1663
Clq binding macromoleculesimmune complexes, head and neck
cancer, 5868tic novo guanylate synthesis
commitment to replication, hepatoma3924A cells, 507
a-difluoromethylomithine-inducedgrowth inhibition
azoxymethane-induced colonie neoplasms, 6498
disorganizing-overstabilizing drugscell proliferation, 4892
drug sensitivity assaymonolayer culture, colon carcinomas,
3236effect of galactose on systemic hemody-
namicsblood flow rate, normal and tumor tis
sues, 14765-fluorouracil metabolites in plasma and
urinewith and without methotrexate, 1680
interleukin 2 andpulmonary tumors in mice, 122
neoplastic growthpolyamine metabolism, 759
nucleic acid flow cytometrylarge cell lymphoma, 6614
oligonucleotidesinhibitors, gene expression, 2659
phenotypic changes in neoplastic cells5-aza-2 '-deoxycytidine, hydroxyurea,
2440prevention of induced testicular injury,
4354recurrent tumor sensitivity
rat model, mammary tumors, 4549roles of cytochrome P-450 enzymes
chemical carcinogenesis, 2946snail neurons as model
neurotoxic side-effects. Vinca alkaloids, 7184
surgery andtiming of, osteosarcoma model, 5533
therapeutic and pharmacological studiestetrachloro(i/, ¡-trans)1,2-diamino-
cyclohexane platinum (IV), 1745Chile
oral contraceptives and cervical carcinoma, 1011
Chinadiet and high risk of stomach cancer,
3518preserved foods and nasopharyngeal car
cinomacase-control study, 1954
women in Shanghairisk factors, breast cancer, 1949
Chinese hamster ovary cells: see Ovarycells, Chinese hamster
Chlorambucilethacrynic acid and piriprost
cytotoxicity effect, 3622|4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio|
acetic acidperoxisome proliferation and DNA syn-
7411
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
thesishepatocarcinogenesis, 6739
Chloroacetaldehyde-treated DNA
interstrand cross-links, ethidium bromide fluorescence, 4804
Chloroaluminumsulfonated phthalocyanine
biological effects, transplantable tumors, 3040
l-{2-Chloroethyl)-3-cyclohexyl-l-nitrosou-rea
-resistant Mer* tumor cells
thermal sensitization, 1086H2-Chloroethyl)-3-(4-methylcyclohexyl)-l-
nitrosoureatreatment-induced changes in sensitivity
multiclonal tumor mixture model,2749
2-Chloroethyl(methylsulfonyl)methanesulfonate
DNA interstrand cross-link formationeffect, C^-methylguanine, 3606
ChloroethylnitrosoureaDNA interstrand cross-link formation
effect, 06-methylguanine, 3606
nitroimidazoles andmixed-function drugs. Mer cells, 798
-treated glioma cellsDNA alkylation products, 4489
3'-|3-(2-Chloroethyl)-3-nitrosoureido|-3'-
deoxythymidineeffect of thymidine
nitrosourea activity, 4272Chlorogenic acid
inhibition of TPA-induced tumor promotion in mouse skin, 5941
Cholesterolalteration of biosynthetic pathways
polycyclic aromatic hydrocarbons,2555
glucocorticoid effectslipopolysaccharide, B-cell leukemia 1
cells, 59site-specific analysis of serum
incident cancer, National Health andNutrition Examination Survey, 452
Cholesterol sulfateaccumulation
esophageal epithelial cells, 5289Choline
-deficient dietmodulation, epidermal growth factor
receptors, 1162protection of Ehrlich ascites tumor cells
nitrogen mustard, S-^V^V-dimethylami-loride, 2454
Chondroitin sulfatedifferentiation-associated changes
U937 cells, 6103Choriocarcinoma
gestationalcase-control study, 1004
kinetics of cell intoxicationricin and ricin A chain immunotoxin,
806Chromatin
activation of B-cellsflow cytometry, 6708
aflatoxin It, adductionactive genes, 7146
melanoma cellsnerve growth factor receptors, colorec-
tal carcinoma, 7200
modifications/V-methylformamide-induced radiosen-
sitization, 5669Chromatograph)
affinitytarget proteins, Bowman-Birk protease
inhibitor, 1798Chromium
effects on liver epithelial cell linesrelevance, in vitro transformation,
6484Chromogranin A
neuroendocrine markersendocrine and nonendocrine tumors,
4078Chromosome 7
cytogenetic analysisrenal cell carcinoma, 2887
Chromosome 11sialyltransferase expression, 1491
Chromosomesaberrations
antitumor topoisomerase II inhibitors,Chinese hamster cells, 512
nonrandomness, 7120primary neoplasia related, 7115radiosensitivity, normal human libro •¿�
blasts, 4535abnormalities
malignant human gliomas, 405pediatrie brain neoplasms, 175
analysis of sixteen human rhabdomy-osarcomas, 983
aneuploidyinterphase nuclei, breast tumors, 5825
cytogenetic instabilityuroepithelial cells, SV40-transformed,
3215damage and repair rates
bleomycin, ataxia-telangiectasia cells,276
DNA ligase deficiencyassociation, T cell acute leukemia,
4038DNA replication pattern
analysis, bromodeoxyuridine labelingmethod, 219
frequent nonrandom abnormalitieslarge cell and immunoblastic Km
phoma, 5557genetic assessment
cancer suppressor gene, hamster cells,46
genetic convergence and divergencetumor progression, 5911
induction of sister chromâtid exchangechronic myeloid leukemia, 3435
infrequent loss of heterozygosityhuman stomach cancer, 2988
internucleosomal cleavage in yeastbleomycin, phleomycin, 6837
in vitro transformationsodium bisulfite, Syrian hamster cells,
7246irradiation-induced markers
metastasizing murine tumor, 999localization of carcinoembryonic antigen
gene familydifferential expression, various tumors,
2550loss
role in ros/m^c-induced Syrian hamster tumors, 1623
malignancy by cell fusion, 3302
molecular cloning of ME491early stages, melanoma tumor progres
sion, 2955molecular mechanisms of carcinogenesis
cancer prevention, treatment, 4135nonrandom alterations
human malignant mesothelioma, 142organization of amplified genes
mult ¡drug-resistam Chinese hamstercells, 3179
Philadelphiaacute lymphoblastic leukemia, molecu
lar heterogeneity, 866acute lymphoblastic leukemia, break
point cluster region, 2876point mutation of ras protooncogenes
acute nonlymphocytic leukemia, 18123p21-3p25
deletion in small cell lung carcinoma,erM-related sequence, 682
premature condensationnuclear fragmentation, heat shock in
CHO cells, 6478reorganization
retinoblastoma susceptibility gene, os-teosarcoma development, 3939
solid tumors, 1049translocations with specific breakpoints
asbestos-induced mesotheliomas, 6455Chronopharmacology
circadiani rhythm and 5-fluorouracil concentrations, 1676
Chrysarobinalterations in epidermal polyamine levels
DNA synthesis, 6390C3H 10T'/2 cells
differential effects of bryostatinsphorbol esters, arachidonic acid re
lease, 3702Ar-methyl-A"-nitro-A'-nitrosoguanidine
spontaneous transformation, 5977partial protein kinase C down-regulation
Ha-ros oncogene, fibroblast transfec-tion, 6535
spontaneous transformation, 5969transformation to focus formation
lead enrómate, 5280CI-921
Phase I trial, 6593Cigarette smoking
bladder cancereffects of timing, tobacco type, 3849motor exhaust-related occupations,
1989relationship in a case-control study,
4405comparative epidemiology of cancer
United States, Italy, 7285detection of O6-methyldeoxyguanosine
human placenta! DNA, 4184drinking and
oral and pharyngeal cancer, 3282incidence of lung cancer
histológica!type, population-basedregistry, 6580
laryngeal canceroccupational risk factors, Texas Gulf
Coast, 1960long-lasting effects
pulmonary drug-metabolizing enzymes, 4695
lung adenocarcinomarisk factors, personal and family his
tory, 7279
7412
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
significance, K ra\ activation, 5730lung cancer
effects in women, 6951tumoricidal activity, alveolar macro
phages, 3949nasal diseases and maxillary sinus cancer
case-control study of past history inJapan, 1651
preserved food and nasopharyngeal carcinoma
case-control study, 1954-related tumors
lung and pancreas, rats, 6912site-specific analysis of total serum cho
lesterolincident cancer, National Health and
Nutrition Examination Survey, 452squamous cell carcinoma
bladder adenocarcinoma, 3853Cimetidine
influence on anticarcinogenic effectgastrin, 1591
Cinnamaldehydecu-diamminedichloroplatinum(ll) and
Synergist ¡ccell inactivation, NHIK3025 cells, 938
Orcadian rhythm5-fluorouracil concentrations, 1676
Cirrhosisinsulin-like growth factor II mRNA
expression, 6844preneoplastic liver
profiles, carbohydrate-metabolizingenzymes, 467( '¡spiatili:see c/'i-Diamminedichloropla-
tinum(II)Cifrai
oxidation of retino! to retinole acidepidermis, 7038
CL 259,763restoration of cytolytic T-lymphocyte re
sponse, 2135Clowes Memorial Award Lecture, 4135c-myc
amplificationperipheral T-cell lymphoma, 4959
cellular distribution of transcriptschemical hepatocarcinogenesis, 5522
c-fos anddifferential expression, familial poly-
posis coli, 4855colon carcinoma
recurrence and survival, 1350DNA amplification
small cell lung cancer, 5163enhanced expression
epidermal growth factor receptor,renal cancer, 6753
expression in HL-60/MRI cells, 6733gene abnormality
xenotransplantability, lung cancers,6025
inhibitory effects of prostaglandin A.cell cycle progression, HL-60 cells,
2813N-myc expression
neoplasia, thyroid C-ceIIs, 4073protooncogene expression
normal and leukemic erythroid cells,3972
sublines of small cell lung carcinoma,2544
Coffee consumptioninfluence of caffeine
mammary gland tumorigenesis, 7,12-dimethylbenz(a)anthracene-induced,2068
squamous cell carcinomabladder adenocarcinoma, 3853
Colchicineeffect on microtubules
cell proliferation, 3T3 cells, 4892Collagen
chemoembolizationcis-diamminedichloroplatinum(II),
liver and kidney, 2446Collagenase
blocking of secretionestramustine, tumor cell invasion,
6262effects of inhibitors
basement membrane invasion, meta-static cells, 3307
lytic activity in host and tumor cellsmacrophage and lymphocyte potentia-
tion, 6832regulation of growth and invasiveness
antiestrogens, MCF-7 cells, 6764Colon
aberrant cryptsinduction of, specificity study, 6183potential preneoplastic lesions, 6187
biomarkers of increased susceptibilitygastrointestinal neoplasms, cancer pre
vention, 235carcinogenesis
effect of dietary eicosapentaenoic acid,4790
effects of ammonium acetate and sodium cholate, 3035
effects of voluntary exercise, 7079inorganic selenium, effect of dietary
excess, 1777oncogene expression, retroviral-like se
quences, 3964comparison of sialylated Le" antigens,
3834-derived substrata material
effect, colon carcinoma cell line, 2825human neoplastic tissues
plasminogli activator profiles, 4520marker for early carcinogenesis
iiHH-in associali-ii oncofetal antigen,
1571normal and neoplastic
mono-, di-, and tri-O-acetylated sialicacids, 483
structural variationblood group A antigens, 181
Colonie cellsstimulation of proliferation
structural requirements, oxidized fattyacids, 1771
Colonie mucosapattern of epithelial cell proliferation,
4121Colonie neoplasms
azoxymethane-inducedo-difluoromethylornithine, growth in
hibition, 6498cathepsin B-like proteinase
biochemical study, 6855characterization of mucin
xenografts, 6678human xenografts
tumor targeting, second antibody,2005
hypotheses for origin, 7323
inhibited nucleoside salvagedipyridamole and acivicin, Phase I
clinical trial, 5585inhibition
dietary omega-3 fatty acids, 6642inhibition of colonie carcinogenesis
dietary ethanol, azoxymethane, 3313intrinsic drug resistance
possible link, detoxification mechanism, 3025
modulation of differentiationcalmidazolium, 12-O-tetradecanoyI-
phorbol-13-acetate, 6173prostaglandin biosynthesis, 4770radioimmunotherapy of xenografts
monoclonal antibodies, carcinoem-bryonic antigen, 3270
reduced genomic 5-methylcytosine content, 1159
role of fecapentaenesmutagenicity, 7324
synergistic inhibition of growthcyclic AMP analogues, 1642
Colony-forming unitsenhancement by monoclonal antibody
treatmentpulmonary endothelial cells, 4964
granulocyte-macrophageeffects, hematopoietic suppressor mol
ecules, 1548role for aldehyde dehydrogenase
survival of progenitors, 4-hydroperox-ycyclophosphamide, 1223
uniqueness of spontaneous transformantclone of BALB/c 3T3 cells, 2512
Colony-stimulating factorgranulocyte-macrophage
intravenous administration, monocyteactivity, 2604
mitogenic responsiveness, HL-60 cells,2683
jV-nitrosomethylurea-induced mammarytumor growth
polyamines, progesterone, 3058production of growth potentiating fac
torsblast cells, acute myeloblastic leukemia
cells, 6424review of hemopoietic growth factors,
5624therapy by directing differentiation in
carcinoma, 1996Colorectal neoplasms
Cora antigen expressiontissue distribution, 2198
modulation of cytotoxic effect of 5-fluo-rouracil
yV-methylformamide, 6193risk
chronic illnesses, operations and medications, 4399
site-specific analysis of total serum cholesterol
incident cancer, National Health andNutrition Examination Survey, 452
tumor detection with human monoclonalantibodies, 4348
whole body protein turnover rateresting energy expenditure, cancer pa
tients, 2590Colorectal polyps
prevention of recurrencevitamins C and E, 4701
Complements
7413
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
Clqimmune complexes, head and neck
cancer, 5868Conjugates
methotrexate conjugated with antitumorantibodies
nature of linkage, mode of action,3330
u-Conotoxinantagonism of voltage-gated calcium
channelssmall cell carcinoma, Lambert-Eaton
myasthéniesyndrome, 4719Contraceptives: see Oral contraceptivesCora antigen
differential expressionmalignant and benign gastrointestinal
epithelia, 2198Crisnatol
Phase I and clinical pharmacology, 4706CSF: see Colony-stimulating factorCurcumin
inhibition of TPA-induced tumor promotion in mouse skin, 5941
2-CyanoethyldiazohydroxideDNA
3-(methylnitrosoamino)propionitrile,6780
Cyanomorpholinyldoxorubicininhibition of ribosomal gene transcrip
tion, 4101Cyclic AMP: see Adenosine 3':5'-mono-
phosphate, cyclicCyclooxygenase
enhanced activity of peritoneal cellsaclacinomycin, respiratory burst, 3440
Cyclophosphamideactive metabolites
cerebrospinal fluid penetration, 2113combined with interferon-a/j3
response of P388 leukemia, 2329contribution of medicine
primary treatment, breast cancer, 2314cytogenetic damage and antineoplastic
effectcaffeine. Ehrlich ascites tumor cells,
1129deficient carboxyphosphamide excretion
cancer patients, 5167effect on pathophysiology
solid tumors, 4206gonadotoxicity
luteinizing hormone-releasing hormone agonist, 2174
low doseeffects on immune system of cancer
patients, 1671metabolite of
acrolein, enhanced immune responses,41
-resistant L1210 cellscharacterization, cytosolic aldehyde
dehydrogenase, 2963response of radiation-induced fibrosar
coma-1"P NMR spectroscopy, 4736
A',Ar',Ar"-triethylenethiophosphoramide
andcombination in vitro and in vivo, 94
tumor specific transplantation antigenand
interleukin 2, active specific chemoim-munotherapy, 101
whole-body hyperthermia and
natural killer cell activity, erythroleu-kemia, 4561
Cyproterone acetateoptimal medical castration in male rats,
6063Cytidine S'-triphosphate
-dependent dolichol kinasedolichol phosphatase and, human lu
pai omas. 3418Cytochrome P-448
Sudan Ill-induced preventionchemical carcinogenesis, mechanism,
254Cytochrome P-450
benzene-induciblemetabolism, liver microsomes, 5387
c and d genesventral prostate and liver, 3045
induction by 5-ethyI-5-phenylhydantointumor promotion, liver and thyroid,
2492interferon-mediated depression
role of xanthine oxidase, 2107isozyme specificity
metabolic activation, 2-amino-3-meth-ylimidazo[4,5-/]quinoline
metabolic activationspecificity, Cytochrome P-450 iso-
zymes, 4513oxidative metabolism of l nitropy rene
liver microsomes, 4261roles of enzymes in chemical carcinogen
esiscancer chemotherapy, 2946
Cytokeratindiagnostic and therapeutic monoclonal
antibodiesmesothelioma cell lines, 5228
different types of human lung cancerchain-specific monoclonal antibodies,
3221embryonic liver epithelial cell lines, 4909
Cytokines: see also specific typecirculating
interleukin 2 and LAK cells, metastatic cancer, 5864
heterogeneous distributionmonoclonal antibodies, interstitial
pressure, 7022modulation of major histocompatibility
antigens, 5818Cytomegalovirus
oncogenes of DNA tumor viruses, 493Cytoplasm
accumulation of ditercaliniummitochondria! damage, hepatocytes,
6542DNA cross-linking by FK973
L1210 cells, 5172suppression of tumorigenicity
reconstructed mouse cells, 830tissue distribution and cellular localiza
tionhuman monoclonal antibodies, 7273
Cytoskeletoncell deformability and metastatic poten
tialcorrelation, melanoma cell variants,
5124tumor cell
platelet adhesion role, platelet aggregation, 3787
Cytosolendocytosis and intracellular routing
antibody-ricin A chain conjugate, 3822Cytotoxic granules
isolation and characterizationLAK cells, 4681
Cytotoxicityantibody-dependent cellular
antitumor effect, LAK cells, 1173noncompeting monoclonal antibodies,
colon carcinoma, 6303•¿�y-interferonand mAb CO 17-1A,
Phase II trial, 2568antitumor topoisomerase II inhibitors
sister chromatid exchange, Chinesehamster cells, 512
m-diamminedichloroplatinum(II)-in-duced
mechanism of, 4484DNA damage and cell kill
9-aminoacridines, 860DNA strand breaks and
bromodeoxyuridine and bleomycin, tumor cells, 4244
generation in LAK cellstumor necrosis factor, interleukin 2,
788hyperthermic
effect, topoisomerase II inhibitors,3932
•¿�y-interferontherapyhuman peripheral blood monocytes,
1042melphalan
glutathione depletion, medulloblas-toma xenograft, 2764
natural killer cellshead and neck cancer, 5017
proliferation-dependenteffect of methotrexate in leukemia,
5638synergistic effect
tumor necrosis factor, hyperthermia,650, 654
6-thioguaninesynergistic enhancement, ADP-ribosyl-
transferase, 5650Cytotoxic T-lymphocytes
augmentation of activity7-interferon gene transduction, 4730
autologous clonetumor antigen characterization, «bu
tyl alcohol, 3892clone specific for stable antigen
LI210 cells, 6450glioma spedile
immunoregulatory effects, interleukin2 and interferon, 2981Lyt-2' and L3T4~
recognition, melanoma antigen, 2730modulation of antibody response
natural killer cell activity, purine micleoside analogues, 4799
restoration of responseCL 259,763, mice, 2135
tumor-specific generationT helper cells and accessory cells,
1422Cytotoxin
augmentation of releasebone marrow macrophages, 7-inter
feron, 1808Cytotrophoblasts
A431 carcinoma cells andepidermal growth factor, receptor syn
thesis, 1105
7414
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
D
Daunorubicininteraction with hepatoma
compromised DNA synthesis, 2404-monoclonal antibody immunoconjugate
acid-labile, compared to free drug,6097
vincristine and methotrexate combination
acute lymphoblastic leukemia, 3515-Deazaaminopterin
5-deazamethotrexate andS-alkyl derivatives of, methotrexate
comparison, 56868-Deaza analogues
methotrexate and aminopterincytotoxicity, polyglutamate formation,
14813-Deazaguanine
DNA-directed actions, 2774Deferoxamine
cell cycle effectshematopoietic progenitor cells, 3571
inhibition of neuroblastoma viabilityproliferation, 7189
Dehydroepiandrosteronegene for ovarian granulosa cell tumor
susceptibility, 5092induction of ovarian granulosa cell tu
mors, 2788novel analogues
enhanced biological activity, reducedside effects, 4817
Dehydroepiandrosterone-sulphatebreast cyst fluid
epidermal growth factor, 58604-Demethoxydaunorubicin
Phase I clinical trialchildren with refractory leukemia,
5348Deoxyadenosine
inhibited DNA damage repairchronic lymphocytic leukemia cells,
39812'-Deoxycoformycin
inhibition of DNA damage repairchronic lymphocytic leukemia cells,
3981Deoxycytidine
thymidine kinase deficiency andsubstrate cycles, deoxyribonucleosides,
36814'-Deoxydoxorubicin
Phase I evaluationleukemia, 5580
DeoxyguanosineI,.V -clhcnodeoxygiiunosiiH' as marker
DNA adduci formation, trans-4-hy-droxy-2-nonenal, 320
12-Deoxy- 16-hydroxyphorbolseed oil ofJatropha curcas, 5800
Deoxyribonucleosideseffects of deoxycytidine
thymidine kinase deficiency, substratecycles, 3681
Desmopressingrowth-promoting activity
leukemia cells, 7055Deuterium
-labeled 1,2-dimethylhydrazinecarcinogenicity in mice, 2162
nuclear magnetic resonance spectroscopymeasurement, tumor blood flow and
perfusion, 3449
Dexamethasonegap-junctional intercellular communica
tiontransformed foci, BALB/c 3T3 cells,
3490induction of neoplastic transformation
Fujinami sarcoma virus, chick embryomodel, 7231
interferons andtumoricidal effects, human leukocyte
cell lines, 567rat ductular oval cells
promotion of growth, primary culture,368
Diabetesinsulin effects
phosphatidylinositol kinase, mammarytumors, 6727
sex steroid hormones andinsulin receptor kinase, mammary ade-
nocarcinoma, 3742squamous cell carcinoma
bladder adenocarcinoma, 3853Diacylglycerols
growth-promoting activity of desmopres-sin
leukemia cells, 7055phospholipid toxicity
adenovirus 12 transformant, 578protein kinase C as receptor
phorbol ester tumor promoters, 1Diallyl sulfide
chemopreventionA'-nitrosomethylbenzylamine-induced
esophageal cancer, 6872effect on liver microsomal nitrosamine
metabolismother monooxygenase activities, 5937
1,2-Diaminocyclohexanecarrier ligand in LI210 cells
intracellular biotransformation, platinum compounds, 5136
cii-DiammineU.l-cyclobutanedicarboxy-lato)platinum(II)
diethyldithiocarbamate inhibitionbone marrow toxicity, 5708
m-DiamminedichloropIatinum(II)acquired resistance in vitro
characterization, small cell lung carcinoma, 6803
alkylating agents andgene expression, Escherichia coli, 4823
D,L-buthionine-5,Ä-sulfoximine effectcytotoxicity, human melanoma cells,
19cinnamaldehyde and
synergistic cell inactivation, M lIK3025 cells, 938
collagen chemoembolizationliver and kidney, 2446
combined with X-raytherapeutic gain, 3158
cross-resistanceX-ray and, human tumor cell lines,
5133cytotoxicity
cw-bis-neodecanoato-frans-/?./?-1,2-diaminocyclohexaneplatinum(II),multilamellar lipid vesicles, 4509
mechanism of, 4484ci'.v-di;unininr( 1,1-cyclobutanedicarboxy-
lato)platinum(II)DNA interaction products, cancer pa
tients, 5597
diethyldithiocarbamate inhibitionbone marrow toxicity, 5708
differential repair of platinum-DNA ad-ducts
bladder and testicular tumors, 3019drug sensitivity assay
monolayer culture, colon carcinomas,3236
effect of alkylating doseclinical correlation, 6417
effects on kidneyrenal proximal tubule cells, 2538
hyperthermia andeffect, resistant cell line, 5101hypoxia and acidosis, cytotoxicity,
2342protection from renal injury, o-(ß-hy-
droxyethyl)-rutoside, 2239radiation and tumor growth delay, fi
brosarcoma, 2693rhodamine 1233, 2335whole body, effect on renal injury, 440
increased resistance in NIH 3T3 cellsraÃoncogenes, 793
-induced DNA adductsformation and repair, fibroblasts, 6058
influence on DNA synthesiscell cycle progression, CHO cells,
6703mitomycin C and
inferieron action, human mesotheli-oma xenografts, 64
model for nephrotoxicitythiol rescue agents, 6017
myelotoxic concentrationsantitumor activity, 3135
pharmacokineticshead and neck cancer patients, 3869
platinum analogues andaccumulation, murine leukemia cells, 9
ovarian neoplasmsaccumulation, sensitive and resistant
cells, 68mechanism of acquired resistance,
DNA repair, 5713resistant sublines, 3355
synergy with 1-/3-D-arabinofuranosylcyto-sine
in vivo pharmacodynamics, 117therapeutic and pharmacological studies
tetrachloro(</,/-/ran.j) 1,2-diaminocy-clohexane platinum (IV), 1745
Diazacholesterolalteration of cholesterol biosynthetic
pathwayspolycyclic aromatic hydrocarbons,
2555Diaziquone
sister chromatid exchange inductionhuman and mouse lymphocytes, 27
Dibutyryl cyclic adenosine 3':5'-monophos-
phateactin polymerization in HL-60 cells,
6721gap-junctional intercellular communica
tiontransformed foci, BALB/c 3T3 cells,
3490cu-Dichloro-bis-isopropylamine plati-
num(II)identification of iproplatin metabolite,
3533Dicoumarol
modulation of mitomycin C cytotoxicity
7415
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
mammary tumor cells, 54715,10-Dideazatetrahydrofolic acid
antifolate drug interactions, 24211,9-Dideoxyforskolin
partial reversaldoxorubicin resistance, murine sar
coma S180 variants, 539Diet: see also Nutrition
comparative epidemiology of cancerUnited States, Italy, 7285
effect of excessinorganic selenium, colon carcinogene-
sis, 1777esophageal carcinoma, 3843fat and caloric restriction
exercise, mammary tumorigenesis,4276
high risk of stomach cancer in China,3518
ingestion of cod with vegetablesurinary level, A'-nitrosothioproline,
4049mesothelioma and
case-control study in Louisiana, 2911sodium-deficient diet
restriction, tumor growth, 3445Dietary fat
biomarkers of increased susceptibilitygastrointestinal neoplasms, cancer pre
vention, 235breast cancer epidemiology, 5615
10-|Diethylaminopropylamino)-6-methyl-5//-pyrido|3',4':4,5|pyrrolo(2,3-g)-
isoquinoline: see PZEDiethyldithiocarbamate
inhibition of bone marrow toxicityfii-diamminedichloroplatinum(II),
5708Di(2-ethylhexy)phthalate
peroxisome proliferation and DNA synthesis
hepatocarcinogenesis, 67395,5-Diethylhydantoin
cytochrome P-450 inductiontumor promotion, liver and thyroid,
2492Diethylnitrosamine
comparative propertiesaltered hepatocyte foci, hepatic tu
mors, 41711.2 \ r/Mdimot liyIhylira/i IK-and
hepatocyte initiation, 988Diethylstilbestrol
breast cancer epidemiology, 5615estrogen-stimulated hormone receptor
profilesprostatic carcinoma, 3077
evaluation of cytotoxic activityprostatic carcinoma cells, 2867
-induced pituitary neoplasmsglandular kallikrein, prolactin, 4158
role of metabolism and DNA adduct formation
sister chromatid exchange, lymphocytes, 335
Differentiation antigensCD3
endocytosis and degradation, I colls,2249
CDSradioimmunotoxins, nude mouse
model, 7107CD19andCD22
clinical trial evaluation, ricin A chain-
containing immunotoxins, 26102',2'-Difluorodeoxycytidine
comparison, toxicity, 4024a-Difluoromethylornithine
combined with «2a-interferonPhase I study, 6584
gastric adenocarcinoma xenograftgrowth, 3265
-induced inhibition of growthazoxymethane-induced colonie tumors,
6498methylglyoxal bis(guanylhydrazone) and
Phase I evaluation, hematological malignancies, 1367
properties of LI 210 resistant cells, 2678DL-2-Difluoromethylornithine
curative effectmutant LI210 leukemia cells, 4807
/nin.v-3,-4-1)ih>Urodiolmetabolitesoxidation of 7,12-dimethyl-
benz(a)anthracene3a-hydroxysteroid-dihydrodiol dehy-
drogenase, 1227Dihydrofolate reducÃase
antifolate drug interactions, 24215a-Dihydrotestosterone
testosterone-mediated increaseandrogen-independent prostate carci
noma, 6091,25-Dihydroxyvitamin I),
receptor measurementrenal cell carcinoma, 2458
receptor-mediated modulationhuman myeloma cell line, 1213
regulationepidermal growth factor receptor,
breast cancer cells, 27345-/V,/V-Dimethylamiloride
protection of Ehrlich ascites tumor cellsantiproliferative effect, nitrogen mus
tard, 24543,2'-Dimethyl-4-aminobiphenyl
variation in tumor yieldprostate and other target organs, 4629
7,12-Dimethylbenz(a)anthraceneestrogen-like effects
anterior pituitary dopamine receptors,6434
mammary adenocarcinogenesissuppression, genetic factor, 2204
mammary neoplasmsdietary flavonol quercetin, 5754effects, aromatase inhibitor, 6808glucocorticoids, growth alterations,
7212mammary tumorigenesis
influence of caffeine, coffee consumption, 2068
adrenal regulation, 3801, 3808oxidation of irans-3,4-dihydrodiol me
tabolites3a-hydroxysteroid-dihydrodiol dehy-
drogenase, 1227rapid induction of ovarian granulosa cell
tumorsneonatally estrogenized mice, 425
skin tumorigenesisprotection, fannie acid, 2361
1,2-Dimethylhydrazinedeuterium-labeled
carcinogenicity, 2162diethylnitrosamine and
hepatocyte initiation, 9883,7-Dimethyl-2,6-octadienal: see Cifrai
Dimethyl sulfoxideeffect of sodium butyrate
ovarian adenocarcinoma, 6161induction of erythropoietin receptor
murine erythroleukemia cells, 1818mitogenic responsiveness to GM-CSF
HL-60 cells, 2683soluble tetrazolium/formazan assay
cell growth and drug sensitivity, 48273',5'-Dioctanoyl-5-fluoro-2'-deoxyuridine
selective accumulation of prodrug, 41791,2-Dioctanoyl-^n-glycerol
inhibition of MCF-7 cell growthprotein kinase C activity, 6943
Diphenylmethaneantiestrogen binding site ligands
antiproliferative action, 3954Dipyridamole
acivicin andbiochemical assessment, 5591inhibited nucleoside salvage, Phase I
clinical trial, 5585intraperitoneal administration
pharmacokinetics, cancer patients, 215potentiation of Adriamycin cytotoxicity
I loi.a and sarcoma 180 cells, 1208Ditercalinium
cell treatmentloss of mitochondrial DNA, 4982
cytoplasmic accumulationmitochondrial damage, hepatocytes,
6542DNA
accumulation of strand breaksmethotrexate, A^-propargyl-S.S-didea-
zafolic acid, 2036aldehyde dehydrogenase gene expression
hepatoma, 7009alkylation
A'-(2-chloroethyl)-A'-nitrosourea,glioma cells, 4489
estrous cycle modification, jV-methyl-A'-nitrosourea, 3090
4-(ALmethyl-ALnitrosamino)-l-(3-pyri-dyl)-l-butanone, lung, 4215
A'-nitrosomethyl-(2-hydroxy-ethyl)amine, 1537
thymidine effect, nitrosourea activity,4272
amplificationadeno-associated virus, cellular geno-
toxic stress, 3123myc family, small cell lung cancer,
51631-jS-D-arabinofuranosylcytosine
5-hydroxymethyl-2'-deoxyuridine,HL-60 cells, 3117
binding of progesterone receptormodulation, polyamines, 1217
5-bromo-2'-deoxyuridine incorporationtissue-specific pharmacodynamics,
VX-2 tumors, 6900chromosomal replication pattern
bromodeoxyuridine labeling method,219
chromosome-specific repetitive probesinterphase nuclei, breast tumors, 5825
cisplatin-induced adductsformation and repair, fibroblasts, 6058
cleavageinternucleosomal, bleomycin and
phleomycin in yeast, 6837phorbol ester-induced changes in leu
kemia cells, 6625
7416
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
resistance, DNA topoisomerase II,3537
complementaryCTL activity, 7-interferon gene trans-
duction, 4730p32 clone isolation, 4795
compromised synthesisdaunorubicin interaction, hepatoma,
2404content
tumor spread, renal cell carcinoma,3165
content and proliferative activityclinical outcome, non-Hodgkin's lym-
phoma, 6608cyanoethylation
3-(methylnitrosoamino)propionitrile,6780
-directed actions of 3-deazaguanine,2774
double-strand breaksm-diamminedichloroplatinum(II), cy-
totoxicity, 4484effect of hyperthermia
cw-diamminedichloroplatinum(II),rhodamine 1232, 2335
elevated sister chromatid exchangesethylene oxide-exposed primates, 5045
fingerprint analysiscross-contamination, esophageal squa-
mous cell carcinoma, 5660flow cytometry
advanced germ cell cancer, survival,3864
fragmenting activitiestumor necrosis factor, 6006
galactoside-binding lectinsshared sequence homology, 645
glycosylasemutagenicity, 5-hydroxymethyl-2 ' -
deoxyuridine, 5466granulocyte
iododeoxyuridine incorporation, fluo-rodeoxyuridine, 2933
hepatocellular carcinomanon-A/non-B hepatitis association,
7294hypomethylation
carcinoembryonic antigen, colonie carcinoma, 5674
inhibition of ionizing radiation recoveryprocesses
polyamine-depleted Chinese hamstercells, 4881
in situ hybridizationhuman papillomavirus types, uterine
cervix adenocarcinoma, 993interaction of second-generation anthra-
cyclines with, 6962integration by type 5 adenovirus
methyl methanesulfonate effect, libroblast cells, 3050
interaction of melphalan in lymphocyteschronic lymphocytic leukemia, 1972
-interactive agentsether lipid analogues and, antiprolifer-
ative activity, 1788lesions
doxorubicin content, myeloma cells,6360
growth inhibition, colon adenocarcinoma, 3319
leucovorin-5-fluoropyrimidine, colonadenocarcinoma, 4153
ligase activityheme effect, erythroleukemia cells,
6278ligase deficiency
association with acute T-cell leukemia,4038
mammalian topoisomerase Idrug target, camptothecin, 1722
methylbenzylnitrosamine-induced formation
esophageal O6-methylguanine, ellagic
acid, 7088mitochondria!
loss of, ditercalinium treatment, 4982resistance to mutagenesis, Ik-la cells,
4578molecular mechanisms of carcinogenesis
cancer prevention, treatment, 4135nuclear matrix
antileukemia agents, CCRF-CEM leukemia cells, 1850
papillomavirus types 16 and 18immortalization, exocervical epithelial
cells, 4620placenta!
detection, O'-methyldeoxyguanosine,
4184ploidy
flow cytometry, canine mammary neoplasms, 3411
polymerase chain reaction analysisparaffin-embedded thin-tissue sections,
4564precipitation
alkali unwinding assays, 6444protection of Ehrlich ascites tumor cells
nitrogen mustard, 5-7VyV-dimethylami-loride, 2454
PZE-induced breaksLI210 cells, 1404
rat liverlack of binding, methapyrilene, 6475
reactivity with basesSalmonella typhimurium, methylchry-
sene diol epoxide enantiomers, 1781replication in Syrian hamster cells
transient exposure to hydroxyurea,6298
sodium chromate-induced lesionspolyadenosine diphosphoribose stimu
lation, V79 cells, 1100strand break formation
bromodeoxyuridine and bleomycin, tumor cells, 4244
strand scissionapurinic sites, photoactivated afla-
toxin, 3070tumor virus oncogenes, 493
DNA adductsaflatoxin K,
chromatin, active genes, 7146effect of butylated hydroxyanisole,
2688in vivo immunological detection, 6328
aflatoxin B,-dichloridestructural characterization, calf thy
mus DNA, 5391antibodies against 7-methyldeoxyguano-
sine, 5065benzo(a)pyrene
species formation differences, dermalfibroblasts, 7132
7,12-dimethylbenz(a)anthraceneSyrian hamster cheek pouch epithe
lium, 20251»A^-ethenodeoxyguanosineas marker
Ãra«Ã-4-hydroxy-2-nonenal,320immunochemical quantitation
4-aminobiphenyl, 6336levels
inhibition of renal carcinogenesis, ta-moxifen, 779
8-methoxypsoralenflow cytometry, keratinocytes, 7013
4-nitroquinoline 1-oxide andcell sensitivity, hereditary cutaneous
malignant melanoma, 5145platinum
cancer patients, 5597repair, bladder and testicular tumors,
3019polycyclic aromatic hydrocarbons
white blood cells, foundry workers,2288
putative premalignant hepatic nodules2-acetylaminofluorene carcinogenesis,
5270sister chromatid exchanges
diethylstilbestrol, lymphocytes, 335DNA cross-linking
acquired cisplatin resistance in vitrocharacterization of small cell lung car
cinoma, 6803D,L-buthionine-S')/?-sulfoximine effect on
cytotoxicitycytostatic drugs, human melanoma
cells, 19chloroacetaldehyde
ethidium bromide fluorescence, 4804effect of O'-methylguanine
chloroethylnitrosoureas, 3606FK.973
L1210 cells, 5172influence of WR2721
nitrogen mustard, bone marrow andleukemia cells, 6002
DNA damagebenoxaprofen and phagocytes, 3094cell kill produced by 9-aminoacridines,
860DNA precipitation and alkali unwinding
assays, 6444estrogen-induced potentiation
breast cancer cells, topoisomerase II-interactive antitumor drugs, 297
flavone acetic acid-inducedGlasgow osteogenic sarcoma, 1279
genotoxicity of W-nitroso compoundshepatocytes, 4144
inhibition of repair2'-deoxycoformycin, chronic lympho
cytic leukemia cells, 3981repair of 4,5',8-trimethylpsoralen dam
agenormal and Fanconi's anemia cell
lines, 2015role of oxygen radicals in induction
benzene metabolites, 4762VP-16-induced
mechanism of action, breast tumorcells, 5096
DNA ligase Irelation of fibroblast strain 46BR
Bloom's syndrome, 6343
DNA methylationexpression of rat pepsinogen gene, 1603organ and cell specificity
A'-nitrosomethylamylamine, 5482
7417
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
DNA polymerase ß1-0-D-arabinofuranosyltransferase
effects on incorporation, elongation,1494
DNA repairdefect
ultraviolet light response, trichothiod-ystrophy, 6090
domain-orientedxeroderma pigmentosum cells, 844
effect of thymidinenitrosourea activity, 4272
enhancement of 6-thioguanine cytotoxic-ity
ADP-ribosyltransferase inhibitors,5650
genotoxicity of yV-nitroso compoundshepatocytes, 4144
mechanism of acquired resistancem-diamminedichloroplatinum(II),
ovarian cancer, 5713multifactorial resistance to Adriamycin,
3595normal <. •¿�chromosomal radiosensitivity
cell survival, cancer family syndrome,2579
regeneration of 0"-alkylguanine-DNA al-
kyltransferasenitrosourea exposure, lymphocytes,
5368urinary bladder epithelial cells
W-hydroxy derivatives, arylamines,4227
DNA synthesisalterations in epidermal polyamine levels
chrysarobin, 6390butyrate effects
epidermal growth factor receptor binding, hepatocytes, 6560
gallium effecthuman T-cell lymphoblasts, 3014
influence of c/5-diamminedichloropIa-tinum(II)
cell cycle progression, CHO cells,6703
growth andoxygen-dependent regulation, Ehrlich
ascites tumor cells, 2053peroxisome proliferation
hepatocarcinogenesis, 6739replicative
reduction of potential, hepatocytes,1618
DNA topoisomerase IIdamage and cell kill
9-aminoacridines, 860low levels
resistance, leukemic and normal lymphocytes, 3537
proliferation-dependent regulationcultured human cells, 3230
strand breaksreduced doxorubicin cytotoxicity, oua-
bain, 725Dodecylglycerol
activation of macrophagescancerous tissues, 6044
Dolichol kinasedolichol phosphatase and
microsomal fractions, human hepato-mas, 3418
i -Dopa decarboxylaseneuroendocrine markers
endocrine and nonendocrine tumors.
L-DOPA, 4078L-DOPA methyl ester
cytotoxicity of catechol analogueshuman malignant melanoma, 5178
Dopaminereceptors
7,12-dimethylbenz(<z)anthracene, anterior pituitary, 6434
Dorsal rootparaneoplastic ganglionopathy
antigen expression, small cell lung carcinoma, 430
Doxorubicin: see also Adriamycinconcentration in multidrug-resistant
myeloma cells, 6360differing mechanisms of resistance
human tumor cell lines, 2793distribution of metabolites
B-cells, chronic lymphocytic leukemia,503
escalating dose concurrently with <>.-in-terferon
Phase I trial, 2574lysis of drug-resistant tumor cells
activated lymphocytes, 2372partial reversal of resistance
forskolin, murine sarcoma S180 variants, 539
reduction of cytotoxicity by ouabain, 725reversal of resistance by verapamil
multidrug-resistant myeloma cells,6365
tolerated doseICRF-187 pretreatment, 6918
Doxycyclinecombination chemotherapy of leukemia,
6686Drinking
smoking andoral and pharyngeal cancer, 3282
Drug-antibody conjugatesendocytosis of monoclonal antibody
MCF-7 cells, 3188gallium-labeled antibodies
immunoscintigraphy, 1189Drug resistance
Adriamycin-resistant cells85-kDa protein, 7082
antitumor activity of MX2murine tumor cells, 6653
detection ofenzymatic amplification, human tu
mors, 5775cú-diamminedichloroplatinum(II) and
platinum analoguesaccumulation, murine leukemia cells, 9sensitive and resistant cells, ovarian
carcinoma, 68doxorubicin
differing mechanisms, tumor cell lines,2793
etoposide-resistant human KB cell linescombined modalities of resistance,
5956glucose metabolism in breast cancer cells
magnetic resonance spectroscopy, 870lysis of tumor cells
activated lymphocytes, 2372molecular mechanisms
ribonucleotide reducÃase,2029possible link
colon tumors, detoxification mechanism, 3025
reversal of resistance to vincristine
quinacrine, 2064treatment-induced changes in sensitivity
multiclonal tumor mixture model,2749
tumor cellsflow cytometric enumeration, 6037
U.S.-Japan Cooperative Cancer Research Program Conference, 6249
Drug screeningpanels of human tumor cell lines
microculture tetrazolium assay, 589DU-PAN-2
CA 19-9 andexpression in tumor tissue and serum,
pancreatic cancer, 1435Dysplastic nevi
association with multiple primary melanoma, 1016
E
Effector cellsantibody-mediated killing
human tumor cells, 624isolation and reactivity
concomitant tumor immunity, 1153LAK cells
administration, interleukin 2, 1965phenotype in rats, 884subset of giant autofluorescent lym
phocytes, 2184local interleukin 2 therapy
mouse mammary tumors, various inimunogenicities, 2193
tumor rejectiondelayed-type hypersensitivity, T-cells,
5922Effusions
human malignantmultiplicity, transforming growth fac
tors, 1792prognosis and tumor burden
marker, transformiing growth factor-o,5023
Ehrlich ascites tumor cellsantitumor effects of l-hexylcarbamoyI-5-
fluorouracilhyperthermia, Nakahara-Fukuoka sar
coma cells, 3977circulating glutamine
contribution by host tissues, 1551cytogenetic damage and antineoplastic
effectcaffeine, cyclophosphamide, 1129
DNA synthesis and growthoxygen-dependent regulation, 2053
protection against antiproliferative effectnitrogen mustard, 5-AVV-dimethylami-
loride, 2454zinc metabolism, 3381
Eicosanoidsprostaglandin production
therapeutic response predictor, indomethacin, 3002
Eicosapentaenoic acideffect on colon carcinogenesis
azoxymethane-induced, 4790Electromagnetic fields
low energy microwave fieldsornithine decarboxylase activity, phor-
bol ester, 4222Electron microscopy
ultrastructureCALLA-positive myeloma, 6234
Ellagic acid
7418
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
methylbenzylnitrosamine-induced formation
esophageal O^-methylguanine, 7088
Embryo cellsmouse
genotoxicity of chromâtes,5280EMT6 tumors cells
modulation of mitomycin C cytotoxicitydicoumarol, 5471
Endocrine therapyresponse of rat mammary tumors
nuclear magnetic resonance spectros-copy, 89
Endocrine tissuetumor-associated Ewing's sarcoma anti
gen, 6127Endocytosis
intracellular routing andantibody-ricin A chain conjugate, 3822
monoclonal antibodymilk fat globule membrane-associated
antigen, MCF-7 cells, 3188Endometrial neoplasms
human chorionic gonadotropinnew marker, 1356
new hypodiploid human cell line I'MEC-1, 1864
Endometriumdisparate actions of tamoxifen
breast tumor growth, athymic mouse,812
hyperplastic and neoplasticprogesterone receptors, 6132
Endothelial cells-derived interleukin 1
chemotactic activity, tumor cells, 7041differential photosensitivity
porphyrin photodynamic therapy,4539
effects of hyperthermia on cell survivalprotein synthesis patterns, 2101
heat-induced vascular damagerelationship to thermosensitivity, 7226
interaction of intravascular tumor cellssubendothelial matrix, 4065
mechanism of injuryLAK cells, 5528
proliferating area of human gliomaintercapillary distance, 2938
pulmonary capillarylung tumor colony formation, mono
clonal antibodies, 4964Enrichment
lymphatic metastasis of mammary ade-nocarcinoma
soybean agglutinin binding cells, 1451Enterobacter cloacae
significance in inhibition of lung métastases, 3031
Environmentmolecular mechanisms of carcinogenesis
cancer prevention, treatment, 4135rare events as clues to cancer etiology,
3544Enzymes
mono- and bifunctional inducers in liver,4776
pulmonary drug-metabolizinglong-lasting effects, tobacco smoking,
4695Epidermal cells
behaviorinitiated and noninitiated skin, 435
cell line development
papillomas in skin grafts, ras"', 165
contrasting actions of staurosporine onneutrophils, 4646
inhibition of cell-cell communicationphorbol 12,13-dibutyrate, bryostatin 1,
447modulation of transglutaminases
TPA, retinole acid, 74Epidermal growth factor
amplification of receptor geneesophageal cancers, 5119
amplified and overexpressed receptorgene
breast carcinoma, 161antagonism of progestin action
breast carcinoma cells, 5071breast cyst fluid
cation and androgen conjugate content, 5860
cepharanthine and lysosomal function,1307
differential regulationplasminogen activators, urothelium,
5552effects of bryostatins and phorbol esters
arachidonic acid release, C3H lOT'/icells, 3702
gene expressionprogestins, breast cancer cells, 4555
growth modulation of mouse keratino-cytes
transforming growth factors, 1596-induced mitogenesis
kidney epithelial cells, 4886nerve growth factor receptors
chromatin, melanoma cells, 7200oncogenes of DNA tumor viruses, 493pro-l andpro-2 transfectants
tumor promoters and antipromoters,mouse cells, 6076
receptoramplification, human glioma xeno-
grafts, 2231c-myc expression, renal cancer, 67531,25-dihydroxyvitamin Dj, breast can
cer cells, 2734glioblastoma cells, 5433growth of neoplastic thyroid cells,
3652human gastric and colonie carcinomas,
137lung cancer cell line, 1132modulation, liver tumor promoters,
1162plasminogen activators, human breast
cancer, 6603relation to steroid receptors, breast
cancer, 1343restriction fragment length polymor
phisms, 4045selective amplification, glioblastoma
multiforme, 2711reduction of binding
alkyl-lysophospholipid, breast cancer,6033
regulatory effects of cell density, 4266reversible induction of anchorage-inde
pendent growthnormal mouse keratinocytes, 1566
stimulationcharacterization, A-431 cells, 2377cytotrophoblasts, A-431 cells, 1105
transforming growth factor-ahamster oral keratinocytes, 3130
variants in urine of rats bearing humantumors, 1428
Epidermal neoplasmsclonogenic keratinocytes
two-stage carcinogenesis. 6285Epidermis
oxidation of retinol to retinoic acid,7038
phosphorylation of M, 34,000 to 40,000proteins
protein kinase C, 4018Epirubicin
Phase 111 studymultiple myeloma, 6246
Epithelial cellsbile ductular cell culture, 6145breast
phenotypical changes, carcinogens,2837
bronchialacrolein, pathobiological effects, 1717differentiation, oxygen radicals, 816T-antigen transformation, 1904
embryonic liverdifferentiation patterns, 4909
esophagealcholesterol sulfate accumulation, 5289
exocervicalimmortalization, papillomavirus DNA,
4620expression of fibronectin
tumor line, mouse alveolus. 4933keratin subtypes
small cell lung cancer, 2724kidney
epidermal growth factor, mitogenesis,4886
liverchromium effects, transformation,
6484transforming growth factors, 850
mammarygrowth factor expression, oncogenes,
7041transformation, oncogenic retrovi-
ruses, 4689mammary and urinary bladder
DNA repair, arylamine metabolites,4227
pattern of proliferationcoleircela I mucosa, 4121
Epithelial neoplasmsbiosynthesis and secretion of laminin
cultured human keratinocytes, 5193keratin-like antigen
monoclonal antibodies, 4969Epithelium
biomarkers of increased susceptibilitygastrointestinal neoplasms, cancer pre
vention, 235epithelial-like markers
class I MHC, mammary carcinoma,7237
gastrointestinaldifferential expression, Cora antigen,
2198human breast
keratins 13 and 16, 5831reconstitution of site preference
mammary tumors, 3698Syrian hamster cheek pouch
DNA adduci formation, 7,12-dimeth-ylbenz(<z)anthracene, 2025
thymic
7419
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
analysis of tumors, PE-45 monoclonalantibody, 1896
Epitopescarbohydrate
human squamous lung cancer, 2125Epoxide hydrolases
metabolizing enzymes in mammarygland and liver
effects of inducers, 1390Epstein-Barr virus
oncogenes of DNA tumor viruses, 493Erythrocytes
aflatoxin II, adductionchromatin, active genes, 7146
Erythroleukemiamaturation
Superoxide dismutase, 6674protooncogene expression, 3972whole-body hyperthermia and cyclophos-
phamidenatural killer cell activity, 4S61
Erythroleukemia cellsheme effect
DNA ligase activity, 6278murine
erythropoietin receptor induction,1818
Erythropoietin-induced polycythemia
transplantation, renal carcinoma, 3430induction of receptor
murine erythroleukemia cells, 1818Escherichia coll
yV-ethyl-yV-nitrosourea-induced lesionsneighboring base sequence, distribu
tion and repair, 4455gene expression
alkylating agents, cu-diamminedichlo-roplatinum(II), 4823
Esophageal cellsDNA fingerprint analysis
cross-contamination, squamous cellcarcinoma, 5660
Esophageal neoplasmsamplification
epidermal growth factor receptor gene,5119
A'-nitrosomethylbenzylamine-induced
chemoprevention of, diallyl sulfide,6872
EsophagusBarrett's
ornithine decarboxylase, polyaminelevels, 3288
biomarkers of increased susceptibilitygastrointestinal neoplasms, cancer pre
vention, 235DNA cyanoethylation
3-(methylnitrosoamino)propionitrile,6780
epithelial cellscholesterol sulfate accumulation, 5289
hydroxy metabolites of methyl-n-amylni-trosamine, 5663
precancerous lesionsvitamin intervention, 2280
EsorubicinPhase I evaluation in leukemia, 5580
Estradioleffects on estrogen receptor in mela
noma, 3720-induced kidney tumors
biochemical analysis of development,971
insulin-like growth factor I receptors inbreast cancer, 6429
long-term antiestrogen administrationtamoxifen-stimulated growth, MCF-7
tumors, 5183vs. tamoxifen
effects on normal breast cells, 719317/3-Estradiol
differential responsivenessgrowth factors, breast cancer cells,
4083growth of estrogen receptor-positive mel
anoma, 7093Estramustine
antiinvasive activitymalignant MO., mouse cells, human
prostate carcinoma, 1842-binding associated protein
expression, lung cancer cell lines, 4615tumor cell invasion
blocking of collagenase secretion, 6262Estrogen
action of 2-phenylindole derivatives, 784aromatization of testosterone
ovarian epithelial tumor cells, 6491bromine-80m-labeled
therapy in ER-positive cancers, 899bromine-80m radiotoxicity
receptor-directed therapy, Auger electrons, 5805
case-control study of male breast cancer,1326
cause of human cancer, 246differential responsiveness of breast can
cer cellsgrowth factors, 17/3-estradiol, 4083
effects of phenol redbreast cancer cell growth, 3693
epidermal growth factorinsulin-like growth factor I, breast can
cer, 1343hepatic effects of steroids
structure-activity studies, 2462-induced kidney tumors
drug metabolism enzymes, 5726-induced pituitary neoplasms
glandular kallikrein, prolactin, 4158-induced renal carcinogenesis
inhibition by tamoxifen, 779interactions with intracellular receptor
complexmouse Leydig cells, preneoplastic hy-
perplasia, 14-like effects
7,12-dimethylbenz(a)anthracene, anterior pituitary dopamine receptors,6434
neonatally estrogenized micerapid induction, ovarian granulosa cell
tumors, 425plasminogen activators
human breast cancer, 6603potentiation of DNA damage and cyto-
toxicitybreast cancer cells, topoisomerase II-
interactive antitumor drugs, 297receptor
antiestrogen growth regulation, MCF-7 cells, 6764
hormone responsiveness, medullarythyroid carcinoma, 2760
localization, human breast tissue, 6517SAMBA 200 analysis, breast carci
noma, 1578
receptor concentrationbreast cancer survival model, 5565
receptor-negative breast cancer cellsbiological activity, transforming
growth factor-/3, 3905receptor status
cathepsin D, breast cancer cytosols,462
replacement therapybreast cancer epidemiology, 5615
-sensitive proliferation patternkidney tumor cells, 3676
steroid insensitivitybreast cancer cells, 4340
-stimulated hormone receptor profilesprostatic carcinoma, 3077
Estrous cyclemodification by ALmethyl-/V-nitrosourea
rat mammary gland DNA alkylation,3090
Ethacrynic acidpiriprost and
cytotoxicity effect, 3622Ethanol
esophageal carcinoma, 3843-inducible cytochrome P-450
benzene metabolism, liver micro-somes, 5387
inhibition of colonie carcinogenesishigh-dose azoxymethane, 3313
1,iV''-Mllicnudfiiv yijiiiiiiiisiiiv
potential marker for DNA adduci formation
rrufls-4-hydroxy-2-nonenal, 320Ether lipid analogues
DNA-interactive agents andantiproliferative activity, human tumor
cells, 1788Ethidium bromide
fluorescencechloroacetaldehyde-DNA, 4804
Ethinylestradiolmetabolism and binding
a-naphthoflavone, hepatocarcinogene-sis, 5460
Di.-Ethionineformation of 5-adenosylethionine in
liver, 446410-Ethyl-lO-deazaaminopterin
Phase I trialadvanced cancer, 5573
Ethylene oxide-exposed primates
elevated sister chromatid exchanges,5045
Ethylmethane sulfonateresistance of mitochondrial DNA to mu-
tagenesisHeLa cells, 4578
yV-Ethyl-W-nitrosourea-induced lesions in Escherichia coli
neighboring base sequence, distribution and repair, 4455
-induced tumorigenesismouse major histocompatibility com
plex (H-2), 6634tumor size and morphology
gestational development, lung tumors,379
5-EthyI-5-phenylhydantoincytochrome P-450 induction
tumor promotion, liver and thyroid,2492
Etoposide
7420
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
DNA strand breaksmechanism of action, breast tumor
cells, 5096metabolism and excretion
rat liver models, 5692-resistant human KB cell lines
combined modalities of resistance,5956
topoisomerase H-interactive drugsestrogen and DNA damage, breast
cancer cells, 297Etoposide glucuronide
major metabolite of etoposiderat and rabbit, 1829
Exercisemammary carcinogenesis
effect on induction, 2720mammary tumorigenesis
dietary fat, caloric restriction, 4276voluntary
effects on colon carcinogenesis, 7079Exotoxins
cepharanthine and lysosomal function,1307
Extracellular matrixassay for tumor cell invasion
protein gels, 6933bile duct »lar epithelial cell cultures, 6145collagen-binding glycoproteins
MDAY-D2 tumor cells, 4743degradation with cathepsin D
breast cancer cells, 3688interaction of melanoma with murine
mesentery, 5296platelet-derived growth factor-like pro
teinsconstitutive production, prostate carci
noma, 1930Extravasation
interaction of intravascular tumor cellsendothelial cells, subendothelial ma
trix, 4065
Fab fragmentsantibody-guided targeting
non-small cell lung cancer, 1977monoclonal antibody delivery
osmotic blood-brain barrier disruption,4725
monoclonal antibody Mel-14glioma localization, 5701
Factor Xloss of activator capabilities
vitamin K, Lewis lung carcinoma,6504
Familial polyposis colic-myc and c-fos differential expression,
4855Fat
bladder cancermotor exhaust-related occupations,
1989mammary tumorigenesis
caffeine and, 2074caloric restriction, voluntary exercise,
4276prostate cancer
dietary /3-carotene, case-control study,1331
Fatty acidsomega-3
colon tumor inhibition, 6642oxidized
colonie cell proliferation, structural requirements, 1771
Fecapentaenescolon cancer
hypotheses for origin, 7323role in mutagenicity, 7324
Ferritineffects of hematopoietic suppressor mol
eculesgranulocyte-macrophage progenitor
cells, 1548Fertility
gestational choriocarcinomacase-control study, 1004
Ferulic acidinhibition of TPA-induced tumor promo
tion in mouse skin, 5941a-Fetoprotein
differential regulationhepatocyte X hepatoma hybrids, 6371
embryonic liver epithelial cell lines, 4909lack of mRNA expression
peroxisome proliferators, liver tumors,4919
rat ductular oval cellspromotion of growth, primary culture,
368Fibrin
coagulationprotection against cytotoxic cells,
5216-fibronectin degradation
ovarian carcinoma, 3507Fibrinogen
influx and accumulationcross-linked fibrin, mouse carcinoma,
1920Fibroblast growth factor
-like activityincreased levels in urine, bladder or
kidney cancer, 2083modulation of plasminogen activator ac
tivityendometrial adenocarcinoma cells,
6384regulatory effects of cell density, 4266
Fibroblastsdermal
DNA adduci formation,benzo(a)pyrene, 7132
effects of SV40 transformationintercellular gap junctional communi
cation, 3485fetus-derived
identification, transformation-associated cell surface antigen, 2798
formation and repair of cisplatin-DNAadducts, 6058
1la-iuv transfectionprotein kinase C down-regulation,
C3H 10T'/2 cells, 6535invasiveness in monolayers
metastatic potential, T-cell hybrido-mas, 3405
malignancy by cell fusion, 3302methyl methanesulfonate effect
type 5 adenovirus DNA integration,3050
normal humangrowth inhibition, salivary adenocarci
noma cells, 2819radiosensitivity, 4535
proliferation-dependent regulationDNA topoisomerase II, 3230
src oncogene expressionreversal of transformed phenotypes,
1587strain 46BR
relation to Bloom's syndrome, 6343lOT'/i
postconfluence growth arrest, cAMP,1874
transformation by human papillomavirus16, 2505
-tumor cell interactionenhancement, metastatic capacity,
1456xeroderma pigmentosum
antioxidant enzymes, 2132Fibronectin
colon carcinomacarcinoembryonic antigen secretion,
transforming growth factor-/3, 4059effect, colon-derived substrata mate
rial, 2825down modulation of messenger RNA
prostatic cancer, 2042enhanced receptor expression
sarcoma virus-induced tumors, 5510epithelial cell strains, 4933receptors
alteration of, phorbol ester-treatedpromonocytic cell lines, 5730
stromalstaining pattern and metastatic ability,
breast carcinoma, 6227Fibrosarcoma
cell surface cathepsin B-like activityidentification, butano! extraction,
14165-deazaaminopterin
5-alkyl derivatives, methotrexate comparison, 5686
effect of interferon-aA/Dtumor cell growth, 2366
elimination of T-suppressor activitybleomycin, tumor-bearing rats, 6658
growtheffects, glucocorticoid receptor, 2703
laser Doppler flowhyperglycemia, murine tumors, 7102
metastasis marker polypeptides in cancer, 572
metastaticstimulation, transforming growth fac
tor-/?, 6999platelet aggregation in metastasis, 1460role of serotonin
antitumor effects, tumor necrosis factor-«,4250
site-specific brain metastasis, 3478spontaneous tumors
quantitative transplantation assays,C3H mouse, 4525
tumor growth delay and cell survivaltrimodality therapy, 2693
tumor transplantabilityquantitative studies in mice, 6510
ultraviolet light-inducedbutano! extraction, tumor-specific an
tigens, 7004Fibrosarcoma-1
radiation-inducedcyclophosphamide response, "P NMR
spectroscopy, 4736Fibrosarcoma cells
glucocorticoid-induced alterations ofgrowth
7421
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
mammary tumor, 7212Fish
ingestion of cod with vegetablesurinary level, A'-nitrosothioproIine,
4049progressive growth of tumors
transplantation, thymus-aplastic mice,741
FK973antitumor activity
hematotoxicity, 1166DNA cross-linking, 5172
Flavone acetic acidDNA damage
Glasgow osteogenic sarcoma, 1279modulation of tumor physiology
NMR spectroscopy, 4749Phase I study, 5878
Flavonol quercetin7,12-dimethylben7(u)anthracene induced
mammary cancer, 5754Flow cytometry
activation of B-cellschromatin structure, 6708
advanced germ cell cancerproliferative activity, survival, 3864
analysis of DNA ploidycanine mammary tumors, 3411
cell cycle and viable cell isolationexposure to cytotoxic agents, 5742
cell kinetics in human malignanciesbromodeoxyuridine, 6238
compared to clonogenic assaydrug testing, 5722
cytogenetic and ultrastructural studiesnonfamilial renal carcinoma, 2890
cytokinetic effectsmethotrexate, L1210 cells, 4288
enumeration of drug-resistant tumorcells, 6037
8-methoxypsoralen-DNA photoadductskeratinocytes, 7013
nucleic acidlarge cell lymphoma, 6614
prognostic factors for survivalnon-small cell lung carcinoma, 2923
protein-tyrosine kinase activitypp60' "' expression, 4633
Fluctuation analysisLuria-Delbruck
pitfalls and practice, 1060Fluocinolone acetonide
gap-junctional intercellular communication
transformed foci in BALB/c 3T3 cells,3490
Fluoranthene-hemoglobin adductsisolation and characterization, 4756
/V-2-Fluorenylacetamidelate target protein in liver, 6745
Fluorescencegiant autofluorescent lymphocytes
LAK cells as subset, 21842-Fluoro-0-alanine
biliary metabolites in liver, 201016a-Fluoro-5-androsten-17-one
novel dehydroepiandrosterone analoguesenhanced biological activity, reduced
side effects, 48175-Fluoro-2-deoxyuridine
biliary metabolites of fluoropyrimidines,2010
elimination by liver, 3561growth inhibition
colon adenocarcinoma, 3319incorporation of iododeoxyuridine
granulocyte DNA, Phase I study, 2933recurrent tumor sensitivity
rat model, mammary tumors, 45495-Fluoroorotate
liposome-based therapyhuman ovarian cancer, 5237
S-Fluoropyrimidineincreased levels of DNA lesions
colon adenocarcinoma, 41535-Fluorouracil
circadian rhythm, 1676contribution of medicine
primary treatment in breast cancer,2314
drug sensitivity assaymonolayer culture, colon carcinomas,
3236folate pools
xenografts, colon adenocarcinoma,3062
formation of conjugates5-fluoro-^-alanine, bile acids, 2010
i.-histidinolmetabolism, murine tumor system,
6664specificity, proliferation dependence,
1470leucovorin and
disseminated cancer treatment, pancreas, 5570
mechanisms of innate resistancethymidylate synthase inhibition, 5894
metabolites in plasma and urinewith or without methotrexate, 1680
modulation of cytotoxic effectA'-methylformamide. colon carcinoma,
6193pharmacokinetics
mass spectrometry, 6956maximum tolerated dose, continuous
venous infusion, 459yV-(phosphonacetyl)-i.-aspartate
biochemistry, 4434prognostic factors
hepatocellular carcinoma, 7314Fluosol-DA
photodynamic therapy-induced hypoxiacarbogen breathing, 3350
Folateeffects of deficiency
metastatic potential, melanoma cells,4529
mechanisms of innate resistancethymidylate synthase inhibition, 5894
Folie acidantagonists in chemotherapy, 4131
Folylpolyglutamate synthetaseregulation
methotrexate, hepatoma cells, 2426Forebrain
fetal transplantsA'-nitrosoethylurea induction, oligo-
dendrogliomas, 2871Forestomach neoplasia
/3-propiolactone-inducedinhibition, 4-mercaptobenzene, 2740
Formaldehydeingestion of cod with vegetables
urinary level, A'-nitrosothioproIine,4049
Formylmethionylleucylphenylalaninephorbol ester inhibition
chemotactic signals, HL-60 cells, 2707Forskolin
partial reversaldoxorubicin resistance, murine sar
coma S180 variants, 539Friend erythroleukemia
electrophoretic analysis, 1110protooncogene expression, 3972
Friend virus complexpolycythemia-inducing strain
curative effect, irradiation, 2399Fucosyltransferase
Le* and Le* antigen expression
human pancreatic cancer, 475a-2-i-Fucosyltransferase
significance of altered levelsserum, leukemic patients, 3998
Galactosebinding activity
ricin-monoclonal antibody conjugates,4469
effect on systemic hemodynamicsblood flow rate, 1476
/J-D-Galactosidasequantification of actinomycin D by
ELISA, 4843Galactoside
-binding lectinsshared sequence homology, 645
Galactosyltransferase isozyme IItumor-associated
immunoassay, 5325, 5335Gallbladder
tumor markers CA 19-9 and CA-50carcinoembryonic antigen, pancreatic
neoplasms, 1985Gallium
effect on DNA synthesishuman T-cell lymphoblasts, 3014
-labeled antibodiesimmunoscintigraphy, drug-antibody
conjugates, 1189Gangliosides
detection of monosialogangliosidemonoclonal antibody, tumor-infiltrat
ing macrophages, 2524GMÕ
residue discrimination, monoclonalantibodies, 6154
inhibited melanoma growthIgG3 monoclonal antibody, GM.<lac-
tone immunization, 5680melanoma-associated
fish genus Xiphophorus, 3454neosynthesis
transfection, Gardner-Arnstein strainfeline sarcoma virus-DNA, 1753
Gap junctionc-raf protooncogene expression
7-glutamyltranspeptidase, liver neoplasms, 1610
intercellular communicationeffects, SV40 transformation, 3485transformed foci, BALB/c 3T3 cells,
3490metastatic capacity
mammary carcinoma, 5129selective killing of transformed cells
therapeutic applications, 3203Garlic
diallyl suItidechemoprevention, carcinogen-induced
7422
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
esophageal cancer, 6872liver microsomal nitrosamine metabo
lism, 5937Gastric mucosa
differential proliferative responsecarcinogenesis, /V-methyl-Ar'-nitro-Ar-
nitrosoguanidine, 5215Gastric neoplasms
human model of gastric carcinogenesis,3554
Gastrinbombesin-stimulated
gastric cancer, 2296receptor antagonists
antibodies, colon carcinoma, 7179Gastrin,7
binding to human gastric carcinoma celllines, 932
Gastrin-releasing peptideeffects of bombesin antagonists
growth, small cell lung cancer, 4783molecular forms
human medullary thyroid carcinoma,2412
Gastrointestinal neoplasms-associated glycoprotein
CA 19-9 expression, 1505biomarkers of increased susceptibility
cancer prevention, human subjects,235
cancer in migrants to Australia, 751Cora antigen expression, 2198monoclonal antibody reaction
high-molecular-weight glycoprotein,4053
Gastrointestinal tractintervention of T-cells in transportation
mouse mammary tumor virus, mammary gland cells, 6555
Gel electrophoresis: see AssaysGenes
amplifiedchromosomal organization, multidrug-
resistant Chinese hamster cells,3179
cancer suppressorassessment, hamster cells, 46
EIAphospholipid toxicity, adenovirus 12
transformant, 578galactoside-binding lectins
shared sequence homology, 645hepatocellular carcinoma
in vitro translation analysis, 2382human a-interferon
coding, functional properties of proteins, 1763
multidrug resistanceRNA detection, in situ hybridization,
4334NM2Ì
RNA levels in metastasis, 6550oligodeoxynucleotides
inhibitors of expression, 2659pro
transfer of promotion sensitivity, 1195specific chromosomal abnormalities
malignant human gliomas, 405WDNM1
differential expression, mammary ade-nocarcinoma cells, 5203
Geneticsrare events as clues to cancer etiology,
3544
Genotoxicitychromâtesin mouse embryo cells, 5280
Germ cell neoplasmsadvanced
proliferative activity, survival, 3864blood group-related antigens, 5342estrogens as cause of human cancer, 246stage migration
complete responders, 3524Germinal cell aplasia
procarbazine-inducedpartial prevention, testosterone, 4354
Gestational choriocarcinomacase-control study, 1004
Glia maturation factortherapy by directing differentiation in
carcinoma, 1996Glioblastoma
analysis of lymphoid infiltrates, 6926I AK cell generation and antitumor ac
tivity, 6069multiforme
selective amplification, epidermalgrowth factor receptor, 2711
Glioblastoma cellsexpression of altered epidermal growth
factor receptor, 5433Glioma
antiproliferative effect of verapamil,3617
blood-brain disruptionmethotrexate, rat brain tumors, 694
diagnostic imagingisoquinoline, benzodiazepine binding,
5837expression of mRNAs
platelet-derived growth factor, transforming growth factor-a, 3910
humanproliferation, intercapillary distance,
2938receptor expression, insulin-like
growth factors, 1233specific chromosomal abnormalities,
405human xenografts
amplification, epidermal growth factorreceptor gene, 2231
antiglioma monoclonal antibody, therapeutic efficacy, 559
intrue-ranial. radioimmunotherapy,
2904localization
monoclonal antibody fragment, 5701malignancy stages
clonal genomic alterations, 5546-specific cytotoxic T-lymphocytes
immunoregulatory effects, interleukin2 and interferon, 2981
tumor transplantabilityquantitative studies in mice, 6510
Glioma cellsyV-(2-chloroethyl)-./V-nitrosourea-treated
DNA alkylation products, 4489plasminogen activator
modulation, sodium butyrate, 291Gliosarcoma
new cell linebiological and karyotypic characteriza
tion, 731nuclear magnetic resonance spectros-
copy, 5610tumor bioenergetics, histology, 676
0-1,3-Glucan
lentinandenaturation and renaturation, T cell
responses, 671Glucocorticoids
CA 125 tumor marker expressionovarian carcinoma, 3502
-induced alterationsfibrosarcoma growth, mammary tu
mor, 7212lipid lateral diffusion and membrane
compositionlipopolysaccharide, B-cell leukemia 1
cells, 59mammary tumorigenesis
adrenal regulation, 3808receptor
effects, fibrosarcoma growth, 2703protein level, 2636tyrosine aminotransferase modulation,
Reuber hepatoma cells, 5188Glucose
blood flow and venous pHWalker 256 carcinoma, hyperglycemia,
1201-deprived L929 cells
nucleoside-restored heat resistance,suppressed protein synthesis, 1442
diffusivitymulticellular tumor spheroids, 3905
energy substrate utilizationMorris hepatoma 7777 cells, 602
estrogen-induced kidney neoplasmsdrug metabolism enzymes, 5726
hydralazine andpH modification, air or carbon dioxide
mixture, 1543metabolism in breast cancer cells
magnetic resonance spectroscopy, 870metabolism in vivo
human breast cancer xenografts, 7264role of hypovolemic hemoconcentration
flow decline, 7102tumor metabolic changes
•¿�"Pnuclear magnetic resonance, 5917Glucose-6-phosphate
mitochondria! bound hexokinasehepatoma cells, 913
/3-Glucuronidascidentification of etoposide glucuronide
major metabolite, rat and rabbit, 1829Glutamine
circulationcontribution by host tissues. Ehrlich
asdics tumor cells, 1551energy substrate utilization
Morris hepatoma 7777 cells, 602Glutamylation
role of folylpolyglutamate synthetasemethotrexate, hepatoma cells, 2426
7-Glutamyltransferasesequential development of aneuploidy
skin papillomas, 3253•¿�v-Glutamyltranspeptidase
estrogen-induced kidney neoplasms,5726
expression of c-ra/protooncogeneliver neoplasms, 1610
lack of mKNA expressionperoxisome proliferato», liver tumors,
4919Glutathione
acquired cisplatin resistance in vitrocharacterization, small cell lung carci
noma, 6803
7423
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
buthionine sulfoximine-mediated depletion
enhanced melphalan cytotoxicity, me-dulloblastoma xenograft, 2764
cellular levelsrodent and human tumor cells, 3657
depletionheat shock protein synthesis, Chinese
hamster ovary cells, 7033elicci on Adriamycin tolerance
Chinese hamster ovary cells, 4493growth and cell cycle
yV-methylformamide effects, lym-phoma cells, 3389
human and rodent tumor cellsvarious phases of cell cycle, 3661
impaired biosynthesisataxia-telangiectasia cells, 5374
levels in medulloblastomamelphalan transport, glutathione-51-
transferase, 5397resistance to quinone antitumor agents
characterization, L5178Y murine lym-phoblasts, 1727
Glutathione peroxidaseeffect on Adriamycin tolerance
Chinese hamster ovary cells, 4493Glutathione transferase
anionic formpresence in human tumors and cell
lines, 527estrogen-induced kidney neoplasms,
5726multifactorial resistance to Adriamycin,
3595Glutathione 5-transferase
conjugation and aflatoxin H, I )\A binding
effects, butylated hydroxyanisole, 2688U.S.-Japan Cooperative Cancer Re
search Program Conference, 6249Glutathione-5-transferase P
lack of mRNA expressionperoxisome proliferators, liver tumors,
4919purification and characterization
normal and preneoplastic liver nodules, 2805
Glyceraldehyde-3-phosphate dehydrogenaseincreased gene expression
pancreatic adenocarcinoma, 6354Glycolipids
lactoneotetraosylceramidedetection in patients with cancer, 1512
neutralmonoclonal antibody, HTLV-I and
adult T cell leukemia, 3148sulfated
thrombospondin binding, melanoma,6785
Glycoproteinscell surface
colorectal carcinoma, 7257collagen-binding
MDAY-D2 tumor cells,4743gp70
mutagen-treated murine tumor cells,1137
gploOradioimmunotherapy, lung cancer cell
lines, 2768high-molecular-weight
monoclonal antibody reaction, gastrointestinal cancer, 4053
IRGpIIb/IIIatumor cell cytoskeleton, platelet adhe
sion, 3787lamÃnin-associated
biosynthesis and secretion, keratino-cytes, 5193
M, 95,000melanocytes and melanomas, mAb,
1286mucin
monoclonal antibodies, sera frombreast cancer patients, 2138
serum type 1 chain antigens, 3856Glycosphingolipid
changes accompanying differentiationhuman squamous SQCC/Y1 cells,
2121disulfated
monoclonal antibodies, hepatocellularcarcinoma, 6769
Glycosylationgene transcription
carcinoembryonic antigen family, 3153sialosyl-Tn epitope
monoclonal antibody preparation,2214
Glycosyltransferaseseffect of hyperthermia
Chinese hamster ovary cells, 5717human blood group gene-encoded
normal and malignant bladder urothe-lium, 4427
Glycyrrhetinic acidantitumor promotion by oleanane-type
triterpenoids12-0-tetradecanoylphorbol-13-acetate,
5210Gompertzian model
breast cancer growth, 7067Gonadotoxicity
cyclophosphamideluteinizing hormone-releasing hor
mone agonist, 2174Gonadotropin-releasing hormone
analogueoptimal medical castration, male rats,
6063partial prevention
germinal cell aplasia, procarbazine-in-duced, 4354
Granulocytesheat shock and differentiation
HL-60 cells, 6715incorporation of iododeoxyuridine into
DNAfluorodeoxyuridine modulation, 2933
maturationl\rosine phosphorylation in HL-60
cells, 52Granuloma
imeobaclcrmni induced infectiousXenopus, 958
Granulosa cell neoplasmsgenetics
dehydroepiandrosterone, 5092Granulosa cells
inhibition of thymidine uptakeLHRH agonist, 7252
Great Britaincancer in homozygotes and hétérozy
gotesataxia-telangiectasia, xeroderma pig-
mentosum, 2929Griseofulvin
effect on microtubulescell proliferation, 3T3 cells, 4892
Growth factorautocrine
lung carcinoma cell lines, 4976differential responsiveness
17/3-estradiol, breast cancer cells, 4083hemopoietic, 5624expression in mammary epithelial cells
oncogenes, 7041peptide
steroid hormones and c-fos expressionin breast cancer cells, 802
platelet-derivedret rovinii expression, transformed
cells, 4874stimulation of metastatic fibrosarcoma
transforming growth factor-/3, 6999Growth-inhibitory factor
low-molecular-weightcharacterization, V79 cells, 3737
Guaninemodulation of 6-thioguanine activity
HL-60 cells, 3648Guanine nucleotide-binding protein
identification in human neuroblastoma,2756
Guanosine triphosphateactivation of ornithine decarboxylase
human squamous cell carcinoma, 1252Guanylate
de novo synthesiscommitment to replication, hepatoma
3924A cells, 507Gynecological neoplasms
human chorionic gonadotropinnew marker, 1356
H
hCG: see Human chorionic gonadotropin11-2complex
¿V-ethyl-A'-nitrosourea-inducedtumori-genesis, 6634
Heartcardiotoxicity
acodazole hydrochloride, Phase I trial,4423
Heat shock protein synthesisdifferentiation and
HL-60 cells, 6715glutathione depletion
thermotolerance development, Chinesehamster ovary cells, 7033
premature chromosome condensationnuclear fragmentation, CHO cells,
6478suppression by glucose-deprived L929
cellsnucleoside restoration, heat resistance,
1442thermotolerance
bone marrow progenitors, 3630Height: see StaturelÃela cells
cepharanthine and lysosomal function,1307
intranucleolar localization of p 120, 6523mitochondrial DNA mutagenesis, 4578phorbol ester-induced <. delay
time lapse photography, 1759potentiation of Adriamycin cytotoxicity
dipyridamole, 1208scraped
optimal loading, nucleolar antibodies,
7424
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
5246Hematological malignancies
a-difluoromethylomithinemethylglyoxal bis(guanylhydrazone)
and, Phase I study, 1367Hematopoiesis
suppressionLAK cell fraction, 534
Hematopoietic cellssuppressor molecules
effects, purified granulocyte-macro-phage progenitor cells, 1548
Hematopoietic progenitor cellscell cycle effects
deferoxamine, 3571differentiation antigens
anti-K562 monoclonal antibodies,5759
Hematoporphyrin derivativephotodynamic effect
bladder tumor, 6115photosensitizing effects
plasma membrane enzymes, mammaryadenocarcinoma, 3360
Hematotoxicityantitumor activity of FK973, 1166
Hemeeffect on fate of DNA ligase activity
differentiating erythroleukemia cells,6278
Heme oxygenasep32 cDNA clone isolation, 4795
Hemin-induced cell protection
anthracyclines, 3566Hemodynamics
systemicblood flow, galactose injection, 1476
Hemoglobinbinding to fluoranthene
major adduct formation, characterization, 4756
Superoxide disunitasi-erythroleukemia maturation, 6674
Hemopoietic cellshemin-induced cell protection
anthracyclines, 3566Hemopoietic growth factors, 5624Hepatitis
non-A/non-Bhepatocellular carcinoma, 7294
Hepatitis B virusduck
geographical pathology, 1319influence of aflatoxin Bi, 1559
Hepatocarcinogenesischemical
cellular distribution, c-myc transcripts,5522
a-naphthoflavone influenceethinylestradiol metabolism, liver mi-
crosomes, 5460peroxisome proliferation and DNA syn
thesis, 6739plasma membrane polarity, 6882purification and characterization
glutathione 5-transferase-P, liver nodules, 2805
HepatocytescÃs-bis-neodecanoate-frans-/Ã,/Ã-1,2-dia-
minocyclohexaneplatinum (II)cellular pharmacology, 1300
ditercalinium accumulation in cytoplasmmitochondria! damage, 6542
DNA replicationunscheduled DNA synthesis in hepato-
cytes, 1618effects of butyrate
epidermal growth factor receptor binding, 6560
formation of 5-adenosylethioninechronic feeding of DL-ethionine, 4464
genotoxicity of W-nitroso compounds,4144
hybridsdifferential regulation, a,-fetoprotein,
6371initiation
continuous administration of diethyl-nitrosamine and 1,2-sym-dimethyl-hydrazine, 988
intercellular communicationkinetics, phénobarbitalinhibition,
2519invasiveness in monolayers
metastatic potential, T-cell hybrido-mas, 3405
metabolism of ALnitroso-Ar-methyl-(2-ox-opropyl)amine
Z and E isomers, 3347phenotypic properties of altered foci
hepatic tumors, 4171preneoplastic
lack of albumin as marker, albumin-positive liver, 387
rat ductular oval cellspromotion of growth, primary culture,
368tumor promoters
epidermal growth factor receptors,modulation, 1162
Hepatomaaldehyde dehydrogenase gene expression,
7009daunorubicin interaction
compromised DNA synthesis, 2404differentiated state
tumorigenicity, 3258dolichol kinase and phosphatase, 3418hepatocyte hybrids
differential regulation, «,-fetoprotein,6371
increased mannose-6-phosphatecathepsin D carbohydrate moiety, 362
Novikoffalterations in protein synthesis, 1554
nuclear proteinsisolation, monoclonal antibodies, 5495
selective accumulation3' ,5 '-dioctanoyl-5-fluoro-2 ' -deoxyuri-
dine prodrug, 4179thymidine incorporation
linoleic acid, arachidonic acid, 3106vitamin B,,metabolism
McA-RH7777 cells, 1080Hepatoma cells
commitment to replicationde novo guanylate synthesis, 507
energy substrate utilization, 602mitochondria! bound hexokinase, 913modulation of hormonal induction
tyrosine aminotransferase, glucocorti-coid receptors, 5188
rat ascitesfactor with antiinvasive potential in
liver, 3760role of folylpolyglutamate synthetase
methotrexate, 2426
Hepatotoxicitysaporin immunotoxins, 7072
Herbimycin-Aretinoic acid and
neuronal cell differentiation, neuroblastoma, 6530
reversal of transformed phenotypesire oncogene, rat fibroblasts, 1587
Herpes simplex virusinducible repair
xeroderma pigmentosum, 6054oncogenes of DNA tumor viruses, 493
Heterochromatinresistance to nickel(II) ions
characterization, mouse cell lines,6850
Hexamethylene bisacetamideheterogeneous responses
human colon carcinomas, 5487induction of differentiation
promyelocytic leukemia cells, 3613metabolism of
leukemic cells, 1712Phase I trial, 7304Superoxide dismutase
erythroleukemia maturation, 6674therapy by directing differentiation in
carcinoma, 1999Hexokinase
mitochondria! boundhepatoma cells, 913
l -Hexylcarbamoyl-5-fluorouracilcombined with hyperthermia
enhanced antitumor effects, Ehrlichascites tumor, 3977
Histamineantiestrogen binding site ligands
antiproliferative action, 3954L-Histidinol
5-fluorouracilmetabolism in a murine tumor system,
6664specificity, proliferation dependence,
1470Histone
variant synthesiscomparison, lymphocytic leukemia
and normal cells, 3670111.A complex
antigens in locoregional métastasesmelanoma, 1019
class II antigens in retinoblastoma, 1633dexamethasone and interferons
tumoricidal effects, human leukocytecell lines, 567
effect on U937 cell differentiationendogenous and exogenous interfer
ons, 82human a-interferon genes and pseudo-
genefunctional properties, proteins, 1763
111.-6(1leukemia cellsactin polymerization, 6721alteration in tyrosine kinase phosphoryl-
ationgranulocytic maturation, 52
l -ß-D-arabinofuranosylcytosineactivation
bromodeoxyuridine enhancement, 5175-hydroxymethyl-2 '-deoxyuridine, me
tabolism, 3117bryostatin 1-induced phosphor yhition
pattern mimicryphorbol ester, 5984
7425
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
chemotactic peptide-induced elevation ofcalcium
inhibition, phorbol 12-myristate 13-acetate, 2707
differentiationtiazofurin effects, protooncogene
expression, 5965heat shock and differentiation, 6715induction of differentiation
hexamethylene bisacetamide metabolites, 3613
inhibitory effects of prostaglandin Ac-myc expression, cell cycle progres
sion, 2813interferon interactions
halogenated pyrimidine antimetabo-lites, 4868
low molecular weight factorgrowth inhibition, myeloid leukemia
cells, 4201maturation
cell cycle changes, retinoic acid, 5989mechanisms of multidrug resistance,
3959membrane-bound lectin
monocytic maturation, 280mitogenic responsiveness
granulocyte-macrophage CSF, 2683modulation of 6-thioguanine activity
guanine, 3648phorbol ester-induced changes
topoisomerase II DNA cleavage, 6625phorbol ester-induced differentiation
thioether phospholipid effects, proteinkinase C, 6669
protooncogene expression, 6733role of protein kinase C
vinculin phosphorylation, 3324tyrosine kinase and phosphotyrosine
phosphatasebiochemical characterization, 4299
variantsdifferent activities, protein kinase C,
2744Hodgkin's disease
molecular pathways of adhesionspontaneous rosetting, T-cells, 37
T-cell receptor gene rearrangementsimmunoglobulins, 3591
therapy-related acute nonlymphocyticleukemia
O*-alkylguanine DNA alkyltransferase,
3084Homocysteine
patterns of methionine dependencetumor cells, 6775
Hormones-dependent and -independent tumors
antitumor effects, CGS 16949A, 834growth of Sinclair swine melanoma,
1708prediagnostic serum
risk of prostate cancer, 3515HTLV-I
adult T-cell leukemia andneutral glycolipid, monoclonal anti
body, 3148polyclonal lymphocytosis of T-cells,
2585seroepidemiology in Taiwan, 5042
Human chorionic gonadotropindevelopment of highly sensitive inumi
noassaysapplication to malignancies, 1361
free 0-subunit and /3-core fragmentmarker for gynecological cancers,
1356Hybridoma, T-cell
metastatic potentialinvasiveness, hepatocyte and fibroblast
monolayers, 3405Hybridomas
human-humanmonoclonal antibodies, breast cancer
patients, 3208Hydantoins
tumor promotioncytochrome P-450 induction, liver and
thyroid, 2492Hydralazine
glucose andpH modification, air or carbon dioxide
mixture, 1543Hydrocarbons
polycyclic aromaticalteration, cholesterol biosynthetic
pathways, 2555cytochrome P-450c and -450d, ventral
prostate and liver, 3045detection of DNA adducts in foundry
workers, 2288fluoranthene-hemoglobin adducts,
characterization, 47564-Hydroperoxycyclophosphamide
cytotoxicity for blast progenitorsacute myeloblastic leukemia, 2348
effect on hemopoietic progenitors, 1223Hydroxyalkylnitrosamines
carcinogenicityF344rats, 1533
/3-Hydroxybutyrateenergy substrate utilization
Morris hepatoma 7777 cells, 6020-(/9-Hydroxyethyl)-rutoside
protection from renal injury<»illumini m-d¡ehIdroplani! mud I), hy-
perthermia, 2239S-Hydroxymethyl-2'-deoxyuridine
mutagenicityChinese hamster cells, 5466
4-Hydroxy-jV-desmethyltamoxifenidentification as metabolite of tamoxifen
in human bile, 2304frani-4-Hydroxy-2-nonenal
1^-ethenodeoxyguanosine as markerDNA adduci formation, 3204-ci'j-Hydroxy-i .-proline
differential growth sensitivitytransformed rodent cell lines, 2483
3o-Hydroxysteroid-dihydrodiol dehydrogen-ase
oxidation of frans-3,4-dihydrodiol metabolites
7,12-dimethylbenz(a)anthracene, 1227Hydroxyurea
molecular mechanisms of drug resistanceribonucleotide reducÃase,2029
phenotypic changes in neoplastic cells,2440
-resistant leukemia I.I 2 Id cellscross-resistance patterns, 5796
transient exposureDNA replication, Syrian hamster cells,
6298Hypercalcemia
bone-resorbing activityinterleukin 1»,adult T-cell leukemia,
4284
Hyperglycemiablood flow and venous pH
Walker 256 carcinoma, 1201laser Doppler flow
murine tumors, 7102Hyperoxia
effects on growth characteristicsmetastatic lung tumors, 2779
Hyperplasiapreneoplastic
estrogen receptor complex, mouseLeydig cells, 14
Hypersensitivitydelayed-type
T-cells, effector cells in tumor rejection, 5922
Hyperthermiaacute pH 6.6 and 42.0°C
Chinese hamster ovary cells, 497bleomycin and
pH values, murine tumor cells, 615radiation, combination therapy devel
opment, 6291cell survival effects
protein synthesis patterns, endothelialcells, 2101
chronic pH 6.6 effectsChinese hamster ovary cells, 2417
combined with l-hexylcarbamoyl-5-fluo-rouracil
Ehrlich ascites tumor, Nakahara-Fu-kuoka sarcoma, 3977
cytotoxicityeffect, topoisomerase II inhibitors,
3932cú-diamminedichloroplatinum(II) and
protection from renal injury, o-(ß-hy-droxyethyl)-rutoside, 2239
rhodamine 1232, 2335squamous cell carcinoma line, 5101tumor growth delay, fibrosarcoma,
2693galactose effect on systemic hemody-
namicsblood flow rate, normal and tumor tis
sues, 1476glucose-deprived L929 cells
nucleoside-restored heat resistance,suppressed protein synthesis, 1442
glycosyltransferase activityChinese hamster ovary cells, 5717
hypoxia and acidosis effects on cytoxic-ity
platinum complexes, 2342irradiation and
lymphoblastic leukemia, 3576poly(ADP-ribose)
mechanism, metabolism alteration,4233
poly(ADP-ribose) glycohydrolase effect,4240
sensitizationnitrosourea-resistant Mer* tumor cells,
1086tumor necrosis factor and
synergistic effect, 650, 654whole body
advanced cancer, 6587cyclophosphamide, natural killer cell
activity, 4561c»-diamminedichloroplatinum(II),
renal injury, 440Hypoxia
development of combination therapies
7426
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
bleomycin, hyperthermia and radiation, 6291
effect on cytotoxicityplatinum complexes, 2342
intracapillary o\> hemoglobintumor energy metabolism, 5440
kryptocyanine dye phototoxicitymitochondria, red cell membranes,
6794photodynamic therapy-induced
fluosol-DA (20%), carbogen breathing,3350
SR 4233 metabolismChinese hamster ovary cells, 5947
Hypoxie cellsmixed-function drugs
Mer cells, 798therapeutic attack
solid tumors, 775
I
ICRF-187effect of pretreatment
tolerated doxorubicin dose, 6918Idarubicin
monoclonal antibody conjugatesimmunochemotherapy, thymoma, 926
Phase I clinical trialchildren with refractory leukemia,
5348Ifosfamide
active metabolitescerebrospinal fluid penetration, 2113
Imidazole-induced tyrosinase expression
testosterone effect, B16 melanoma,3586
Immune complexesClq binding macromolecules
induction chemotherapy response,head and neck cancer, 5868
Immune responseCTL clone specific for stable antigen
LI210 cells, 6450enhancement by acrolein, 41mild immunodeficiency
papillomavirus-16, bladder carcinoma,7207
natural immunityinterleukin 2 effect, immunodeficiency
states, 6081restoration with new immunopotentiator
CL 259,763, cytolytic T-lymphocytes,2135
Immunityconcomitant
effector mechanism, murine plasmacy-toma, 1398
host effectors, isolation and reactivity,1153
Immunizationbacterial vaccines
muramyl peptides, tumor necrosis factor production, 5766
GMJIgG.i monoclonal antibody, inhibited
melanoma growth, 5680transfection with foreign gene
induction, immunogenic tumor variants, 2975
Immunochemotherapymurine thymoma
use of idarubicin mAb conjugates, 926Immunoconjugates
anti-CD5 radioimmunotoxinshuman tumors, nude mouse model.
7107anti-human CD3 monoclonal antibodies
endocytosis and degradation, T-cells,2249
daunorubicin-monoclonal antibodyacid-labile, compared to free drug,
6097increased antitumor effect
tumor necrosis factor, 3607monoclonal antibody-drug conjugates
dual label fluorescence technique,6211
Immunoelectronmicroscopyintranucleolar localization of p 120, 6523
Immunoglobulin Gdelivery of antibody and Fab fragments
osmotic blood-brain barrier disruption,4725
IgG2a monoclonal antibodymembrane sialoglycoprotein, small cell
lung carcinoma, 4318IgG3 monoclonal antibody
Tn antigen, blood group A antigen,4361
methotrexate conjugatenature of linkage, mode of action,
3330novel mouse monoclonal antibodies
reaction, mucinous type ovarian tumors, 4639
Immunoglobulin Mcarbohydrate epitope
human squamous lung cancer, 2125Immunoglobulins
gene rearrangement and immunopheno-type
clonal analysis, non-Hodgkin's lym-
phoma, 6272T-cell receptor gene rearrangements
Hodgkin's disease, 3591
Immunomodulationrecombinant murine and human tumor
necrosis factor, 544Immunoscintigraphy
gallium-labeled antibodiestumor targeting, drug-antibody conju
gates, 1189Immunotherapy
active specificmelanoma. Phase I trial, 5883
adoptivebrain tumors, LAK cells, 2047CTL activity, 7-interferon gene trans-
duction, 4730generation of antitumor effectors,
LAK cells, 3461interleukin 2, LAK cells, 4409, 5007OK-432, pantropic killer cells, 4163
biotechnology products in cancer therapy, 223
delayed-type hypersensitivity T-cellseffector cells, tumor rejection, 5922
establishment of childhood T-cell lym-phoma
growth in nude mice, 1312interleukin 2 and o-interferon
antitumor effects, hepatic métastases,5810
interleukin 2 and LAK cellsmalignant brain tumors, 5011
production of monoclonal antibodymesothelioma cell lines, 5228
synergistic antitumor effectsinterleukin 2, tumor necrosis factor-«,
4011Immunotoxins
antibody-ricin A chain conjugateendocytosis, intracellular routing,
3822anti-CD5 radioimmunotoxins
human tumors, nude mouse model,7107
enhancement of activityovarian and epidermoid carcinoma,
3919preparation with deglycosylated ricin A
chainhindered disulfide linkages, 6396
ricin A chainclinical trial evaluation, CD 19 and
CD22 antigens, 2610mediation, pulmonary métastasesre
duction, 3496monoclonal antibodies, 1119ricin and, kinetics of cell intoxication,
806tumor-reactive, pharmacokinetics,
2618, 2626ricin-monoclonal antibody conjugates
galactose binding activity, 4469inhibition, T-cell tumor growth, 4862
saporinhepatotoxicity, 7072
transplantation of non-T-leukemia cellstumor regression, 4673
Indium-Ill-labeled anti-melanoma monoclonal anti
body, 4417Indomethacin
augmented antitumor effecthuman interleukin la, 584
increased tumor radioresponse, 3008interleukin 2 and
cure of B16F10 melanoma lung metastasis, killer cells, 1072
prostaglandin productionpredictor for therapeutic response,
3002Inflammatory response
whole body protein turnover rateresting energy expenditure in cancer
patients, 2590Influenza virus
induction of immunogenic tumor variants
transfection, foreign gene, 2975Insulin
exogenousbody composition changes, cancer
cachexia, 2784-like growth factor 1
autocrine growth factor, lung carcinoma, 4976
membrane-associated phosphatidylinosi-tol kinase
mammary tumors, 6727phenotype and growth of melanomas
serum-free medium, 686Insulin-like growth factor I
autocrine mitogenic stimulationlung cancer cells, 3716
receptors in human breast cancer, 6429relation to steroid receptors in breast
cancer, 1343Insulin-like growth factor II
mRNA expression
7427
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
human breast cancer, 6691liver tumors, 6844
Insulin-like growth factorstwo types of receptors
human malignant glioma, 1233a-Interferon
A/D hybridseffect on tumor cell growth, 2366
human genes and pseudogenecoding, functional properties of pro
teins, 1763interleukin 2 and
antitumor effects, hepatic métastases,5810
ini rape-ritinu-aÃadministrationovarian cancer, 5853
modulationmajor histocompatibility antigens,
5818ar Interferon
escalating dose doxorubicin andPhase I trial, 2574
cr2a-Interferonaction in human mesothelioma xeno-
graftscw-diamminedichloroplatinum(II), mi
tomycin C, 64combined with a-difluoromethylorni-
thinePhase I study, 6584
a/j9-Interferoncombined with cyclophosphamide
response of P388 leukemia, 2329/9-Interferon
interleukin 2 andPhase I study, 3875
7-Interferonantiproliferative activity
tryptophan concentration, culture media, 346
circulating cytokines in metastatic cancerpatients
interleukin 2, LAK cells, 5864class II antigens in retinoblastoma, 1633clearance and distribution in mice, 2021cytotoxin release
bone marrow macrophages, 18081,25-dihydroxyvitamin 1), and
requirement of differentiative signals,interleukin 1 secretion, 1740
divergent dose-related effectscytotoxicity, human peripheral blood
monocytes, 1042effects of hematopoietic suppressor mol
eculesgranulocyte-macrophage progenitor
cells, 1548gene transduction
augmentation, CTL activity, 4730-mediated depression
hepatic cytochrome P-450 system,xanthine oxidase role, 2107
Phase II trialmonoclonal antibody CO 17-1A, colo-
rectal carcinoma, 2568synergy with tumor necrosis factor and
interleukin 2successful therapy, pulmonary métas
tases, 2245Interferons
comparisons of combinationsmurine B- and I cell lymphomas,
4196dexamethasone and
tumoricidal effects, human leukocytecell lines, 567
endogenous and exogenousdifferentiation, U937 cells, 82
-induced revenants of transformedmouse cells
transcriptional inhibition, I la-rav.5157
interactions with antimetabolitesadenocarcinoma 38, HL-60 cells, 4868
interleukin 2 andantitumor activity, syngeneic murine
tumors, 260immunoregulatory effects, glioma-spe-
cific CTL, 2981Interleukin 1
endothelial cell-derivedchemotactic activity, tumor cells, 7041
receptor bindingcell growth response correlation, 5455
reduction of myelotoxicityradioantibody-induced, 5403
secretion7-interferon, 1,25-dihydroxyvitamin
D.,, 1740Interleukin la
antitumor activitymurine solid tumors, 6011
augmented antitumor effectindomethacin, 584
production of bone-resorbing activityadult I cell leukemia cells in humans,
4284Interleukin 2
activated lymphocyteslysis, drug-resistant tumor cells, 2372
active specific chemoimmunotherapytransplantation antigen, cyclophospha
mide, 101antitumor and antiviral natural immu
nityimmunodeficiency states, 6081
characterization of circulating Leu I1'cells, 6597
clinical and immunological effectsrepetitive weekly cycles to cancer pa
tients, 2561combined effects of chemotherapy
pulmonary tumors in mice, 122continuous vs. bolus infusion
cardiopulmonary effects in sheep,2221
indomethacin andcure of B16F10 melanoma lung metas
tasis, killer cells, 1072-inducible killer cells
asci lie fluid, pleural effusions, 6321a-interferon and
antitumor effects, hepatic métastases,5810
/3-interferon andPhase I study, 3875
interferons andantitumor activity, syngeneic murine
tumors, 260immunoregulatory effects, glioma-spe-
cific T-lymphocytes, 2981LAK cells and
activity, 1965adoptive immunotherapy, 2047, 3461,
4409, 5007antitumor effect, antibody-dependent
cellular cytotoxicity, 1173characterization, cytotoxic granules.
4681circulating cytokines, metastatic can
cer, 5864cytolysis enhancement, increased
yields to cancer patients, 5696giant autofluorescent lymphocytes,
2184malignant brain tumors, 5011mechanism, endothelial injury, 5528monoclonal antibody, B16 melanoma
lung métastases,7140natural killer cells, tumor-infiltrating
lymphocytes, 1180rats, 878
local therapymammary tumors, various immuno-
genicities, 2193modulation
major histocompatibility antigens,5818
-stimulated lymphocytesmotility, tumoricidal activity, 3374
tumor-infiltrating lymphocytesrenal cell cancer, 206
tumor necrosis factor andactivation, cytotoxic lymphocytes, 788synergistic antitumor effects, 4011synergy with -y-interferon, pulmonary
métastases,2245Interleukin 3
review of hemopoietic growth factors,5624
Intestinebiomarkers of increased susceptibility
gastrointestinal neoplasms, cancer prevention, 235
bombesin-stimulated gastringastric cancer, 2296
A'-ethyl-Ar-nitrosourea-induced tumori-genesis, 6634
inhibition of 0-propiolactone-inducedneoplasia
4-mercaptobenzene, 2740restoration by polyethylene glycol
differentiation, colonie adenocarcinoma, 2498
significance of bacterial florainhibition, lung métastases,3031
lodobenzylguanidinecytotoxic effects
neuroblastoma cell lines, 2993lododeoxyuridine
incorporation into granulocyte DNAfluorodeoxyuridine modulation, 2933
IproplatinCM-dichloro-bis-isopropylamine plati-
num(II) metabolite, 3533Iron
Adriamycin andreappraisal of association, 5645
neuroblastoma viability and proliferationinhibition of deferoxamine, 7189
Irradiationcancer family syndrome and cell survival,
2579hyperthermia and
lymphoblastic leukemia, 3576incidence and nature of tumors
induction, Sprague-Dawley rats, 2451-induced inhibition of lung métastases
significance, bacterial flora, 3031-induced marker chromosomes
metastasizing murine tumors, 999inhibition of DNA damage repair
7428
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
2'-deoxycoformycin, chronic lympho-
cytic leukemia, 3981split low dosage total-body
curative effect, Friend virus complex,2399
X-ray combined with cu-diamminedi-chloroplatinum(II)
therapeutic gain, 3158Isoquinoline
peripheral-type benzodiazepine bindingglioma, diagnostic imaging, 5837
Italycomparative epidemiology of cancer,
7285
Japancancer of the prostate
case-control study, 1331case-control study of past history
nasal diseases, maxillary sinus cancer,1651
Jatropha curcasseed oil of
tumor promoter, 5800JB6 cells
transfer of pro gene transfectiontumor promoter-sensitive phenotype,
1195
K
Kallikreinglandular
prolactin, estrogen-induced pituitarytumors, 4158
Katacalcinmolecular forms
human medullary thyroid carcinoma,2412
K562 cellshematopoietic differentiation markers,
5759Keratinocytes
biosynthesis and secretion of laminin,5193
biphasic effects of TPAdown regulation, protein kinase C, 964
clonogenictwo-stage carcinogenesis, 6285
epidermalreversible induction, anchorage-inde
pendent growth, 1566growth modulation
transforming growth factors, 15968-methoxypsoralen-DNA photoadducts
flow cytometry, 7013oral
transforming growth factor-«,3130Keratins
13 and 16human breast epithelium, 5831
-like antigenmonoclonal antibodies, epithelial tu
mors, 4969sequential development of aneuploidy
skin papillomas, 3253subtypes
small cell lung cancer, 2724transcript ional control of gene expres
sionskin carcinogenesis, 3245
Ketoconazoleoptimal medical castration in male rats,
6063
KG-1 cellsphorbol ester-induced differentiation
thioether phospholipid effects, proteinkinase C, 6669
Kidneyclearance and distribution
•¿�y-interferonused in mice, 2021collagen chemoembolizationc/'j-diamminedichloroplatinum(II) and,
2446epithelial cells
epidermal growth factor, mitogenesis,4886
o-(/3-hydroxyethyl)-rutoside-mediatedprotection
r/.v-ilium mined ich loroplat in uin(l I) and
hyperthermia, 2239inhibition of estrogen-induced carcino
genesistamoxifen, 779
phosphoinositide turnoverserotonin as a major serum factor,
6697renal cell carcinoma
1,25-dihydroxyvitamin D, receptormeasurement, 2458
renal injuryci'i-diamminedichloroplatinum(II),
whole body hyperthermia, 440renal proximal tubule cells
cu-diamminedichloroplatinum(II),2538
Kidney neoplasmsactivated H-ras oncogenes, 5251estradiol-induced
biochemical analysis of development,971
estrogen-induceddrug metabolism enzymes, 5726
estrogen-sensitive proliferation pattern,3676
increased levelsfibroblast growth factor-like activity,
2083Killer cells
interleukin 2-inducibleascitic fluid, pleural effusions, 6321
metastasis cureindomethacin plus interleukin 2, 1072
pan tropicadoptive immunotherapy, OK-432,
4163Kryptocyanine dye
phototoxicitymitochondria, red cell membranes,
6794Kupffer cells
CM-bis-neodecanoato-frani-Ä,/?-1,2-dia-minocyclohexaneplatinum (II)
cellular pharmacology, 1300
Lactatemetabolism in vivo
human breast cancer xenografts, 7264Lactation
risk factor for breast cancerChinese women in Shanghai, 1949
Lactoneimmunization
IgGj monoclonal antibody, inhibitedmelanoma growth, 5680
Lactoneotetraosylceramidedetection of patients with cancer
monoclonal antibody, 1512Lacto/V-fucopentaose II: see CA 19-9LAK cells
adoptive immunotherapybrain neoplasms, 2047generation, antitumor effectors, 3461pantropic killer cells, OK-432, 4163
alteration of activitymanipulation, protein kinase C and cy-
tosolic calcium, 635antitumor effect
antibody-dependent cellular cytotoxic-ity, 1173
cell fractionsuppression, hematopoiesis, 534
enhancement of cytolysisincreased yields to cancer patients,
5696fibrin coagulation
protection against cytotoxic cells,5216
generation and antitumor activityglioblastoma, 6069
injury of human endothelium, 5528interleukin 2 and
adoptive immunotherapy, 4409, 5007circulating cytokines, metastatic can
cer, 5864generation of cytotoxicity, tumor ne
crosis factor, 788induction of activity, 1965malignant brain tumors, 5011monoclonal antibody, B16 melanoma
lung métastases,7140natural immunity, 6081tumor-infiltrating lymphocytes, 1180
isolation and characterizationcytotoxic granules, 4681
progenitor and effector phenotyperelationship to natural killer cells in
rats, 884selection of effectors
recycling intermediates, light-scattering properties, 2184
tissue and strain distributionontogeny in rats, 878
Lambert-Eaton myasthéniesyndromeantagonism of voltage-gated calcium
channels«j-conotoxin,small cell carcinoma,
4719Laminin
biosynthesis and secretioncultured human keratinocytes, 5193
colon-derived substrata materialeffect on colon carcinoma cell line,
2825-dependent and -independent adhesion
sulfatides, melanoma cells, 3367induction of carcinoembryonic antigen
secretiontransforming growth factor-/3, colon
carcinoma, 4059Laryngeal neoplasms
occupational risk factors on the TexasGulf Coast, 1960
Laser Doppler flowhyperglycemia in murine tumors, 7102
L929 cellsglucose-deprived
nucleoside-restored heat resistance,suppressed protein synthesis, 1442
I 12111cells: see also Leukemia, 1.12111CTL clone specific for stable antigen,
7429
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
6450cyclophosphamide-resistant
characterization of cytosolic aldehydedehydrogenase, 2963
cytokinetic effects of methotrexate, 4288DNA cross-linking by FK973, 5172DNA damage and cell kill
9-aminoacridines, 860DNA-directed actions of 3-deazaguanine,
2774effect of thymidine
nitrosourea activity, 4272hydroxyurea-resistant
cross-resistance patterns, 5796intracellular biotransformation of plati
num compounds1,2-diaminocyclohexane carrier ligand,
5136methotrexate effects
methylenetetrahydrofolate depletion,3398
methotrexate transport, 5995production of protein-associated DNA
breaks by PZE, 1404properties of resistant cells
a-difluoromethylornithine, 2678Lead chromate
mutagenesis in mouse embryo cells,5280
Lectins-binding proteins
nuclear preparations, rat liver and malignant tumors, 551
galactoside-bindingshared sequence homology, 645
monocytic maturationHL-60 cells, 280
Lentinandenaturation and renaturation
expression, T-cell-mediated responses,671
Leu 19* cells
appearance and phenotypic characterization
interleukin 2 treatments, 6597I-cucine
altered metabolismnoncachectic sarcoma patients, 1374
Leucovorin5-fluorouracil and
disseminated cancer treatment, pancreas, 5570
Leucovorin-5-fluoropyrimidineincreased levels of DNA lesions
colon adenocarcinoma, 4153Leukemia
acute nonlymphocyticpoint mutation, ras protooncogenes,
1812antitumor activity of quinocarmycin,
60298-deaza analogues of methotrexate and
aminopterincytotoxicity, polyglutamate formation,
1481doxycycline in combination chemother
apy, 6686Phase I evaluation
esorubicin, 5580proliferation-dependent cytotoxicity
methotrexate, 5638refractory
Phase I pediatrie trial, 4-demethoxy-daunorubicin, 5348
significancealtered a-2-i.-fucosyltransferase levels,
3998site-specific analysis of total serum cho
lesterolincident cancer, National Health and
Nutrition Examination Survey, 452Leukemia, B-cell
lipopolysaccharide-activatedglucocorticoid effects, lipid lateral dif
fusion, 59Leukemia, I 12III: see also L1210 cells
(II clone specific for stable antigen,6450
polyamine uptake deficiencycurative effect, DL-2-difluoromethylor-
nithine, 4807resistance to ribonucleotide reducÃasein
hibitors, 839Leukemia, lymphoblastic
acutegrowth requirements, clonogenic as
say, 5901molecular heterogeneity, 866Philadelphia chromosome-positive,
2876radiobiological features, bone marrow
progenitor cells, 5788vincristine, methotrexate and other
agents, 351association of DNA ligase deficiency
I cell acute leukemia, 4038childhood acute
involvement, bovine leukemia virus,2919
interactionshyperthermia, irradiation, 3576
Leukemia, lymphocyticchronic
abnormal blood monocytes, 4812B-cells, distribution of doxorubicin
metabolites, 503DNA interaction of melphalan, 1972inhibited DNA damage repair, 2'-de-
oxycoformycin, 3981compared to normal lymphocytes
historic variant synthesis, 3670Leukemia, lymphoid
acuteautocrine production, malignant pre-B
cells, 6438Leukemia, myeloblastic
acuteblast progenitors, 4-hydroperoxycyclo-
phosphamide, 2348differentiation-induced MI.-1 cells
transformation, carcinogen target,4389
Leukemia, myelocyticPh-positive
sister chromatid exchange, normalbone marrow, 745
Leukemia, myelogenouscell line establishment
megakaryoblastic crisis, 6137chronic
discordant maturation, primary biological defect, 1035
Leukemia, myeloidcell cycle changes in maturing HL-60
cells, 5989chronic
sister chromatid exchange, busulfan,3435
Leukemia, nonlymphocyticacute
C^-alkylguanine DNA alkyltransferase,3084
Leukemia, P388antitumor activity of MX2
murine tumor cells, 6653mull ¡factorialresistance to Adriamycin,
3595reversal of resistance to vincristine
quinacrine, 2064schedule-dependent response variations
cyclophosphamide, a//3-interferon,2329
Leukemia, T-cellacute
DNA ligase deficiency, 4038adult
bone-resorbing activity, interleukin la,4284
neutral glycolipid, monoclonal antibody, 3148
history, 4131tyrosine kinase YT16 expression, 856
Leukemia cellsAbelson virus-infected promonocytic
viral oncogene expression, 1702acute myeloblastic
growth potentiating factors, aiuologous blast cells, 6424
CCRF-CEMantileukemia agents, nuclear matrix-
bound DNA replication, 1850DNA cross-linking
influence of WR2721, nitrogen mustard, 6002
glucocorticoid receptor at protein level,2636
growth-promoting activitydesmopressin, 7055
inactivation of O^-alkylguanine-DNA al
kyltransferasenitrosourea potentiation, 1521
metabolism of hexamethylene bisacetam-ide, 1712
microtubule changes and cytotoxicity oftaxol, 4093
modulation of arabinonucleoside metabolism
arabinosylnucleotides, 329multidrug-resistant cell line
cytogenetic and molecular characterization, 393
murineaccumulation, ci's-diamminedichloro-
platinum(II) and platinum analogues, 9
myeloidlow molecular weight factor, differen
tiation and growth, 4201non-T-cell
anti-human immunotoxins, 4673phorbol ester-induced changes
topoisomerase II DNA cleavage, 6625phorbol ester-treated promonocytic
alteration, fibronectin receptors, 5730promyelocytic
1-jS-D-arabinofuranosylcytosine, 5-hy-droxymethyl-2'-deoxyuridine, 3117
resistance to drug-induced DNA cleavagelow levels, DNA topoisomerase II,
3537Leukemia virus
bovine
7430
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
childhood acute lymphoblastic leukemia, non-Hodgkin's lymphoma,
2919Leukocytes
DNA damagebenoxaprofen and phagocytes, 3094
tumoricidal effectsdexamethasone and interferons, 567
Lewis lung carcinoma tumorfibrinogen influx and accumulation
cross-linked fibrin, 1920growth and metastasis
1-/3-n-arabinofuranosylcytosine conjugates, lipids, 826
loss of factor X activator capabilitiesvitamin K, 6504
tumor-induced myelopoiesisregulation, prostaglandin I, 6826
Leydig cellsestrogen interactions
intracellular receptor complex, preneo-plastic hyperplasia, 14
Li-Fraumeni syndromecancer families
susceptibility to neoplasia, 5381cancer family syndrome in twenty-four
kindreds, 5358Ligands
antiestrogen binding siteantiproliferative action, 3954
bromine-SOm-labeled estrogenstherapy, ER-positive cancers, 899
LigaseDNA deficiency
association with I cell acute leukemia,4038
Light-induced DNA damage
4,5',8-trimethylpsoralen, Fanconi's
anemia, 2015Linoleic acid
arachidonic acid andthymidine incorporation, hepatoma,
3106effect of dietary eicosapentaenoic acid
azoymethane-induced colon carcino-genesis, 4790
Lipidsactivation of macrophages
alkylglycerols, cancerous tissues, 60441-/3-D-arabinofuranosylcytosine conju
gatesgrowth and metastasis, Lewis lung car
cinoma, 826Lipiodol
accumulation of 3',5'-dioctanoyl-5-flu-oro-2'-deoxyuridine prodrug
hepatoma, 4179Lipopolysaccharidc
-activated B-cell leukemia 1 cellsglucocorticoid effects, lipid lateral dif
fusion, 59production of tumor necrosis factor
mnraim I peptides, bacterial vaccines,5766
Liposomes-based therapy
human ovarian cancer, 5237entrapment of c/s-bis-neodecanoato-
frans-Ä,Ä-l,2-diaminocyclohex-aneplatinum(ll)
cu-diamminedichloroplatinum(II)cy-totoxicity, 4509
encapsulated Adriamycin
alterations, murine host defense functions, 130
-encapsulated immunomodulatorsAdriamycin therapy, monocyte activa
tion, 52568-Lipoxygenase
phorbol ester inductioncomparison, SENCAR and C57BL/6J
mice, 658Liver
albumin-positivelack of albumin as marker, preneoplas-
tic hepatocytes, 387biliary epithelial and hepatocytic cell
linesrelationships in embryonic rat liver,
4909biliary metabolites of fluoropyrimidines,
20105-bromo-2 '-deoxyuridine incorporation
pharmacodynamics, VX-2 tumors,6900
carcinogenesiscytochrome P-450 induction, hydan-
toins, 2492collagen chemoembolization
m-diamminedichloroplatinum(II),2446
cytochrome P-450 systeminterferon-mediated depression, xan-
thine oxidase role, 2107depletion of adenosine diphosphate-ribo-
syl transferaseexposure, /V-2-acetylaminofluorene,
3581differential expression
cytochrome P-450c and -450d genes,3045
DNA cyanoethylation3-(methylnitrosoamino)propionitrile,
6780duck
hepatitis B virus, geographical pathology, 1319
effect of aflatoxin Bglucocorticoid receptors, tyrosine ami-
notransferase, 5188effects of steroids
structure-activity studies, 2462elimination of 5-fluoro-2'-deoxyuridine,
3561epithelial cells
transforming growth factors, 850epithelial cell lines
chromium effects, transformation,6484
epoxide-metabolizing enzymeseffects of inducers, 1390
/V-ethyl-yV-nitrosourea-induced tumorigenesis, 6634
factor with antiinvasive potentialrat ascites hepatoma cells, 3760
formation of 5-adenosylethioninechronic feeding of Di.-ethionine, 4464
hepatocellular carcinomain vitro translation analysis, 2382
hydroxy metabolites of methyl-n-amylni-trosamine, 5663
lack of DNA bindingmethapyrilene, 6475
late target proteinW-2-fluorenylacetamide, 6745
métastasesantitumor effects, interleukin 2 and .••
interferon, 5810mono- and bifunctional enzyme inducers,
4776normal and preneoplastic nodules
purification, glutathione S-transferase-P, 2805
nuclear preparationslectin-binding proteins, 551
organ cell specificityDNA mei IHlatimi, A'-nitrosomethyla-
mylamine, 5482peroxisomal /3-oxidation mRNAs in rat
tissues, 5316peroxisome proliferation and DNA syn
thesis in hepatocarcinogenesis, 6739preneoplastic
carbohydrate-metabolizing enzymes,profiles, 467
putative premalignant hepatic nodulesDNA adducts, 2-acetylaminofluorene
carcinogenesis, 5270rat model
etoposide metabolism and excretion,5692
regenerationphénobarbitaltreatment, cellular onco-
genes, 265specificity of cytochrome P-450 isozymes
metabolic activation, 2-amino-3-meth-ylimidazo[4,5-/]quinoline, 4513
tumor promotersepidermal growth factor receptor mod
ulation, 1162Liver microsomes
benzene-inducible cytochrome P-450,5387
inactivation of 4-methyl-5-amino-1 -for-mylisoquinoline thiosemicarbazone
inhibitor of ribonucleotide reducÃase,6375
metabolism of /V-nitrosodialkylamines,1499
tt-naphthoflavone influenceethinylestradiol metabolism, 5460
nitrosamine metabolismdiallyl sulfide effect, 5937
yV-nitrosopyrrolidine «-hydroxylaseactivity
reconstitution, 3987oxidative metabolism of 1-nitropyrene
cytochrome P-450 isozymes, 4261Liver neoplasms
comparative propertiesaltered hepatocyte foci, 4171
dose response study with jV-nitrosomor-pholine, 2089
7-glutamyltranspeptidasec-raf protooncogene expression, gap
junction protein, 1610glutathione-S'-transferase P mRNA
expression, peroxisome prolifera-tors, 4919
insulin-like growth factor II mRNAexpression, 6844
LLC-PK, cellsmodel for cisplatin nephrotoxicity
ihin! rescue agents, 6017Lonidamine
whole body hyperthermia in advancedcancer, 6587
Louisianacase-control study of diet and mesotheli-
oma, 2911L3T4* cells
7431
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
polycythemia-inducing strain of Friendvirus
curative effect, irradiation, 2399Lung
activation and DNA alkylation4-(/V-methyl-yV-nitrosamino)-1 -(3-pyri-
dyl)-l-butanone, 4215B16 melanoma métastases
LAK cells, interleukin 2 and mAb,7140
cardiopulmonary effectsinterleukin 2 infusion, continuous vs.
bolus, 2221developing
stage-specific expression of SSEA-1-related antigens in, 7150
yV-ethyl-yV-nitrosourea-induced tumori-genesis, 6634
irradiation-induced inhibition of métastases
significance of bacterial flora, 3031Kirsten-roj oncogene
clonal diversity, 4941metastasis
cure, indomethacin plus IL-2, 1072synergism of -y-interferon, TNF and
interleukin 2, 2245tissue inhibitor of metalloproteinases,
melanoma cells, 5539small cell cancer
characterization of cell lines, 6891timing of chemotherapy and surgery
murine osteosarcoma model, 5533tobacco-related tumors, 6912tumor tissue and
prntik's. prostaglandin biosynthesis,3140
Lung cellsChinese hamster
sister chromatid exchanges, antitumortopoisomerase II inhibitors, 512
Lung neoplasmsautocrine mitogenic stimulation
somatomedin-C/insulin-like growthfactor I, 3716
cancer in migrants to Australia, 751cancer morbidity and mortality among
phosphate workers, 7298colony formation
monoclonal antibodies, capillary endo-thelial cells, 4964
comparison of intrathoracic models,2880
cytokeratinschain-specific monoclonal antibodies,
3221estramustine-binding associated protein,
4615expression of a-amylase, 3292incidence by histológica!type
population-based registry, 6580induction of tumoricidal activity
alveolar macrophages, monocytes,3949
long-lasting effects of tobacco smokingpulmonary drug-metabolizing en
zymes, 4695malignancy
activity of cytosolic isozyme, thymi-dine kinase, 5001
metastaticeffects of hyperoxia, growth character
istics, 2779non-small cell
antibody-guided targeting, 1977epidermal growth factor receptor
expression, 1132neuroendocrine markers, 4078prostaglandin biosynthesis, 4770
papillaryA'-nitrosoethylurea-induced, cell ori
gin, 148personal and family history
risk factors, adenocarcinoma, 7279selective growth inhibition
gpl60, radioimmunotherapy, 2768site-specific analysis of total serum cho
lesterolincident cancer, National Health and
Nutrition Examination Survey, 452small cell
combined modality treatment, thymo-sin fraction V, 1663
epidermal growth factor receptorexpression, 1132
growth, bombesin antagonists, 4783longitudinal follow-up, 6891keratin subtypes, 2724myc family, DNA amplification, 5163
small cell neuroendocrine carcinomaspecificity, monoclonal antibody, 7319
smoking andwomen, 6951
squamouscarbohydrate epitope, 2125
SSEA-1-related antigensdeveloping human embryos, 7150
tumor size and morphologygestational development in the mouse,
379whole body protein turnover rate
resting energy expenditure, cancer patients, 2590
xenotransplantabilitymyc family gene abnormality, 6025
Luria-Delbruck fluctuation analysispitfalls and practice, 1060
Luteinizing hormoneoptimal medical castration in male rats,
6063Luteinizing hormone-releasing hormone ag
onistgonadotoxicity of cyclophosphamide,
2174inhibition of thymidine uptake, 7252
Lymnaea stagnali!model for testing
neurotoxic side-effects. Vinca alkaloids, 7184
Lymph nodesbreast cancer survival model, 5565fusion of lymphocytes
human-human hybridomas, breast cancer patients, 3208
metastasis of mammary adenocarcinomasoybean agglutinin binding cells, 1451
natural killer cell cytotoxicityhead and neck cancer, 5017
Lymphoblastoid cellstrimetrexate transport
lypophilic antifolates, 6986Lymphoblasts
inhibition of DNA damage repair2'-deoxycoformycin, chronic lympho-
cytic leukemia, 3981L5178Y murine
characterization, resistance to quinoneantitumor agents, 1727
T-celleffect of gallium, DNA synthesis, 3014
Lymphocytesactivated
lysis, drug-resistant tumor cells, 2372antibodies against 7-methyldeoxyguano-
sine, 5065clinical and immunological effects
interleukin 2 in repetitive weeklycycles, 2561
comparison of histone variant synthesislymphocytic leukemia cells, 3670
elevated sister chromatid exchangesethylene oxide-exposed primates, 5045
giant autofluorescentLAK cells as subset, 2184
human and mousesister chromatid exchange induction,
diaziquone, 27interleukin-2-stimulated
motility, tumoricidal activity, 3374intraperitoneal a-interferon administra
tionovarian cancer, 5853
lymph nodehuman-human hybridomas, breast can
cer patients, 3208macrophage potentiation and
host and tumor cell collagenolytic activity, 6832
regeneration of O'-alkylguanine-DNA al-
kyltransferasenitrosourea exposure, 5368
resistance to drug-induced DNA cleavagelow levels, DNA topoisomerase II,
3537role of metabolism and DNA adduct for
mationsister chromatid exchange, diethylstil-
bestrol, 335transferrin-like autocrine growth factor
T-lymphoma cells, normal T-cell proliferation, 3425
tumor-infiltratinganalysis of lymphoid infiltrates, glio-
blastoma, 6926depressed CD8+ responses, 6992
effects of interleukin 2, NK and LAKcells, 1180
interleukin 2, renal cell cancer, 206Lymphocytosis
polyclonalT-cells, human T-cell leukemia virus I,
2585Lymphoid cells
analysis of lymphoid infiltratesglioblastoma, 6926
Lymphokine-activated killer cells: see LAKcells
Lymphokinesbiotechnology products in cancer ther
apy, 223suppressor produced by T-cells
mammary adenocarcinoma, 943synergism of -y-interferon with TNF and
IL 2successful therapy, pulmonary métas
tases, 2245Lymphoma cells
cell cycle and glutathione statuseffects, /V-methylformamide, 3389
Lymphomasantitumor activity of quinocarmycin,
6029
7432
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
B-cellcomparisons, combinations of interfer
ons, 4196xenogeneic tumor model, radioiodine-
labeled monoclonal antibodies, 2475incidence and nature of tumors
•¿�»•-irradiation,Sprague-Dawley rats,2451
large cellchromosome abnormalities, 5557nucleic acid flew cytometry, 6614
murinetumorigenicity, fluorescent cell sort
ing, 270non-Hodgkin's
clonal analysis, Ig gene rearrangement,6272
DNA content, proliferative activity,6608
involvement, bovine leukemia virus,2919
S49 wild type and eye"
tumorigenicity, adenylate cyclase, 641T-cell
amplification, c-myc oncogene, 4959comparisons, combinations of interfer
ons, 4196history of, 4131human, growth in nude mice, 1312
therapy-related acute nonlymphocyticleukemia
C^-alkylguanine DNA alkyltransferase,3084
thy miestages of, ras oncogenes, 5514
LymphosarcomaXenopus
transplantation studies, 954Lymphotoxin
distinctionnatural killer cell cytotoxic factor, tu
mor necrosis factor, 891gene expression
tumor necrosis factor, human tumorcell lines, 5417
Lynch syndromereduced genomic 5-methylcytosine con
tenthuman colonie neoplasia, 1159
Lysisdrug-resistant tumor cells
activated lymphocytes, 2372Lysosomes
intrinsic drug resistancepossible link, detoxification mecha
nism, 3025methotrexate conjugate with antitumor
antibodiesnature of linkage, mode of action,
3330milk fat globule membrane-associated
antigenendocytosis of monoclonal antibody,
MCF-7 cells, 3188Lyt-2* cells
importance in tumor rejection, 4834polycythemia-inducing strain of Friend
viruscurative effect, irradiation, 2399
M
Macromoleculesheterogeneous distribution
monoclonal antibodies, interstitial
pressure, 7022Macrophages
activationrole of tumor necrosis factor, tumori-
cidal activity, 5427activation by alkylglycerols, 6044alterations in murine host defense func
tionsAdriamycin or liposome-encapsulated
Adriamycin, 130alveolar
tumoricidal activity, lung cancer, 3949attached effector cells
antibody-mediated killing, human tumor cells, 624
c/5-bis-neodecanoato-Ãra/ii-A,/?-1,2-dia-minocyclohexaneplatinum (II)
cellular pharmacology, 1300bone marrow
cytotoxin release, -y-interferon, 1808effect of «A/D-interferon
tumor cell growth, 2366function of
clinical trial, tumor necrosis factor,5604
lymphocyte potentiation andhost and tumor cell collagenolytic ac
tivity, 6832tumor-infiltrating
detection by inAh. monosialoganglio-side, 2524
Magnesium-ATPasephotosensitizing effects
hematoporphyrin derivative, mammary adenocarcinoma, 3360
Magnetic resonance spectroscopyglucose metabolism
breast cancer cells, 870metalloporphyrin enhancement
human tumor xenografts, 4604Major histocompatibility complex
antigen modulation by cytokines, 5818class I
epithelial-like markers, mammary carcinoma, 7237
retrovirus transformation, rat celllines, 3816
class IIabnormal blood monocytes, chronic
lymphocytic leukemia, 4812retinoblastoma, 1633
effect on U937 cell differentiationendogenous and exogenous interfer
ons, 82A'-ethyl-A'-nitrosourea-induced tumori-
genesis, 6634Malignancy
activity of cytosolic isozymethymidine kinase, lung tumors, 5001
cell fusion, 3302cell kinetics
bromodeoxyuridine, flow cytometry,6238
Cora antigen expressiongastrointestinal epithelia, 2198
stages of gliomaclonal genomic alterations, 5546
Malignant cellstherapy by directing differentiation in
carcinoma, 1996Mammalian cells
bacteria andmutagenicity, CC-1065 and analogues,
32
DNA topoisomerase Idrug target, camptothecin, 1722
low-molecular-weight growth inhibitorcharacterization, 3737
molecular mechanisms of drug resistanceribonucleotide reducÃase,2029
resistance of noncycling cells to amsa-crine, 310
Mammary glandscarcinomatous and normal development
influence of caffeine consumption,2078
DNA alkylationestrous cycle modification, W-methyl-
A^-nitrosourea, 3090epithelial cells
DNA repair, arylamine metabolites,4227
epoxide-metabolizing enzymeseffects of inducers, 1390
hyperplastic alveolar nodulestransplantation, gland-free fat pads,
3197intervention of T-cells in transportation
mouse mammary tumor virus, 6555tumorigenesis
influence of caffeine, unsaturated fat,2074
influence of caffeine, coffee consumption, 2068
Mammary neoplasms7,12-dimethy lbenz(a)anthracene-induced
dietary flavonol quercetin, 5754DNA ploidy
flow cytometric analysis, 3411effect of exercise
induction of carcinogenesis, 2720fibrosarcoma growth
glucocorticoid-induced alterations,7212
mast cellsprolactin, binding and characteriza
tion, 3765membrane-associated phosphatidylinosi-
tol kinaseinsulin effects, 6727
mixed heterogeneousdominance, tumor subpopulation,
5747modulation of mitomycin C cytotoxicity
dicoumarol, 54711-nitropyrene derivatives and 1-amino-
pyrenecarcinogenic activities, 4256
yV-nitrosourea-induced tumorigenesiscalorie restriction and exercise, dietary
fat, 4276rat model for locally recurring tumors
sensitivity, chemotherapy and X-rays,4549
reconstitution of site preference, 3698response to endocrine therapy
NMR spectroscopy, rat tumors, 89tumorigenesis
adrenal regulation, 3801, 3808various immunogenicities
local interleukin 2 therapy, 2193Mammary serum antigen
detection in seramonoclonal antibody, breast cancer
patients, 7060Mammary tumor virus
intervention of T-cells in transportationmammary gland cells, 6555
7433
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
Mannitolrole of hypovolemic hemoconcentration
in flow decline, 7102Mannose-6-phosphate
elevated activitycathepsin D carbohydrate moiety, hu
man hepatoma, 362Mass spectrometry
pharmacokinetics of 5-fluorouracil, 6956Mast cells
mammary' tumorprolactin, binding and characteriza
tion, 3765McA-RH7777 cells
vitamin H. metabolism, 1080MCF-7 cells
endocytosis of monoclonal antibody,3188
estrogen action of 2-phenylindole derivatives, 784
inhibition of cell growthTPA and 1,2-dioctanoyl-sn-glycerol,
protein kinase C, 6943proliferation effects of melatonin, 6121regulation of growth and invasiveness
antiestrogens, 6764tamoxifen-stimulated growth
long-term antiestrogen administration,5183
VP-16-induced DNA strand breaksmechanism of action, 5096
Medroxyprogesterone acetateproliferation and cell cycle kinetics
mammary carcinoma cells, 5084Medulloblastoma
antiproliferative effect of verapamil,3617
chemotherapybifunctional alkylating agents, 4189
melphalan transportglutathione levels, glutathione-S trans-
ferase, 5397Megakaryopoiesis
cell line establishmentchronic myelogenous leukemia, 6137
Melanocytesidentification
secreted M, glycoprotein, 1286Melanoma
activated ras genesdetection of low frequency genes, tu-
morigenicity assay, 950active specific immunotherapy
Phase I trial, 5883anionic form of glutathione transferase
presence in human tumors and celllines, 527
antibody-mediated killingattached effector cells, 624
-associated gangliosidesfish genus Xiphophorus, 3454
cancer in migrants to Australia, 751cell deformability and metastatic poten
tialcorrelation, 5124
cell surface cathepsin B-like activityidentification, butanol extraction,
1416cure of lung metastasis
indomethacin plus 112. killer cells,1072
cutaneoushistology, 5036
detection of monosialoganglioside
monoclonal antibody, tumor-infiltrating macrophages, 2524
early stages of tumor progressionmolecular cloning, ME491 antigen,
2955effect of ultraviolet-B radiation
cell growth, 4007effects of estradiol
estrogen and progesterone receptors,tyrosinase, 3720
estrogen receptor-positive170-estradiol effect on growth, 7093
hamsterinfluence of retinoids on growth, 1465
hereditary cutaneous malignantcell sensitivity, 4-nitroquinoline 1-ox-
ide, 5145highly pigmented variant
metastasis, skin and brain, 4897HLA antigens
locoregional métastases,1019human malignant
cytotoxicity, catechol analogues, 5178identification
secreted M, glycoprotein, 1286immune system of cancer patients
low dose cyclophosphamide, 1671indium-111-labeled anti-melanoma mon
oclonal antibodysaturable clearance mechanisms, 4417
inhibited growthIgGi monoclonal antibody, GM1lac-
tone immunization, 5680interaction with murine mesentery, 5296M, 97,000 to 250,000 protein antigen
concentrations, autoradiography. 5475metastatic murine
pigmentation, influence of organ mlcroenvironment, 2258
multiceli spheroidsuptake kinetics, monoclonal anti
bodies, 1856multiple primary
association with dysplastic nevi, 1016murine
boron neutron capture therapy, 6313phenotype and growth
serum-free medium, 686progressive growth of fish tumors
transplantation, thymic-aplastic mice,741
retrovirus-associated antigenexpression, modulation, 4954
Sinclair swinegrowth as function of variables, 1708
site-specific brain metastasis, 3478thrombospondin binding
sulfated glycoconjugates, 6785tumor-specific metastasis, 4382wheat germ agglutinin-resistant
metastatic profiles, nude mice, 665Melanoma-associated antigen
molecular cloning of ME491early stages, melanoma tumor progres
sion, 2955mouse-specific epitope
metastatic ability, monoclonal antibody, 7173
recognitionLyt-2" and L3T4~ cytotoxic T-lym-
phocytes, 2730Melanoma cells
adhesion to sulfatideslaminin, 3367
bifunctional DNA-reactive cytostaticdrugs
cytotoxicity, D,L-buthionine-5,/î-sul-foximine cells, 19
chromatinnerve growth factor receptors, colorec-
tal carcinoma, 7200multidrug-resistant
decreased drug accumulation, 6348murine
modulation of metastatic potential,urokinase, 1270
Melanoma cells, B16adhesive cell variant
loss of metastatic responsiveness, cellshape modulation, 1258
effect of testosteroneimidazole-induced tyrosinase expres
sion, 3586effects of folate deficiency
metastatic potential, 4529heat-induced vascular damage
thermosensitivity, 7226lung métastases
LAK cells, interleukin 2 and mAb,7140
Melatoninproliferation effects
breast cancer cells, 6121Melphalan
D,i.-buthionine-S',/?-sulfoximine effect
cytotoxicity, human melanoma cells,19
chemosensitization by misonidazole,3528
effect of alkylating agent doseclinical correlation, 6417
enhanced cytotoxicityglutathione depletion, medulloblas-
toma xenograft, 2764resistance to nitrogen mustards
chronic lymphocytic leukemia, 1972transport in medulloblastoma
glutathione levels, glutathione-5-trans-ferase, 5397
unexpected toxicityuse of body surface for dosing in dogs,
288Meninges
site-specific brain metastasismelanoma and fibrosarcoma, 3478
4-Mercaptobenzeneinhibition of /3-propiolactone-induced
neoplasiaforestomach, large bowel, 2740
Mesenteryinteraction with B16 malignant mela
noma tumor cells, 5296Mesothelioma
anionic form of glutathione transferasepresence in human tumors and cell
lines, 527asbestos-induced
chromosome translocations, specificbreakpoints, 6455
diet andcase-control study in Louisiana, 2911
human malignantnonrandom chromosome alterations,
142human xenografts in nude mice
CM-diamminedichloroplatinum(II) andmitomycin C, Interferon action, 64
production of monoclonal antibody
7434
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
diagnostic and therapeutic potential,5228
Metal dustesophageal carcinoma, 3843
Metalloporphyrinenhancement of magnetic resonance im
aginghuman tumor xenografts, 4604
Metalloproteinaseshuman recombinant tissue inhibitor
metastasis, melanoma cells, 5539Metallopurpurins
photodynamic therapytransplantable bladder tumors, 194
Metallothioneininduction and deinduction
Adriamycin, prostatic carcinoma cells,4503
-like zinc-binding proteinzinc metabolism. Ehrlich cells, 3381
Métastases1-/3-D-arabinofuranosylcytosine conju
gates of lipidsinfluence, Lewis lung carcinoma, 826
augmentation of murine natural killercells
swainsonine, 1410B16 melanoma in lung
LAK cells, interleukin 2 and niAh.7140
bone marrowmurine model, 6876
breast cancercomparison, CA 15-3 and carcinoem-
bryonic antigen, 4107capacity
intercellular communication, mammary carcinoma, 5129
cathepsin B-like proteinasebiochemical study, colon cancer, 6855
circulating cytokinesinterleukin 2 and LAK cells, 5864
colon carcinomasialoglycoprotein expression, 2353
concomitant tumor immunityhost effectors, isolation and reactivity,
1153cure with indomethacin plus interleukin
2killer cells, 1072
determinants of tumor blood flow, 2641differential expression of WDNM1 gene
nonmetastatic mammary adenocarci-noma cells, 5203
differential NM23 RNA levels, 6550epithelial-like markers
class I MHC, mammary carcinoma,7237
fibroblast-mediated enhancement, 1457head and neck squamous cell carcinoma
two new cell lines, 2858hepatic
antitumor effects, interleukin 2 and in-terferon-a, 5810
immunotoxin mediation of reduction,3496
influence of retinoids on growthhamster melanoma in athymic mice,
1465irradiation-induced marker chromo
somes, 999locoregional
level of HLA antigens, melanoma,1019
loss of factor X activator capabilitiesvitamin K, Lewis lung carcinoma,
6504loss of responsiveness
cell shape modulation, B16 melanomaadhesive cell variant, 1258
lungeffects of hyperoxia, growth character
istics, 2779significance of bacterial flora, 3031
lymphaticsoybean agglutinin binding cells, mam
mary adenocarcinoma, 1451melanoma
tissue-specific, 4382orthotopic implantation of colorectal
carcinoma, 6863phenotypic changes in neoplastic cells
5-aza-2'-deoxycytidine, hydroxyurea,
2440platelet aggregation, 1460polypeptide markers
fibrosarcoma cells, 572pulmonary
mechanism of inhibition, sialicacid:nucleoside conjugate, 3728
synergism of-y-interferon, TNF andinterleukin 2, 2245
recombinant tissue inhibitor of metalloproteinases
melanoma cells, 5539role of tumor cell cytoskeleton
platelet adhesion, aggregation, 3787site-specific
brain, melanoma and fibrosarcoma,3478
skin and brainhighly pigmented melanoma variant,
4897synergistic effect
tumor necrosis factor, hyperthermia,650, 654
timing of chemotherapy and surgerymurine osteosarcoma model, 5533
tumor spread and DNA contentrenal cell carcinoma, 3165
wheat germ agglutinin-resistant humanmelanoma mutants
profiles, nude mice, 665Metastatic ability
cell motilityv-Ha-ros oncogene, prostatic cancer
cells, 6050down modulation of fibronectin messen
ger RNAprostatic cancer, 2042
mouse melanoma antigen, 7173radiation-induced injury
tumor bed stroma, sarcomas and carcinomas, 2116
stromal fibronectin staining patternbreast carcinoma, 6227
Metastatic cellsbasement membrane invasion
effects of inhibitors, 3307selection and overgrowth of primary tu
morsgenetic evidence, 6109
selection from surgical specimenscolon carcinomas, 1943
Metastatic potentialactivated ras oncogenes
thyroid cancers, 4459cell deformability and
correlation, melanoma cell variants,5124
cell surface cathepsin B-like activityidentification, butanol extraction,
1416effects of folate deficiency
murine melanoma cells, 4529invasiveness in hepatocyte and fibroblast
monolayersT-cell hybridomas in mice, 3405
modulation by cell surface urokinasemurine melanoma cells, 1270
multiplicity of transforming growth factors
human malignant effusions, 1792semisolid clonogenic medium
growth, mammary adenocarcinomacells, 399
stimulation of metastatic fibrosarcomatransforming growth factor-/3, 6999
visual grading systemcell motility, 4312
Meth A fibrosarcomarole of serotonin
antitumor effects, tumor necrosis factor-«,4250
Methapyrilenelack of binding
liver DNA, <2P-postlabeling, 6475
Methioninepatterns of auxotrophy
tumor cells, 6775Methotrexate
4'-(9-acridinylamino)methanesulfon-m-
anisidide andmetabolic interaction, 5106
blood-brain disruptionrat brain tumors, 694
bromosulfophthalein-sensitive effluxroute
vincristine action, LI210 cells, 5995conjugated with antitumor antibodies
nature of linkage, mode of action,3330
contribution of medicineprimary treatment, breast cancer, 2314
cytokinetic effectsL1210 cells, 4288
5-deazaaminopterin and 5-deazametho-trexate
5-alkyl derivatives of, comparison,5686
8-deaza analoguescytotoxicity, polyglutamate formation,
1481effects on methylenetetrahydrofolate
thymidylate synthesis inhibition,L1210 cells, 3398
etoposide-resistant human KB cell linescombined modalities of resistance,
59565-fluorouracil metabolites
plasma and urine, 1680growth inhibition
colon adenocarcinoma, 3319impaired polyglutamylation
resistance in CCRF-CEM cells, 2149yV'°-propargyl-5,8-dideazafolicacid and
accumulation, DNA strand breaks,2036
proliferation-dependent cytotoxicityleukemia, 5638
role of folylpolyglutamate synthetasehepatoma cells, 2426
7435
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
vincristine combinationother agents, acute lymphoblastic leu
kemia, 351Methotrexate-Y-aspártate
liposome-based therapyhuman ovarian cancer, 5237
9-(|2-Methoxy-4-|inethylsulfonyl)amino|-phenyljamino)-A',5-dimethyl-4-acridinecarbovamide: see CI-921
8-M ethoxypsora len-DNA photoadducts
flow eytometry, keratinocytes, 70134-Methyl-5-amino-l-formylisoquinoline
thiosemicarbazooeliver microsomal inactivation
inhibitor of ribonucleotide reducÃase,6375
Methylbenzylnitrosamine-induced formation of CX'-methylguanine
dietary ellagic acid, 7088Methyl bis(guanylhydrazone)
rhodamine 123anticarcinoma activity, murine renai
adenocarcinoma, 20613-MeIhylcholanthrcnc
-induced skin tumorigenesisprotection, tannic acid, 2361
Methylchrysene diol epoxide enantiomersSalmonella typhimurium
reactivity, DNA bases and mutagenic-ity, 1781
5-Methylcytosinegenomic
reduced content in human colonie neoplasia, 1159
7-Methyldeoxyguanosineantibodies
molecular epidemiology, 5065O6-Methyldeo\\Ruanosine
detection in human placenta! DNA,4184
Methylenetetrahydrofolatemethotrexate effects
thymidylate synthesis inhibition.LI210 cells, 3398
5,10-Methylenetetrahydrofolatescharacterization
xenografts, colon adenocarcinoma,3062
yV-Methylformamideeffects on cell cycle and glutathione sta
tuslymphoma cells, 3389
-induced radiosensitizationchromatin modifications, 5669
modulation of cytotoxic effect5-fluorouracil, colon carcinoma, 6193
Methylglyoxal bis(guanylhydrazone)a-difluoromethylornithine and
Phase 1evaluation, hematological malignancies, 1367
0*-MethylguanineDNA interstrand cross-link formation
chloroethylnitrosoureas, 3603esophageal
methylbenzylnitrosamine-induced formation, ellagic acid, 7088
repair ofoligodeoxynucleotides, 1184
Methyl methanesulfonateeffect on type 5 adenovirus DNA inte
grationembryo fibroblast cells, 3050
Methyl-n-amylnitrosaminehydroxy metabolites, 5663
3-(Methylnitrosoamino)propionitrileDNA cyanoethylation, 6780
yV-Methyl-nitrosoureaconversion of rat urinary bladder carci
nomaslow grade to high grade, 1265
stages of thymic lymphomasras oncogenes, 5514
yV-Methyl-/V'-nirro-yV-nitrosoguanidine
carcinogenesisproliferative response, gastric mucosa,
5275effect of cimetidine on inhibition by te-
tragastrincarcinogenesis in rats, 1591
gastric carcinogenesiscaerulein enhancement, 6332
-induced stomach carcinogenesisphenolic antioxidants, 5310
spontaneous transformationC3H 10T'/2 cells, 5977
-treated murine tumor cellsexpression of gp70, 1137
4-{Ar-Methyl-/V-nirrosamino)-l-(3-pyridyl)-1-butanone
activation and DNA alkylationcarcinogenicity, lung, 4215
jV-Methyl-iV'-nitrosoguanidine-induced colon carcinogenesis
effects, ammonium acetate and sodiumcholate, 3035
resistance of mitochondrial DNA to mu-tagenesis
HeLa cells, 4578/V-Methyl-/V-nitrosourea
estrous cycle modificationrat mammary gland DNA alkylation,
3090-induced skin tumorigenesis
protection, tannic acid, 2361Methylphosphonates
oligodeoxynucleotidesinhibitors, gene expression, 2659
Methylprednisolone acetatemammary tumorigenesis
adrenal regulation, 3801Methylxanthines
antitumor effects of pentoxifyllinethiotepa, human cancer cells, 4375
Metoprincantifolate drug interactions, 2421
Microsomeshepatic: see Liver microsomes
Microtubuleschanges and cytotoxicity
taxol, leukemic cell lines, 4093disorganizing-overstabilizing drugs
cell proliferation, 4892inhibitors
antiinvasive activity, estramustine,1842
role of tumor cell cytoskeletonplatelet adhesion, aggregation, 3787
Microwaveslow energy Ik-Ids
ornithine decarboxylase activity, phor-bol ester, 4222
Milk factorintervention of T-cells in transportation
mouse mammary tumor virus, mammary gland cells, 6555
Milk fat globule
radioimmunotherapybreast carcinoma, 4664
Milk fat globule membrane-associated antigen
endocytosis of monoclonal antibody,MCF-7 cells, 3188
Misonidazolechemosensitization
enhancement of melphalan activity,3528
Mitochondriaanticarcinoma activity
rhodamine 123, murine renai adenocarcinoma, 2061
damageditercalinium accumulation, hepato-
cytes, 6542energy substrate utilization
Morris hepatoma 7777 cells, 602hexokinase
hepatoma cells, 913kryptocyanine dye phototoxicity
red cell membranes, 6794loss of DNA
ditercalinium treatment, 4982picket-fence porphyrins
potential phototherapeutic agents,1148
proton stoichiometryelectron transport, mitoplasts, 628
resistance of DNA to mutagenesisHeLa cells, 4578
Mitogenesisepidermal growth factor-induced
kidney epithelial cells, 4886Mitogens
differential responsiveness of breast cancer cells
growth factors, 17/3-estradiol, 4083responsiveness to GM-CSF
III 60 cells, induced differentiation,2683
Mitomycin Ccompositional stability
artificial heterogeneous tumors, 2669m-diamminedichloroplatinum(II) and
interferon action, human mesotheli-oma xenografts, 64
drug sensitivity assaymonolayer culture, colon carcinomas,
3236modulation of cytotoxicity
dicoumarol, mammary tumor cells,5471
therapeutic attack of hypoxic cellssolid tumors, 775
Mitoplastsproton stoichiometry
electron transport, 628Mitoxantrone
Phase I clinical and pharmacokineticstudy, 5874
resistanceanalysis, human colon carcinoma cell
line, 1882ML-1 cells
differentiation-inducedtransformation, carcinogen target,
4389MO4 cells
antiinvasive activity of estramustine,1842
Monensinimmunotoxin mediation of reduction of
7436
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
métastases,3496Monoclonal antibodies
ability to form ricin A chain-containing¡ninninotoxins, 1119
aflatoxin H, ON A adductsin vivo immunological detection, 6328
antibody-dependent cellular cytotoxicityantitumor effect, LAK cells, 1173
anti-CDS radioimmunotoxinshuman tumors, nude mouse model,
7107antiglioma
therapeutic efficacy, 559antiidiotype antibodies
carcinoembryonic antigen, 4002anti-K562
hematopoietic differentiation antigens,5759
anti-ras M, 21,000 proteinstomach and thyroid cancers, 5503
anti-receptorprogesterone receptor localization,
breast cancer, 6462antitumor effect of immunoconjugates
tumor necrosis factor, 3607binding and endocytosis
milk fat globule membrane-associatedantigen, MCF-7 cells, 3188
binding to cell surface antigenlocalization, colon adenocarcinoma,
6573biotechnology products in cancer ther
apy, 223CA19-9andDU-PAN-2
expression in tumor tissue and serum,pancreatic cancer, 1435
CD3endocytosis and degradation, '1-cells,
2249cell surface glycoprotein expression
colorectal carcinoma, 7257chain-specific
cytokeratins, human lung cancer, 3221characterization of melanoma antigen
metastatic ability, mouse-specific epi-tope, 7173
CO17-1APhase II trial with 7-interferon in co
lorectal carcinoma, 2568combinations of interferons
therapy, murine B- and T-cell lympho-mas, 4196
comparison of tumor targetingcarcinoembryonic antigen, human tu
mor-hamster host model, 1823Cora antigen
differential expression, malignant andbenign gastrointestinal epithelia,2198
daunorubicin immunoconjugateacid-labile compared to free drug,
6097delivery across blood-brain barrier, 4725detection of different antigenic determi
nantshuman osteosarcoma-associated anti
gen, 2273detection of mammary serum antigen in
sera of breast cancer patients, 7060detection of monosialoganglioside
tumor-infiltrating macrophages, 2524detection of necrotic lesions in human
cancers, 5842detection of 06-methyldeoxyguanosine
human placenta! DNA, 4184detection of patients with cancer
lactoneotetraosylceramide, 1512diagnostic and therapeutic potential
mesothelioma cell lines, 5228discrimination of GM2ganglioside resi
dues, 6154disulfated glycosphingolipid
hepatocellular carcinoma, 6769-drug conjugates
dual label fluorescence technique,6211
fetal pancreatic protein as markerpancreatic carcinoma, 6906
fragmentglioma localization, 5701
gallium-labeled for scintigraphytumor targeting, drug-antibody conju
gates, 1189heterogeneous distribution
interstitial pressure in tumors, 7022heterogeneous responses
hexamethylene bisacetamide, coloncarcinomas, 5487
humantissue distribution, cellular localiza
tion, 7273human carcinoma-associated protein
complexquantitation, normal and tumor tissue,
816human-human hybridomas
breast cancer patients, 3208human milk fat globule
radioimmunotherapy, breast carcinoma, 4664
idarubicin conjugatesmurine thymoma, immunochemother-
apy, 926identification
papillomavirus type 18 E6 proteins,2969
identification of platelet-aggregating factor
colon adenocarcinoma, 6411IgG.,
GM3lactone immunization, inhibitedmelanoma growth, 5680
immunohistochemical characterizationprostate-specific antigen, 6938
immunotoxin preparationdeglycosylated ricin A chain, hindered
disillude linkages, 6396indium-111-labeled anti-melanoma
saturable clearance mechanisms, 4417interleukin 2 and LAK cells
combined therapy, B16 melanomalung métastases,7140
isolation of hepatoma nuclear proteins,5495
keratin-like antigenepithelial neoplasms, 4969
keratins 13 and 16differential expression in human breast
epithelium, 5831M, 95,000 glycoprotein
identification, melanocytes and melanomas, 1286
M, 97,000 to 250,000 protein antigenconcentrations, autoradiography, 5475
M, 170,000-180,000 P-glycoproteinstrong expression, adrenal cortex,
4611
reaction, mucinous type ovarian tumors, 4639
mouse melanoma antigenrecognition, Lyt-2~ and L3T4" cyto-
toxic T-lymphocytes, 2730mucin-associated oncofetal antigen
early carcinogenesis in colon, 1571mucin-like carcinoma-associated antigen,
6799nerve growth factor receptors
chromatin, melanoma cells, 7200neutral glycolipid
HTLV-I infection and adult T-cell leukemia, 3148
new tumor-associated antigen ATM-1,4848
noncompetingenhanced cytotoxicity, colon carci
noma, 6303nlicitola r antigen p 150, 7159osteosarcoma-associated cell surface an
tigenexpression, characterization, 5302
PE-35immunohistological analysis, thymic
neoplasms, 1896plasma membrane polarity
hepatocarcinogenesis, 6882precursor of cathepsin D
breast cancer cells, 3709preparation
sialosyl-Tn epitope, 2214proliferation-associated nucleolar anti
genearly G i phase, 1244
pulmonary capillary endothelial cellslung tumor colony formation, 4964
purification of calcium-binding proteinmultidrug resistance, 3173
purification of TAG-72, 6811radiohalogenation
W-succinimidyl 3-(tri-/i-butylstan-nyl)benzoate intermediate, 1446
radioimmunotherapy of colonie cancerxenografts
carcinoembryonic antigen, 3270radioimmunotherapy treatment
intracranial human glioma xenografts,2904
radioiodine-labeledxenogeneic tumor model, human B-
cell lymphoma, 2475radiolabeled
localization, colorectal carcinoma,4324
reaction with high-molecular-weight glycoprotein
body fluid, gastrointestinal cancer,4053
reaction with human cervical adenocarcinoma
uterus, immunodiagnostic potential,6565
reactive with mucin glycoproteinsera of breast cancer patients, 2138
restricted specificity for tumor-associatedantigen
prostate and breast carcinoma, 4543retrovirus-associated antigen
modulation, melanoma cells, 4954retrovirus transformation in rat cell lines
modulation, MHC class I antigens,3816
ricin A-chain conjugates
7437
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
transplantation of non-T-leukemiacells, tumor regression, 4673
ricin A conjugatesdisulfide-linked, galactose binding,
4469scrape loading of nucleolar antibodies
HeLa cells, 5246second generation
radioimmunolocalization, carcinomaxenografts, 4597
tumor-associated glycoprotein 72 antigen, 4588
selective growth inhibitiongpl60 and radioimmunotherapy, lung
cancer, 2768specificity
small cell neuroendocrine carcinoma,lung, 7319
tissue distribution of P-glycoproteinmultidrug-resistant gene, 1926
transplantable carcinomasloss of M, 78,000 marker, 2265
tumor-associated antigenneuraminidase-treated cancer cells,
412tumor detection
colorectal cancer, 4348uptake
blood flow, Clouser and renal cell xenografts, 188
human malignant melanoma multicelispheroids, 1856
Monocytesabnormal blood
chronic lymphocytic leukemia, 4812activation by Adriamycin therapy
liposome-encapsulated immunomodu-lators, 5256
activity in vitrointravenous administration, granulo-
cyte/macrophage colony-stimulatingfactor, 2604
alteration of fibronectin receptorsphorbol ester-treated promonocytic
cell lines, 5730alveolar macrophages and
tumoricidal activity, lung cancer, 3949interleukin 1 secretion
7-interferon, 1,25-dihydroxyvitaminD,, 1740
maturationmembrane-bound lectin, III Mi cells,
280peripheral blood
7-interferon therapy, cytotoxicity,1042
platelet-derived growth factor 1 and 2gene expression, 4498
Mononuclear cells-derived factor
stimulation, tumor cell growth, 5411a-difluoromethylornithine
methylglyoxal bis(guanylhydrazone)and. Phase I study, 1367
generation of antitumor effectorsadoptive immunotherapy, LAK cells,
3461peripheral blood
LAK cell fraction, suppression of he-matopoiesis, 534
Monooxygenaseshepatic effects of steroids
structure-activity studies, 2462liver microsomal nitrosamine metabo
lismdiallyl sulfide effect, 5937
Monos ialogangliosidedetection by monoclonal antibody
tumor-infiltrating macrophages, 2524Morpholinyldoxorubicin
inhibition of ribosomal gene transcription, 4101
Morphometryheterogeneous populations of breast can
cer cells, 3276Mucin
-associated oncofetal antigenearly carcinogenesis, colon, 1571
colon cancercharacterization, xenografts, 6678
glycoproteinmonoclonal antibodies, sera from
breast cancer patients, 2138human model of gastric carcinogenesis,
3554-like antigens
monoclonal antibodies, pancreatic cancer, 3924
-like carcinoma-associated antigenmonoclonal antibodies, 6799
serum type 1 chain antigens, 3856TAG-72 purification
monoclonal antibodies, 6811Mucosa
colorectalpattern, epithelial cell proliferation,
4121Mucus
mucinous variant of colorectal carcinoma
cell culture, 3751Multidrug resistance
antitumor activity of MX2murine tumor cells, 6653
Chinese hamster cellschromosomal organization, amplified
genes, 3179decreased drug accumulation
melanoma cells, 6348cu-diamminedichloroplatinum(II)-resis-
tant sublinesovarian tumor cell lines, 3355
geneP-glycoprotein distribution, mono
clonal antibody, 1926gene overexpression, 5927HL-60 cells, 3959K562/ADM cells
ATPase activity, P-glycoproteins, 4926leukemia cell line
cytogenetic and molecular characterization, 393
myeloma cellsdoxorubicin concentration, DNA le
sions, 6360verapamil reversal, doxorubicin resist
ance, 6365partial reversal of doxorubicin resistance
forskolin, murine sarcoma S180 variants, 539
purification of calcium-binding proteinmonoclonal antibodies, 3173
resistance to mitoxantroneanalysis of human colon carcinoma
cell line, 1882RNA detection by in situ hybridization,
4334verapamil-hypersensitive Chinese ham
ster ovary cellsproperties of, 4477
Multilamellar vesiclesentrapment of cw-bis-neodecanoato-
trans-R,R-1,2-diaminocyclohexane-platinum(II)
m-diamminedichloroplatinum(II) cytotoxicity, 4509
Muramyl peptidesbacterial vaccines
tumor necrosis factor production innude mice, 5766
Mutagenesisevolution of cancer genes, 1697resistance of HeLa cell mitochondria!
DNAchemical carcinogens, 4578
transformation of mouse embryo cellslead eliminate. 5280
MutagenicityCC-1065 and its analogues
mammalian cells and bacteria, 32hypotheses for origin
colon cancer, 7323reactivity with DNA bases
Salmonella typhimurium, methylchry-sene diol epoxide enantiomers, 1781
role of fecapentaenes in colon cancer,7324
Mutagens2-amino-3-methylimidazo[4,5-y]quinoline
metabolic activation, cytochrome P-450 isozymes, 4513
-treated murine tumor cellsexpression of gp70, 1137
MX2antitumor activity in murine tumor cells,
6653Mycobacterium
-induced infectious granulomaXenopus, 958
Myeloid cellslow molecular weight factor
induction, differentiation, 4201platelet-derived growth factor 1 and 2
gene expression, 4498Myeloma
1,25-dihydroxyvitamin D., receptormodulation, 1213
multiplePhase l-II study of epirubicin, 6246
Myeloma cellscommon acute lymphoblastic leukemia
antigen-positiveultrastructure, 6234
multidrug-resistantdoxorubicin concentration, DNA le
sions, 6360verapamil reversal, doxorubicin resist
ance, 6365Myelopoiesis
tumor-inducedprostaglandin E? regulation, Lewis
lung carcinoma, 6826Myelosuppression
antitumor activity and hematotoxicity ofFK973, 1166
Myelotoxicityradioantibody-induced
reduction of, interleukin 1, 5403Myocytes
anthracycline cardiotoxicity modeladenosine triphosphate/protein ratios,
5222
7438
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
Myometriumheterogeneity of progesterone receptor
distributionhuman endemici rial adenocarcinoma,
1889Myosarcoma cells
self-induction of tumor necrosis factorhuman and murine cell lines, 5407
N
Nafarelingonadotoxicity of cyclophosphamide
luteinizing hormone-releasing hormone agonist, 2174
NaHCOjpromotion of bladder carcinogenesis
ascorbic acid amplification, 6317Nanospheres
polymethacrylateAdriamycin antitumor activity, U937
cells, 1835a-Naphthoflavone
influence on ethinylestradiol bindinghepatocarcinogenesis, liver micro-
somes, 5460Nasal diseases
maxillary sinus cancercase-control study of past history in
Japan, 1651Nasal mucosa
DNA cyanoethylation3-(methylnitrosoamino)propionitrile,
6780Natural killer cell cytotoxic factor
distinction from tumor necrosis factorrecombinant human lymphotoxin, 891
Natural killer cellsaugmentation by swainsonine, 1410cytotoxicity in head and neck cancer,
5017effects of interleukin 2
tumor-infiltrating lymphocytes, 1180interleukin 2 effect
natural immunity, 6081intraperitoneal a-interferon administra
tionovarian cancer, 5853
LAK cells in rats, 878progenitor and effector phenotype,
884modulation of activity by serum of can
cer patients, 2596transformation-associated cell surface
antigenidentification, fetus-derived fibroblast,
2798tumorigenicity of murine lymphomas
fluorescence-detected antibody binding, 270
whole-body hyperthermia and cyclophosphamide
activity in erythroleukemia, 4561Necrosis
detection of lesions in human cancers,5842
role in regulating growth saturationmulticellular spheroids, 2432
NeoplasiaN-myc expression
thyroid C-cells, 4073Neoplasia- cells
genetic convergence and divergencetumor progression, 5911
phenotypic changes
5-aza-2'-deoxycytidine, hydroxyurea,
2440Neoplastic growth
target for chemotherapypolyamine metabolism, 759
Neoplastic rearrangementsgenomic
chromosomal bands, 7115Neoplastic transformation
cytogenetic changestrachea! epithelial cells, 702
dexamethasone effectsFujinami sarcoma virus, chick embryo
model, 7231Ar-methyl-yV'-nitro-Ar-nitrosoguanidine
induction of foci, C3H 10T'/2 cells,5977
ivirovirus associated antigenmodulation in melanoma cells, 4954
secreted phosphoproteins, 5770spontaneous
C3H 10T-/2cells, 5969Nephrotoxicity
cû-diamminedichloroplatinum(II) effectskidney, renal proximal tubule cells,
2538thiol rescue agents, LLC-PK, cells,
6017Nerve growth factor
receptorchromatin, melanoma cells, 7200
Neuraminidase-treated human cancer cells
tumor-associated antigen, monoclonalantibody, 412
Neuroblastomaantiproliferative effect of verapamil,
3617cytotoxic effects of iodobenzylguanidine,
2993growth
inhibitory effect, adenosine dialdehyde,5933
I la-ras gene productscorrelation with prognosis, 1030
humanidentification, guanine nucleotide-
binding protein, 2756neuronal cell differentiation
retinoic acid, herbimycin-A, 6530Schwannian cell differentiation
induction by bromodeoxyuridine, 2531viability and proliferation
inhibition by deferoxamine, 7189Neuroblastoma cells
induction of differentiationM, 53,000 protein, 2226
induction of S-100 protein5-bromo-2'-deoxyuridine, 170
Neuroepitheliomapatterns of protooncogene expression,
4307Neurofibromatosis
-like diseasetransmissibility, damselfish, 3828
Neuroleukinphosphohexose isomerase characteriza
tiongastrointestinal carcinoma, 7018
Neurotoxicitysnail neurons as model
testing, antitumor agents, 7184Neutron capture therapy
boron
murine melanoma. 6313Neutrophils
actin polymerization in HL-60 cells,6721
actions of staurosporinccontrast with epidermal cells, 4646
Nickelalloyed with aluminum
decontamination and disposal, nitro-soureas, 522
Nickel(II)resistance to ions
characterization of mouse cell lines,6850
NIH 3T3 cellsdetection of activated oncogenes
human skin cancers, 3341interferon-induced revenants
transcriptional inhibition, Ha-ras,5157
phorbol ester-mediated associationprotein kinasc C, nuclear fraction,
1910ras-transfected
polyamine metabolism, interconversion, 3336
transformation by ras oncogenesincreased resistance, m-diamminedi-
chloroplatinum(II), 793/V-|4-(5-Nitro-2-furyl)-2-thiazolyl|formainidc
metabolite ofeffect of peroxidase inhibitors on uri
nary bladder, 304Nitrogen
bifunctional alkylating agentsmedulloblastoma, transplantable xeno-
grafts, 4189Nitrogen dioxide
nitrosamine formation from amines,1095
Nitrogen mustardeffect of alkylating agent dose
clinical correlation, 6417influence of WR2721
DNA cross-linking, bone marrow andleukemia cells, 6002
melphalanchronic lymphocytic leukemia, 1972
protection of Ehrlich asdics tumor cells5-AVV-dimethylamiloride, 2454
Nitroimidazoleschloroethylnitrosourea and
mixed-function drugs. Mer cells, 7981-Nitropyrene
derivativescarcinogenic activities, 4256
oxidative metabolismliver microsomes, cytochrome P-450
isozymes, 42614-Nitroquinoline 1-oxide
adduct formation andcell sensitivity, hereditary cutaneous
malignant melanoma, 5145Nitrosamine
antibodies against 7-methyldeoxyguano-sine, 5065
ß-and 7-hydroxylatedcarcinogenic-its in F344 rats, 1533
formation from aminesbefore and after nitrogen dioxide expo
sure, 1095liver microsomal metabolism
diallyl sulfide effect, 5937tobacco-related tumors
7439
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
lung and pancreas in rats, 6912Ar-Nitrosobutyl-(4-hydroxybutyl)amine
pharmacokinetic profile, 3666\~Nilroso compounds
genotoxicity in hepatocytes, 4144relevance to human cancer, 4711
/V-Nitrosodialkylaminesmetabolism by human liver microsomes,
1499iV-Nitrosodicthylamine
tumor promotion by hydantoinscytochrome P-450 induction, liver and
thyroid, 2492N¡Irosmlimi-Ili)lamini-
activation and DNA alkylationcarcinogenicity in lung, 4215
jV-Nitrosoethylurea-induced papillary lung tumors
alveolar type II cell origin, 148induction of oligodendrogliomas
fetal lore-brain transplants, 2871Nitrosomethylalkylamines
comparative carcinogenesis, 6648/V-Nitrosomethylamylamine
organ and cell specificityDNA methylation, 5482
iV-Nitrosomethyl-(2-hydro\yethyl)amini'DNA alkylation
dose response, lesion persistence, 1537W-Nitrosomethylurea
-induced mammary cancerflavonol quercetin, 5754
-induced mammary tumor growthpolyamines, progesterone, 3058
-induced mammary' tumorigenesiscalorie restriction and exercise, dietary-
fat, 4276/V-Nitrosomorpholinc
dose response study in F-344 rats, 2089jV-Nitroso-/V-methyl-2-oxopropylamine
metabolism of Z and / isomers in rathepatocytes, 3347
jV-Nitrosopyrrolidine a-hydroxylasereconstitution of activity
liver microsomes, 3987yV-Nitrosothioproline
increase in urinary levelingestion of cod with vegetables, 4049
Nitrosoureaeffect of thymidine on activity, 4272induction of sister chromatid exchange
cytotoxicity, alkylating agents, 3100potentiation of cytotoxicity
leukemic cells, 1521regeneration of O^-alkylguanine-DNA al-
kyltransferasehuman lymphocytes, 5368
related A nitroso compounds anddecontamination, disposal, 522
-resistant Mer* tumor cells
thermal sensitization, 1086NMR: see Nuclear magnetic resonance
spectroscopyNoduligenesis
mammary hyperplastic alveolar nodulestransplantation into gland-free fat
pads, 3197NSC 308847
limited sampling modelspharmacokinetics, 4127
Nuclear magnetic resonance spectroscopy5-fluorouracil metabolites in plasma and
urine, 1680gliosarcoma, 5610
measurement of tumor blood flow andperfusion, 3449
monitoring of tumor physiologyflavone acetic acid-induced modula
tion, 4749Hp
cyclophosphamide response, RIF-1cells, 4736
profiles of neoplastic human breast tissues, 5112
response of rat mammary tumorsendocrine therapy, 89
tumor bioenergetics and histology, 676tumor energy metabolism
intracapillary oxyhemoglobin, 5440tumor metabolic changes with glucose,
5917Nuclear matrix
-bound DNA replicationantileukemia agents, CCRF-CEM leu
kemia cells, 1850Nucleic acids
oxygen-free radicals in carcinogenesis,3882
Nucleolar antigenpl20
intranucleolar localization, 6523optimal loading, scraped HeLa cells,
5246pl50
monoclonal antibodies, 7159proliferation-associated
early G, phase, cell cycle, 1244Nucleosides
inhibited salvagedipyridamole and acivicin. Phase I
clinical trial, 5585,5591restoration of heat resistance
protein synthesis, glucose-deprivedL929 cells, 1442
S'-Nucleotidase
photosensitizing effectshematoporphyrin derivative, mam
mary adenocarcinoma, 3360Nutrition: see also Diet
cancer cachexiaimprovement, exogenous insulin, 2784
parenteralbranched chain amino acids, Yoshida
sarcoma, 2698sodium-deficient diet
restriction, tumor growth, 3445
Obesityestrogens as cause of human cancer, 246
Occupational risksesophageal carcinoma, 3843foundry' workers
PAH-DNA adducts, white blood cells,2288
laryngeal cancerTexas Gulf Coast, 1960
motor exhaust-relatedbladder cancer, 1989
OK-432adoptive immunotherapy
pantropic killer cells, 4163Oleanolic acid
triterpenoid compoundsantitumor action, 12-O-tetradecanoyl-
phorbol-13-acetate, 5210Oligodeoxynucleotides
inhibitors of gene expression, 2659
repair of C^-methylguanine, 1184Oncogenes
activateddetection in skin cancers, 3341
activated rasthyroid cancers, 4459
cellularphénobarbitaltreatment, liver regener
ation, 265changes in expression
retroviral sequences, colon carcinogenesis, 3964
differential NM23 RNA levelsmetastatic potential, 6550
c-fos differential expressionfamilial polyposis coli, 4855
c-Ha-r<winterferon-induced revenants, tran-
scriptional inhibition, 5157malignant properties, bladder cancer
sublines, 4993polyamine metabolism, NIH 3T3 cells,
3336c-myc: see c-mycDNA tumor viruses, 493expression and tumorigenicity
pediatrie cancer, 2715growth factor expression and
mammary epithelial cells, 7041Ha-ros
cell line development, papillomas inskin grafts, 165
correlation with prognosis in neuro-blastoma, 1030
human kidney tumors, 5251mechanism of activation, mouse carci
noma, 556protein kinase C down-regulation,
C3H T 10'/2cells, 6535transformation, normal homologous
cells, 3470transforming growth factor-/?, meta
static fibrosarcoma, 6999human model of gastric carcinogenesis,
3554K-ras
activation, lung adenocarcinoma, 5738clonal diversity, 4941
malignancy by cell fusion, 3302molecular mechanisms of carcinogenesis
cancer prevention, treatment, 4135»IMfamily gene abnormality
lung cancers, xenotransplantability,6025
N-myc expressionneoplasia of thyroid C-cells, 4073
nonrandomness of chromosome aberrations, 7120
pp60'"r expressionprotein-tyrosine kinase activity, flow
cytometry, 4633ras
epidermal growth factor receptor,esophageal cancers, 5119
low frequency, human melanomas,950
resistance to m-diamminedichloropla-tinum(II), NIH 3T3 cells, 793
stages in thymic lymphomas, 5514ras/myc
role of chromosome loss, 1623ras p21
cAMP levels, salivary gland adenocarcinoma, 2898
7440
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
retrovirusestransformation, mammary epithelial
cells, 4689retrovirus transformation in rat cell lines
modulation, MHC class I antigens,3816
selective killing of transformed cellsintercellular communication, therapeu
tic applications, 3203src
reversal of transformed phenotypes,herbimycin A, 1587
transformation-associated cell surfaceantigen
identification, fetus-derived fibroblast,2798
\-fesneosynthesis of gangliosides, 1753
v-Ha-roscell motility, metastatic ability, 6050
viral expressionpromonocytic leukemia cells, Abelson
virus-infected, 1702Ontogenesis
evolution of cancer genesmutation-driven process, 1697
Oral contraceptivesborderline ovarian neoplasms
case-control study, 5849cervical carcinoma in Chile, 1011risk of colorectal cancer, 4399
Oral neoplasmshamster oral keratinocytes
transforming growth factor-«,3130pharyngeal cancer and
smoking and drinking, 3282Ornithine decarboxylase
activation by guanosine triphosphatehuman squamous cell carcinoma, 1252
increased activitymicrowave fields, phorbol ester, 4222
mechanisms of inductiontrachéalepithelial cells, asbestiform
minerals, 709messenger RNA
retinoic acid inhibition, TPA-inducedsynthesis, 2168
polyamine levels andBarrett's esophagus, 3288
Osteosarcoma-associated antigen
expression, characterization, 5302monoclonal antibodies, antigenic de
terminants, 2273chick embryo model
dexameathasone effects, neoplastictransformation, 7231
developmentretinoblastoma susceptibility gene,
chromosomal reorganization, 3939liposome-encapsulated immunomodula-
torsAdriamycin therapy, monocyte activa
tion, 5256murine model
timing of chemotherapy and surgery,5533
Ouabainreduction of doxorubicin cytotoxicity,
725Oval cells
rat ductularpromotion of growth, primary culture,
368
Ovarian granulosa cell neoplasmsgene for susceptibility, 5092induction with dehydroepiandrosterone,
2788rapid induction
7,12-dimethylbenz(a)anthracene, neo-natally estrogenized mice, 425
Ovarian neoplasmsborderline tumors
case-control study, 5849c»-diamminedichloroplatinum(II)-resis-
tant sublines, 3355DNA repair as mechanism of acquired
resistancem-diamminedichloroplatinum(II),
5713increased synthesis
prostacyclin and thromboxane, 2396inhibition of thymidine uptake
LHRH agonist, 7252a-interferon
intraperitoneal administration, 5853interleukin 2-inducible killer cells
ascitic fluid, pleural effusions, 6321liposome-based therapy, 5237mucinous type
reaction, novel mouse monoclonalantibodies, 4639
new growth factor in ascitic fluid, 1066prostaglandin biosynthesis, 4770tumor-associated galactosyltransferase
isozyme IIimmunoassay, 5325, 5335
Ovariectomyheterogeneous populations of breast can
cer cellskinetic and morphometric responses,
3276Ovary cells
Chinese hamsteracute pH 6.6 and 42.0°Cheating, 497camptothecin-resistant mutants, 6404cell cycle progression, cisplatin influ
ence, 6703cell survival and cycle, U-71,184, 109chronic pH 6.6 effects on response to
hyperthermia, 2417glutathione, Adriamycin tolerance,
4493glutathione depletion, thermotoler-
ance, 7033hyperthermia, glycosyltransferase ac
tivity, 5717polyamine-dependent recovery proc
esses, X-rays, 4881porfiromycin cytotoxicity, oxygen de
pendency, 5655premature chromosome condensation,
nuclear fragmentation, 6478SR 4233 metabolism, 5947verapamil-hypersensitive cells, 4477
Oxygenantioxidant enzymes
xeroderma pigmentosum fibroblasts,2132
-dependent regulationDNA synthesis and growth, Ehrlich
ascites, 2053effects of hyperoxia
growth characteristics, metastatic lungtumors, 2779
free radical formationAdriamycin-induced cardiotoxicity,
4766
carcinogenesis, 3882DNA damage induction, benzene me
tabolites, 4762squamous differentiation, bronchial
epithelial cells, 822intracapillary oxyhemoglobin
tumor energy metabolism, 5440porfiromycin cytotoxicity
Chinese hamster ovary cells, 5655
PAH: see HydrocarbonsPalmitate
effects of dietary retinoidsgrowth and differentiation, embryonal
carcinoma, 3772energy substrate utilization
Morris hepatoma 7777 cells, 602Pancreas
comparison of sialylated Le" antigens,
3834disseminated cancer treatment
leucovorin, 5-fluorouraciI, 5570fetal pancreatic protein as marker in car
cinoma, 6906tobacco-related tumors, 6912
Pancreatic neoplasmsexpression of blood group-related anti
gens, 5422expression of CA 19-9 and DU-PAN-2,
1435Le" and Ley antigen expression, 475mucin-like antigens
monoclonal antibodies, 3924site-specific analysis of total serum cho
lesterolincident cancer, National Health and
Nutrition Examination Survey, 452tumor markers CA 19-9 and CA-50
carcinoembryonic antigen, 1985Papilloma
skinaneuploidy, •¿�y-glutamyltransferase,
3253skin grafts on athymic nude mouse hosts
cell line development, ras"', 165
tumor progression in SENCAR miceinitiator dose, 7048
Papilloma virusanalysis of sequences
cell lines derived from cervical cancers,324
early gene expressiongrowth property correlation, cervical
carcinoma, 3780isolation of new type
transforming activity, cervical cancertissue, 7164
oncogenes of DNA tumor viruses, 493polymerase chain reaction analysis
forty-year-old paraffin sections, 4564type 16
mild immunodeficiency, bladder carcinoma, 7207
transformation, C127 mouse fibroblasts, 2505
types 16 and 18immortalization, exocervical epithelial
cells, 4620type 18
E6 proteins, cervical carcinoma cells,2969
types and localization in adenocarci-noma
7441
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
adenosquamous carcinoma, uterinecervix, 993
l'arai rim- growth factortransforming growth factor-j3
ER-negative breast cancer cells, 3898Paraffin sections
DNA sequence analysis by polymerasechain reaction of forty-year-old samples, 4564
Paragloboside: see Lactoneotetraosylceratn-ide
Paraneoplastic syndromesdorsal root ganglionopathy
antigen expression, small cell lung carcinoma, 430
Parasitesrare events as clues to cancer etiology,
3544Parvoviruses
DNA amplificationcellular genotoxic stress, 3123
Pediatrie neoplasmstumorigenicity and oncogene expression,
2715Pentoxifylline
antitumor effectsthiotepa, human cancer cells, 4375
Pepsinogen geneDNA methylation, 1603
Peritoneal cellsenhanced activity after aclacinomycin
respiratory burst, 3440Peritoneal exúdatecells
alterations in murine host defense functions
Adriamycin or liposome-encapsulatedAdriamycin, 130
Peroxidase inhibitorseffect on urinary bladder carcinogen, 304
Peroxisomal 0-oxidationmRNAs in rat tissues, 5316
Peroxisome proliferatorsDNA synthesis and
hepatocarcinogenesis, 6739lack of glutathione-5-transferase P
mRNA expression•¿�y-glutamyltranspeptidasein liver tu
mors, 4919Perspectives in Cancer Research
breast cancer epidemiology, 5615changing concepts in cancer prevention
environmental carcinogenesis, 1381chromosomes in solid tumors, 1049contribution of medicine
primary treatment, breast cancer, 2314evolution of cancer genes
mutation-driven process, 1697genetic convergence and divergence
tumor progression, 5911glucocorticoid receptor at protein level,
2636human model of gastric carcinogenesis,
3554malignancy by cell fusion, 3302oncogenes of DNA tumor viruses, 493polyamine metabolism
neoplastic growth, chemotherapy, 759roles of cytochrome P-450 enzymes
chemical carcinogenesis. cancerchemotherapy, 2946
somatostatin analoguesoncological applications, 6977
tumors as caricaturesprocess of tissue renewal, 1996
P-glycoproteinamplified and overexpressed genes
multidrug-resistant cell lines, 5927chromosomal organization of amplified
genesmultidrug-resistant Chinese hamster
cells, 3179cytogenetic and molecular characteriza
tionmultidrug-resistant leukemia cells, 393
doxorubicin resistancediffering mechanisms, tumor cell lines,
2793M, 170,000 to 180,000
ATPase activity, multidrug resistant-K562/ADM cells, 4926
strong expression, adrenal cortex,4611
mechanisms of multidrug resistanceHL-60 cells, 3959
mull ¡factorialresistance to Adriamycin,3595
tissue distributionmultidrug-resistant gene, monoclonal
antibody, 1926pH
ascorbic acid amplificationbladder carcinogenesis, NaHCO.i pro
motion, 6317chronic 6.6
hyperthermia response, Chinese hamster ovary cells, 2417
degradation of extracellular matrixcathepsin D, breast cancer cells, 3688
elevated temperatures andeffect of bleomycin, murine tumor
cells, 615intracellular
acute pH 6.6 and 42.0°Cheating,
Chinese hamster ovary cells, 497metabolism in vivo
human breast cancer xenografts, 7264mollification in normal and malignant
tissuehydralazine and glucose, air or carbon
dioxide breathing, 1543tumor metabolic changes with glucose
"P nuclear magnetic resonance, 5917uptake of WR-2721 derivatives
transported form of drug, 3634venous
Walker 256 carcinoma, hyperglycemia,1201
Phagocytesbenoxaprofen and
DNA damage, 3094human macrophage function
clinical trial, tumor necrosis factor,5604
Pharyngeal neoplasmsoral cancer and
smoking and drinking, 3282Phénobarbital
choline-deficient diet andmodulation, epidermal growth factor
receptors, 1162kinetics of inhibition
intercellular communication, mousehepatocytes, 2519
regeneration in rat liverretrovirus-like sequences, cellular on
cogenes, 265Phenolic antioxidants
gastric carcinogenesis, 5310
Phenol redestrogenic and antiestrogenic action
growth, breast cancer cells, 3693Phenols
tannic acidprotection against skin tumorigenesis,
23612-Phcn) lindóle
estrogen action of derivatives, 784Phleomycin
bleomycin andinternucleosomal cleavage, yeast, 6837
Phorbol 12,13-dibutyratebryostatin 1 and
inhibition of cell-cell communication,epidermal cells, 447
Phorbol diestersdifferent protein kinase C activities
HL-60 leukemia cell variants, 2744Phorbol ester
adhesion and translocationprotein kinase C, U-937 cells, 3168
binding in mammary carcinoma cellsphospholipids, 1528
bryostatins andeffects, C3H 10T'/2 cells, 3702phosphorylation pattern mimicry, HL-
60 cells, 5984cAMP-dependent protein kinases
retinoic acid, teratocarcinoma cells,3993
changes in topoisomerase II DNA cleavage
leukemia cells, 6625differentiation in HL-60 cells
thioether phospholipid effects, proteinkinase C, 6669
GìdelayI Id a cells, time lapse photography,
17598-lipoxygenase induction
comparison, SENCAR and C57BL/6Jmice, 658
-mediated association of protein kinaseC
nuclear fraction, NIH 3T3 cells, 1910ornithine decarboxylase activity
low energy microwave fields, 4222-stimulated differentiation
retinoic acid, U937 cells, 5779-treated promonocytic cell lines
alteration, fibronectin receptors, 5730tumor promoters
protein kinase C as receptor, 1requirement, transformation, 7126
Phorbol I 2-nivrisiale 13-acetateinhibition of chemotactic peptide-in-
duced elevationintracellular calcium, HL-60 cells,
2707Phosphate
cancer morbidity and mortality amongphosphate workers, 7298
Phosphatidylethanolaminephosphatidylcholine and
phorbol ester binding, mammary carcinoma cells, 1528
Phosphatidylinositolnew growth factor in ascitic fluid
ovarian cancer, 1066Phosphatidylinositol kinase
membrane-associatedinsulin effects, mammary tumors,
6727
7442
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
Phosphohexose isomerasecharacterization
neuroleukin relationship, gastrointestinal carcinoma, 7018
isoelectric focusing patternsgastrointestinal and mammary carci
noma, 2998Phosphoinositide
turnover in kidney cellsserotonin as a major serum factor,
6697Phospholipids
toxicity to adenovirus 12 transformant,578
yV-(Phosphonacetyl)-L-aspartatebiochemistry and clinical activity, 4441
Phosphoproteinsglucocorticoid receptor at protein level,
2636secreted
neoplastic transformation, blood coagulation, 5770
Phosphoramide mustardbifunctional alkylating agents
medulloblastoma, transplantable xeno-grafts, 4189
Phosphorothioatesoligodeoxynucleotides
inhibitors, gene expression, 2659Phosphorylation
antiestrogen binding site ligandsantiproliferative action, 3954
different protein kinase C activitiesML 60 leukemia cell variants, 2744
M, 34,000 to 40,000 proteinsprotein kinase C, epidermis, 4018
Phosphotyrosine phosphatasetyrosine kinase and
biochemical characterization of HL-60cells, 4299
Photoactivationaflatoxin
DNA strand scission, apurinic sites,3070
Photodynamic therapyhematoporphyrin derivative
bladder tumor, 6115-induced hypoxia
fluosol-DA (20%), carbogen breathing,3350
metallopurpurin derivativestransplantable bladder tumors, 194
porphyrindifferential cell photosensitivity, 4539
Photosensitizationbiological effects of phthalocyanine dyes
transplantable tumors, 3040effects of pyronin Y and toluidine blue
O, 1295hematoporphyrin derivative
plasma membrane enzymes, mammaryadenocarcinoma, 3360
Phototherapeutic agentspicket-fence porphyrins, 1148
Phthalocyaninebiological effects of dyes in transplanta
ble tumors, 3040Pigmentation
influence of organ microenvironmentmetastatic murine melanoma, 2258
Pineal glandproliferation effects of melatonin
breast cancer cells, 6121Piriprost
ethacrynic acid andcytotoxicity effect, 3622
Pituitary growth hormonesomatostatin analogues
oncological applications, 6977Pituitary neoplasms
anterior pituitary dopamine receptorsestrogen-like effects, 7,12-dimethyl-
benz(a)anthracene, 6434compositional stability
artificial heterogeneous tumors, 2669estrogen-induced
glandular kallikrein. prolactin, 4158Placenta
detection of O6-methyldeoxyguanosine
human DNA, 4184Plasma
proteins cleaved during blood coagulation
secreted phosphoproteins, neoplastictransformation, 5770
urine and5-fluorouracil metabolites, 1680
Plasmacytomaeffector mechanism of tumor immunity,
1398Plasma membrane
enzymesphotosensitization, mammary adeno
carcinoma, 3360tnethotrexate transport in LI210 cells,
5995polarity
hepatocarcinogenesis, 6882tyrosine kinase and phosphotyrosine
phosphatasebiochemical characterization, HL-60
cells, 4299Plasminogen
levels of urokinase and its receptorcolon carcinoma, 3112
Plasminogen activatordifferential regulation
epidermal growth factor, urothelium,5552
effects of inhibitorsbasement membrane invasion, meta
static cells, 3307inhibitor activity and
human glioma cells, modulation by sodium butyrate, 291
modulation of activityendometrial adenocarcinoma cells,
growth factors, 6384profiles in neoplastic tissues
human colon, 4520relation to estrogen and epidermal
growth factorhuman breast cancer, 6603
tissue-typenew prognostic marker, breast cancer,
1348urokinase-type
modulation of metastatic potential,melanoma cells, 1270
Platelet-aggregating factoridentification of
monoclonal antibodies, colon adenocarcinoma, 6411
Platelet-derived growth factorexpression of mRNAs
glioma cell lines, 3910gene expression
myeloid cell lines, monocytes, 4498
-like proteinsconstitutive production, prostate carci
noma, 1930regulatory effects of cell density, 4266retroviral expression in transformed
cells, 4874Platelets
aggregationtumor cell cytoskeleton, IRGpIIb/IIIa,
3787aggregation in metastasis, 1460significance of «-2-i.-fucosyltransferase
serum of leukemic patients, 3998Platinum
-DNA adductsrepair, bladder and testicular tumors,
3019Platinum analogues
fi.s-diamminedicliloroplatinum(ll) andaccumulation in murine leukemia
cells, 9Platinum compounds
c/i-diamminedichloroplatinum(II) resistance
effect on hyperthermia, 5101effect of hypoxia and acidosis on cyto
toxicitynormal and hyperthermic tempera
tures, 2342intracellular biotransformation
1,2-diaminocyclohexane carrier ligand,L1210 cells, 5136
Polyadenosine diphosphoribosestimulation of synthesis by DNA lesions
sodium chromate, V79 cells, 1100Poly(ADP-ribose) glycohydrolase
effect of hyperthermia, 4240metabolism alteration by hyperthemia,
4233Polyamines
alterations in epidermal levelsDNA synthesis, chrysarobin, 6390
autocrine control of mammary tumorgrowth
progesterone, 3058-depleted Chinese hamster cells
inhibition, ionizing radiation recoveryprocesses, 4881
«-difluoromethylornithinemethylglyoxal bis(guanylhydrazone)
and, Phase I study, 1367importance of metabolism
neoplastic growth, chemotherapy, 759metabolism and interconversion
NIH 3T3 cells, ras transfection, 3336modulation of binding
progesterone receptor to DNA, 1217mutant LI210 cells
curative effect, m.-2-difluoromethylor-nithine, 4807
synthesis and interconversionresponse to blockade, normal and ma
lignant urothelium, 357Polycyclic aromatic hydrocarbons: see Hy
drocarbonsPolycythemia
erythropoietin-inducedtransplantation, renal carcinoma, 3430
-inducing strain of Friend virus complexcurative effect, irradiation, 2399
Polyethylene glycolrestoration
colon cancer cell differentiation, 2498Polyglutamates
7443
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
formation8-deaza analogues, methotrexate and
aminopterin, 1481Polyglutamylation
impairedmethotrexate, resistance in CCRF-
CEM cells, 2149Polyisoprenoids
dolichol kinase and phosphatasemicrosomal fractions, human hepato-
mas, 3418Polymerase
chain reaction analysisforty-year-old paraffin sections, 4564
Polymorphismsrestriction fragment length
epidermal growth factor gene, 4045Polypeptides
metastasis markersfibrosarcoma cells, 572
Polypsadenomatous
epithelial cell proliferation, colorectalmucosa, 4121
Porfiromycincytotoxicity
oxygen dependency, Chinese hamsterovary cells, 5655
Porphyrinphotodynamic therapy
differential cell photosensitivity, 4539potential phototherapeutic agents, 1148
Positron emission tomographyglioma imaging
isoquinoline, benzodiazepine binding,5837
Potassiumbreast cyst fluid
epidermal growth factor, 5860proteases in cyst fluid
human gross cyst breast disease, 6379Potassium tetrachloroplatinate
effect of hyperthermia, 2335Pregnancy
risk factor for breast cancerChinese women in Shanghai, 1949
Presidential Address, 775Princess Takamatsu Cancer Research Fund
eighteenth annual symposiumrare events, cancer etiology, 3544
Procarbazine-induced germinal cell aplasia
partial prevention, testosterone, 4354therapy-related acute nonlymphocytic
leukemiaCX'-alkylguanine DNA alkyltransferase,
3084Progenitor cells
bone marrowthermotolerance, heat sensitivity, 3630
fresh leukemic bone marrowradiobiological features, acute lympho-
blastic leukemia, 5788granulocyte-macrophage
effects of hematopoietic suppressormolecules, 1548
leukemicbone marrow purging, acetaldophos-
phamide, 339Progesterone
antagonism of actionepidermal growth factor, breast carci
noma, 5071estrogen action of 2-phenylindole deriva
tives, 784insulin-like growth factor I receptors in
breast cancer, 6429A'-nitrosomethylurea-induced mammary
tumor growthpolyamines, autocrine control, 3058
receptor binding to DNAmodulation by polyamines, 1217
receptor distributionheterogeneity in endometrial adeno-
carcinoma, 1889receptor localization
anti-receptor monoclonal antibodies,breast cancer, 6462
receptor structure and protease activityprimary human endometrial carci
noma, 1143receptors
hyperplastic and neoplastic endome-tria, 6132
Progestinhepatic effects of steroids
structure-activity studies, 2462steroid insensitivity
breast cancer cells, 4340Progestins
medroxyprogesterone acetate effectcell cycle kinetics, mammary carci
noma, 5084regulation of epidermal growth factor
gene expressionhuman breast cancer cells, 4555
Proglumidegastrin antibodies
colon carcinoma, 7179Prolactin
binding and localizationmammary tumor mast cells, 3765
estrogen action of 2-phenylindole derivatives, 784
glandular kallikreinestrogen-induced pituitary tumors,
4158somatostatin analogues
oncological applications, 6977A^-Propargyl-S.S-dideazafolic acid
methotrexate andaccumulation, DNA strand breaks,
20360-Propiolactone
11 r«.\oncogene activationmouse carcinoma, 556
Prostacyclinthromboxane and
increased synthesis, ovarian malignancy, 2396
Prostaglandin A.,inhibited c-myc expression
cell cycle progression, HL-60 cells,2813
Prostaglandin analoguesethacrynic acid and piriprost
cytotoxicity effect, 3622Prostaglandin E
effects of hematopoietic suppressor molecules
granulocyte-macrophage progenitorcells, 1548
Prostaglandin Iregulation of tumor-induced myelo-
poiesisimmune suppressor cells, Lewis lung
carcinoma, 6826Prostaglandins
biosynthesis in human tumor cells, 4770effect of dietary eicosapentaenoic acid
azoxymethane-induced colon carcino-genesis, 4790
production by murine tumorspredictor for therapeutic response, in
dornet hucin. 3002profiles of biosynthesis
normal lung and tumor tissue, lungcancer patients, 3140
Prostatecadmium carcinogenesis
dose-response, 4656optimal medical castration in male rats,
6063-specific antigen
characterization, monoclonal antibodies, 6938
ventraldifferential expression, cytochrome P-
450c and -450d, 3045Prostatic neoplasms
cell motility and metastatic abilityv-Ha-ros oncogene, 6050
cytotoxic activitydiethylstilbestrol, 2867
dietary /3-carotene andcase-control study in Japan, 1331
down modulation of fibronectin messenger RNA, 2042
partial inhibition of growthSandostatin, 4651
Prostaglandin biosynthesis, 4770risk
prediagnostic serum hormones, 3515variation in tumor yield
3,2'-dimethyl-4-aminobiphenyl, 4629
Proteasescyst fluid
human gross cyst breast disease, 6379differential regulation of plasminogen ac
tivatorsepidermal growth factor, urothelium,
5552progesterone receptor structure
primary human endometrial carcinoma, 1143
Proteinadenosine triphosphate ratios
anthracycline cardiotoxicity model,5222
anti-ro?p21 monoclonal antibodiesstomach and thyroid cancers, 5503
branched chain amino acidsparenteral nutrition, Yoshida sarcoma,
2698estramustine-binding associated
lung cancer cell lines, 4615functional properties
human a-interferon gene, pseudogene,1763
glucocorticoid receptor, 2636induction of carcinoembryonic antigen
secretiontransforming growth factor-/3, colon
carcinoma, 405985-kDa
Adriamycin resistance, 7082lectin-binding
nuclear preparations from rat liver andmalignant tumors, 551
M, 53,000differentiation induction, neuroblas
toma cells, 2226
7444
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
M, 78,000loss of marker, primary pancreatic car
cinoma, 2265M, 97,000 to 250,000 antigen concentra
tionsmelanoma, quantitative autoradiogra-
phy, 5475p32 cDNA clone isolation, 4795P55
late target protein, ./V-2-fluorenylace-tamide in liver, 6745
pl20intranucleolar localization, 6523
pl50nucleolar antigen, monoclonal anti
bodies, 7159p 190
epidermal growth factor receptor, glio-blastoma cells, 5433
patterns of synthesishyperthermia, endothelial cells, 2101
retinoid-bindingretinoblastoma tumors, 1124
S-100induction by 5-bromo-2'-deoxyuridine,
neuroblastoma cells, 170synthesis alterations
Novikoff hepatoma, Yoshida sarcoma,1554
-tyrosine kinase activitypp60"~'" expression, flow cytometry,
4633whole body turnover rate
resting energy expenditure in cancerpatients, 2590
Proteinasecathepsin B-like
biochemical study of colon cancers,6855
Protein kinasecAMP-dependent
phorbol ester effect, teratocarcinomacells, 3993
Protein kinase Cantiestrogen binding site ligands
antiproliferative action, 3954colonie cancer cell differentiation
calmidazolium, 12-O-tetradecanoyl-phorbol-13-acetate, 6173
contrasting actions of staurosporineneutrophils, epidermal cells, 4646
cytosolic calcium andalteration, LAK cell activity, 635
different activitiesHL-60 leukemia cell variants, 2744
L-a-dioctanoylglyceroltumor promoter in mouse skin, 1736
DNA damagebenoxaprofen and phagocytes, 3094
effects of thioether phospholipidphorbol ester-induced differentiation
in HL-60 cells, 6669growth-promoting activity of desmopres-
sinleukemia cells, 7055
inhibition of MCF-7 cell growth1,2-dioctanoyl-i/i-glycerol, TPA, 6943
molecular mechanisms of carcinogenesiscancer prevention and treatment, 4135
ornithine decarboxylase mRNAretinoic acid inhibition, TPA-induced
synthesis, 2168partial down regulation
Ha-roj, C3H lOT'/z cells, 6535
phorbol 12,13-dibutyrate and bryostatin 1inhibition of cell-cell communication, epidermal cells, 447
phorbol ester-induced adhesion andtranslocation
U-937 cells, 3168phorbol ester-mediated association
nuclear fraction, NIH 3T3 cells, 1910phorbol ester-stimulated differentiation
retinoic acid, U937 cells, 5779phosphorylation of M, 34,000 to 40,000
proteinsmouse epidermis, 4018
receptorphorbol ester tumor promoters, 1
specific and direct bindingimmobilized tamoxifen analogue, 3626
translocation and down regulationTPA biphasic effects, keratinocytes,
964vinculin phosphorylation
HL-60 cells, 3324Proteoglycans
chondroitin sulfatedifferentiation-associated changes,
U937 cells, 6103thrombospondin binding
sulfated glycoconjugates in melanoma,6785
Protonstoichiometry
electron transport, mitoplasts, 628Protooncogenes
c-erbB-2gene copy number and protein in
breast tumors, 1238c-fos
steroid hormones and peptide growthfactors, breast cancer cells, 802
c-myc. see also c-mycepidermal growth factor receptor,
renal cancer, 6753infiltrating ductal carcinoma of the
breast, 199c-raf
7-glutamyItranspeptidase, liver neoplasms, 1610
expression in HL-60/MRI cells, 6733expression in normal and leukemic
erythroid cells, 3972HER2/neu
sporadic amplification, adenocarcino-mas, 1517
myc familyDNA amplification, small cell lung
cancer, 5163ras
point mutation, acute nonlymphocyticleukemia, 1812
tiazofurin effectsHL-60 cell differentiation, 5965
tumor expressionEwing's sarcoma, neuroepithelioma,
4307\-fms
inhibition of tumor growth, castanos-permine, 1091
Pseudomonascepharanthine and lysosomal function,
1307enhancement of immunotoxin activity
ovarian and epidermoid carcinoma,3919
Pulmonary neoplasms
combined effects of chemotherapy andinterleukin 2 in mice, 122
Furineantifolate drug interactions, 2421
Purine nucleoside analoguesmodulation of antibody response
natural killer cell activity, 4799Pyridoxal S'-phosphate
vitamin B6 metabolism in McA-RH7777cells, 1080
l'y rinudine
halogenated antimetabolitesinterferon interactions, adenocarci-
noma and HL-60 cells, 4868Pyronin Y
toluidine blue O andphotosensitizing effects, 1295
PZEproduction of protein-associated DNA
breaksLI210 cells, 1404
Quinacrinereversal of resistance to vincristine
P388 leukemia, 2064Quinocarmycin
antitumor activityleukemia, lymphoma cell lines, 6029
Quinoneantitumor agents
resistance of L5178Y murine lympho-blasts, 1727
Quinone reducÃaseestrogen-induced kidney neoplasms,
5726mono- and bifunctional enzyme inducers
in liver, 4776
Radiationbleomycin and hyperthermia
combination therapy development,6291
cancer morbidity and mortalityphosphate workers, 7298
fij-diamminedichloroplatinum(II) cross-resistance
human tumor cell lines, 5133tumor growth delay, fibrosarcoma,
2693increase in radioresponse
murine tumors, indomethacin treatment, 3008
-induced fibrosarcoma-1cyclophosphamide response, 3'P NMR
spectroscopy, 4736-induced injury
tumor bed stroma, sarcomas and carcinomas, 2116
ionizinginhibition of recovery processes,
Chinese hamster cells, 4881nul inani ¡bodyinduced myelotoxicity
reduction of, interleukin 1, 5403rare events as clues to cancer etiology,
3544stages of thymic lymphomas
ras oncogenes, 5514ultraviolet-B
growth effect, melanoma cells, 4007Radiohalogenation
monoclonal antibodyyV-succinimidyl 3-(tri-/i-butylstan-
7445
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
nyl)benzoate intermediate, 1446Radioimaging
detection of necrotic lesions in humancancers, 5842
Radioimmunolocalizationantibody-guided targeting
non-small cell lung cancer, 1977Radioimmunotherapy
human colonie cancer xenograftsmonoclonal antibodies, carcinoem-
bryonic antigen, 3270monoclonal antibodies
human milk fat globule, breast carcinoma, 4664
selective growth inhibitionHP160. lung cancer cell lines, 2768
treatmentintracranial human glioma xenografts,
2904Radioimmunotoxins
anti-CD5human tumors, nude mouse model,
7107Radioiodine
-labeled monoclonal antibodiesxenogeneic tumor model, B-cell lym-
phoma, 2475Radiolocalization
polyclonal and monoclonal antibodiescarcinoembryonic antigen, 1823
Radioresponseincrease
indomethacin treatment in murine tumors, 3008
Radiosensitivitycancer family syndrome and cell survival,
2579Radiosensitization
¿V-methylformamide-inducedeliminatili modifications, 5669
Radiotherapycell kinetics in human malignancies
bromodeoxyuridine, flow cytometry,6238
combined modality treatmentthymosin fraction V, small cell lung
cancer, 1663Radiotoxicity
bromine-80mestrogen receptor-directed therapy,
Auger electrons, 5805Radon
cancer morbidity and mortalityphosphate workers, 7298
ReceptorsM
analysis, A-431 cells, 23881,25-dihydroxyvitamin D3
measurement, renal cell carcinoma,2458
modulation, human myeloma cell line,1213
dopamine7,12-dimethylbenz(a)anthracene, ante
rior pituitary, 6434epidermal growth factor
amplification, human glioma xenografts, 2231
characterization, A-431 cells, 2377c-myc expression, renal cancer, 6753cytotrophoblasts, A-431 cells, 11051,25-dihydroxyvitamin D,, breast can
cer cells, 2734effects of butyrate on hepatocytes.
6560expression in human lung cancer cell
lines. 1132gene amplification in esophageal can
cers, 5119glioblastoma cells, 5433growth of neoplastic thyroid cells,
3652human gastric and colonie carcinomas,
137modulation by liver tumor promoting
regimens, 1162overexpression in breast carcinoma,
161plasminogen activators in human
breast cancer, 6603relation to steroid receptors in breast
cancer, 1343restriction fragment length polymor
phisms, 4045selective amplification, glioblastoma
multiforme, 2711erythropoietin
induction, MEL cells, 1818estrogen
antiestrogen growth regulation inMCF-7 cells, 6764
bromine-80m radiotoxicity. Augerelectrons, 5805
17/3-estradiol effect, melanomagrowth, 7093
estradiol effects on melanoma, 3720hormone responsiveness, medullary
thyroid carcinoma, 2760localization, human breast tissue, 6517medicine and treatment, breast cancer,
2314medroxyprogesterone acetate, mam
mary carcinoma, 5084preneoplastic hyperplasia, mouse Ley-
dig cells, 14prostatic carcinoma, 3077SAMBA 200 analysis, breast carci
noma, 1578survival, epithelial ovarian carcinoma,
6222tamoxifen-stimulated growth, MCF-7
tumors, 5183transforming growth factor-/3, breast
cancer cells, 3905fibronectin
alteration of, phorbol ester-treatedpromonocytic cell lines, 5730
sarcoma virus-induced tumors, 5510gastrin
antibodies, colon carcinoma. 7179glucocorticoid
effects on fibrosarcoma growth, 2703protein level, 2636tyrosine aminotransferase modulation
of Reuber hepatoma cells, 5188insulin
diabetes and sex steroids, mammaryadenocarcinoma, 3742
insulin-like growth factor Ihuman breast cancer, 6429human malignant glioma, 1233
interleukin 1binding, cell growth response correla
tion, 5455nerve growth factor
chromatin, melanoma cells, 7200platelet-derived growth factor
mRNA expression in glioma, 3910
progesteroneanti-receptor monoclonal antibodies,
breast cancer, 6462epidermal growth factor, breast carci
noma cells, 5071estradiol effects on melanoma, 3720heterogeneity, endometrial adenocarci
noma, 1889hyperplastic and neoplastic endome-
tria. 6132medicine and treatment, breast cancer,
2314medroxyprogesterone acetate, mam
mary carcinoma, 5084modulation of binding to DNA by
polyamines, 1217structure and protease activity, endo
metrial carcinoma, 1143progestin
survival in epithelial ovarian carcinoma, 6222
protein kinase Cphorbol ester tumor promoters, 1
steroidsurvival in epithelial ovarian carci
noma, 6222T-cell
gene rearrangements, Hodgkin's dis
ease, 3591transforming growth factor-«
mRNA expression in glioma, 3910urokinase
levels, colon carcinoma cell lines, 3112vasoactive intestinal peptide
cellular processing, 6201Red blood cells
laser Doppler flowhyperglycemia, murine tumors, 7102
mitochondriakryptocyanine dye phototoxicity, 6794
Reed-Sternberg cellsmolecular pathways of adhesion
T-cell resetting, Hodgkin's cell line,
37T-cell receptor gene rearrangements
immunoglobulins, Hodgkin's disease,
3591Renal cell neoplasms
enhanced c-myc expressionepidermal growth factor receptor,
6753tumor-infiltrating lymphocytes
interleukin 2, 206Reproduction
borderline ovarian neoplasmscase-control study, 5849
factors and risk of canceruterine corpus, 6217
gestational choriocarcinomacase-control study, 1004
Respirationair or carbon dioxide mixture
pH modification, hydralazine and glucose, 1543
Respiratory burstenhanced activity of peritoneal cells
aclacinomycin, 3440Retinoblastoma
class II antigens, 1633susceptibility gene
chromosomal reorganization, osteosar-coma development, 3939
Retinoblastoma neoplasmsretinoid-binding proteins, 1124
7446
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
Retinole acidactin polymerization in HI, 60 cells,
6721cell cycle changes in maturing HL-60
cells, 5989cholesterol sulfate accumulation
esophageal epithelial cells, 5289chondroitin sulfate proteoglycan
differentiation-associated changes,U937 cells, 6103
effect of phorbol estercAMP-dependent protein kinases, ter-
atocarcinoma cells, 3993effect of sodium butyrate
ovarian adorn»carcinoma.6161effect on neoplastic salivary cells, 7219epidermal oxidation of retinol, 7038gap-junctional intercellular communica
tiontransformed foci, BALB/c 3T3 cells,
3490herbimycin-A and
neuronal cell differentiation, neuroblastoma, 6530
inhibition of TPA-induced synthesisornithine decarboxylase mRN A. 2168
phorbol ester-stimulated differentiationprotein kinase C, U937 cells, 5779
protooncogene expressionHL-60/MRI cells, 6733
terminal differentiationgrowth inhibition, rhabdomyosarcoma,
5264therapy by directing differentiation in
carcinoma, 1999TPA and/or
modulation of transglutaminases, 74Retinoids
-binding proteinsretinoblastoma tumors, 1124
effect on xenoplanted human mammarycarcinoma
athymic mice, 3733growth and differentiation of tumors
murine embryonal carcinoma celllines, 3772
influence on growth and metastasishamster melanoma in athymic mice,
1465Retinol
risk of colorectal cancer, 4399vitamin intervention
precancerous lesions of esophagus inChina, 2280
Retroviruses-associated antigen
modulation, melanoma cells, 4954changes in oncogene expression
colon carcinogenesis, 3964evolution of cancer genes
mutation-driven process, 1697expression in transformed cells
platelet-derived growth factor, 4874history of human T-lymphotropic vi
ruses, 4131Kirsten-ra.s oncogene
clonal diversity, 4941-like sequences and oncogene expression
phénobarbitaltreatment, liver regeneration, 265
oncogenictransformation, mammary epithelial
cells, 4689transformation in rat cell lines
modulation, MHC class I antigens,3816
Rhabdomyosarcomachromosomal analysis, 983terminal differentiation
growth inhibition, retinoic acid, 5264Rhoads Memorial Award Lecture, 1Rhodamine 123
anticarcinoma activitymurine renal adenocarcinoma, 2061
m-diamminedichloroplatinum(II) resistance
effect of hyperthermia, 5101Rhodamine 12.Ì
action of c/i-diamminedichloropla-tinum(II)
effect of hyperthermia, 2335Riboflavin
vitamin interventionprecancerous lesions of esophagus in
China, 2280Ribonucleosides
-restored heat resistancesuppressed protein synthesis, glucose-
deprived L929 cells, 1442Ribonucleotide reducÃase
effect of gallium on DNA synthesishuman T-cell lymphoblasts, 3014
hydro* yurea-resist ant leukemia LI 210cells
cross-resistance patterns, 5796inhibitors
leukemia LI210 cell lines, 839liver microsomal inactivation
4-methy 1-5-amino-1 -formylisoquino-line thiosemicarbazone, 6375
molecular mechanisms of drug resistance, 2029
Ml subunit in cellular proliferationquiescence, differentiation, 5151
Ricincytoplasmic suppression of tumorigenic-
ityreconstructed mouse cells, 830
Ricin Aability of niAh to form immunotoxins,
1119antibody conjugate
endocytosis, intracellular routing,3822
-containing immunotoxinsclinical trial evaluation, CD 19 and
CD22 antigens, 2610deglycosylated
immunotoxin preparation, hindereddisultidc linkages, 6396
enhancement of immunotoxin activityovarian and epidermoid carcinoma,
3919hepatotoxicity of saporin immunotoxins,
7072inhibition of T-cell tumor growth
T101, athymic mouse model, 4862kinetics of cell intoxication, 806-monoclonal antibody conjugates
disulfide-linked, galactose binding,4469
transplantation of non-T-leukemiacells, tumor regression, 4673
pulmonary metastasisimmunotoxin mediation of reduction,
3496tumor-reactive immunotoxins
pharmacokinetics, 2618, 2626
RIF-1 cellsthermoresistance
isolation and characterization, 1803RNA
amplified and overexpressed genesmultidrug-resistant cell lines, 5927
carcinoembryonic antigen familychromosomal localization, various tu
mors, 2550detection of drug resistance
enzymatic amplification, human tumors, 5775
detection of multidrug resistance genein situ hybridization, 4334
gene amplificationepidermal growth factor receptor,
esophageal cancers, 5119glyceraldehyde-3-phosphate dehydrogen-
ase gene expressionpancreatic adenocarcinoma, 6354
hepatocellular carcinomain vitro translation analysis, 2382
L-histidinol effect5-fluorouracil metabolism, 6664
inhibition of ribosomal gene transcription
morpholinyl anthracyclines, 4101interaction of second-generation anthra
cyclines with, 6962levels in metastasis
NM23 gene, 6550messenger: see RNA, messengertranscriptional inhibition of Ha-ras
interferon-induced revenants, mousecells, 5157
RNA, messengerfibronectin
down modulation, prostatic cancer,2042
genomic status of c-myc locusinfiltrating ductal carcinoma of the
breast, 199insulin-like growth factor II
human breast cancer, 6691liver tumors, 6844
oligonucleotidesinhibited gene expression, 2659
ornithine decarboxylaseretinoic acid inhibition, TPA-induced
synthesis, 2168p32 cDNA clone isolation, 4795peroxisomal .¿oxidation
rat tissues, 5316platelet-derived growth factor
transforming growth factor-a, 3910prostaglandin A: and c-myc expression
HL-60 cells, 2813protooncogene expression
HL-60/MRI cells, 6733Rosenthal Foundation Award Lecture, 5381RU 23908
optimal medical castration in male rats,6063
Salivary cellsneoplastic
effect of retinoic acid, 7219Salivary glands
adenocarcinomagrowth inhibition, normal human lì
broblasts, 2819ras p21, cAMP levels, 2898
Salmonella typHÃmurÃum
7447
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
i.-arabinose resistance testprimary tool in carcinogen screening,
907reactivity with DNA bases and mutage-
nicitymethylchrysene diol epoxide enantio-
mers, 1781Sandos tatin
partial inhibition of growthDunning rat prostate tumors, 4651
Sa porinimmunotoxins
hepatotoxicity, 7072Sapporo Cancer Seminar
primary and secondary prevention ofcancer, 4434
Sarcomacancer families
susceptibility to neoplasia, 5381cancer family syndrome
twenty-four kindreds, 53585-deazaaminopterin
5-alkyl derivatives, methotrexate comparison, 5686
Ewing's
patterns of protooncogene expression,4307
tumor-associated antigen, endocrinetissue, 6127
Glasgow osteogenicflavone acetic acid-induced DNA dam
age, 1279heat-induced vascular damage
thermosensitivity, 7226murine S180 variants
doxorubicin resistance reversal, for-skolin, 539
noncachectic patientsaltered leucine metabolism, 1374
radiation-induced injurytumor bed stroma, 2116
reproductive factorsrisk of cancer, uterine corpus, 6217
Yoshidaalterations in protein synthesis, 1554branched chain amino acids, paren
lerai nutrition, 2698Sarcoma cells
Nakahara-Fukuoka1-hexylcarbamoyl-5-fluorouracil, hy-
perthermia, 3977Sarcoma 180 cells
potentiation of Adriamycin cytotoxicitydipyridamole, 1208
Sarcoma virusFujinama
dexamethasone effects, neoplastictransformation, 7231
Gardner-Arnstein strain felineneosynthesis of gangliosides, 1753
-induced tumorstÃbroneciinreceptor expression, 5510
Schwärmcellsdifferentiation of neuroblastoma cell
linesinduction by bromodeoxyuridine, 2531
neurofibromatosis-like diseasetransmissibility in damselfish, 3828
Seleniuminorganic
effect of dietary excess on colon carci-nogenesis, 1777
phenotype and growth of melanomasserum-free medium, 686
Seminomagerm cell neoplasms
blood group-related antigens, 5342Serine proteinases
effects of inhibitorsbasement membrane invasion, mela
static cells, 3307Serotonin
antitumor effectstumor necrosis factor-a, 4250
major serum factorphosphoinositide turnover, kidney
cells, 6697Serum
cancer patientsnatural killer cell activity, coloréela!
adenocarcinoma, 2596significance of a-2-L-fucosyltransferase
leukemic patients, 3998Shanghai
risk factors, breast cancer in women,1949
Sialic acidmono-, di, and tri-O-acetylated
normal and neoplastic colon, 483mucin-like antigens
monoclonal antibodies, pancreatic cancer, 3924
Sialic acidmucleoside conjugateinhibition of pulmonary metastasis
colon adenocarcinoma, 3728Sialoglycoprotein
expression on metastatic colon carcinoma, 2353
membraneIgG2a monoclonal antibody, small cell
lung carcinoma, 4318Sialosyl-Tn epitope
preparation of monoclonal antibodies,2214
Sialyl-fucosyl type 1 chaincancer-associated serum glycoprotein an
tigens, 3856Sialyltransferase
comparison of Le" antigens
human colon and pancreas, 3834expression correlated with human chro
mosome 11, 1489Simian virus 40
effects of transformationintercellular gap junctional communi
cation in fibroblasts, 3485human bronchial epithelial cells
T-antigen transformation, 1904-transformed uroepithelial cells
cytogenetic instability, chromosomechanges, 3215
Sinus cancermaxillary
case-control study in Japan, 1651Sister chromatid exchange
antitumor topoisomerase II inhibitorsChinese hamster cells, 512
assessment of cell cycle durationsomatic and spermatogonial cells,
5953cytotoxicity
alkylating chemotherapeutic agents,tumor cells, 3100
Ehrlich ascites tumor cells treated withcyclophosphamide
antineoplastic effect, caffeine, 1129induction by busulfan
chronic myeloid leukemia, 3435
induction by diaziquonehuman and mouse lymphocytes, 27
normal bone marrowPh-positive chronic myelocytic leuke
mia, 745persistently elevated
ethylene oxide-exposed primates, 5045role of metabolism and DNA adduct for
mationlymphocytes, diethylstilbestrol, 335
Skinalteration of cholesterol biosynthetic
pathwayspolycyclic aromatic hydrocarbons,
2555carcinogenesis
transcriptional control, keratin geneexpression, 3245
L-a-dioctanoylglyceroltumor promoter, 1736
inhibition of TPA-induced tumor promotion
curcumin, chlorogenic acid, 5941metastasis
highly pigmented melanoma variant,4897
nitrosamine formation from aminesbefore and after nitrogen dioxide,
1095papillomas
aneuploidy, 7-glutamyltransferase,3253
tumorigenesisprotection, tannic acid, 2361
tumor progression in SENCAR miceinitiator dose, papilloma, 7048
Skin neoplasmsalterations in epidermal polyamine levels
DNA synthesis, chrysarobin, 6390detection of activated oncogenes
sun-exposed body sites, 3341herpes simplex virus
inducible repair, xeroderma pigmento-sum, 6054
ultraviolet-inducedrejection, role of helper T-cells, 2325
Sodiumbreast cyst fluid
epidermal growth factor, 5860-deficient diet
restriction of tumor growth, 3445proteases in cyst fluid
human gross cyst breast disease, 6379Sodium bisulfite
chromosome alterationsSyrian hamster cells, 7246
Sodium butyrateeffect on ovarian adenocarcinoma, 6161modulation
plasminogen activator, glioma cells,291
rat ductular oval cellspromotion of growth, primary culture,
368Sodium etiolate
effects on colon carcinogenesis7V-methyl-A''-nitro-./V-nitrosoguani-
dine-induced, 3035Sodium dirimÃate
-induced DNA lesionspolyadenosine diphosphoribose syn
thesis, V79 cells, 1100Sodium n-butyrate
modulation of calcitonin gene expression
7448
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
medullary thyroid carcinoma, 2096Sodium-potassium-ATPase
photosensitizing effects of hematopor-phyrin derivative
mammary adenocarcinoma, 3360Somatic cells
assessment of cell cycle durationsister chromatid exchange, 5953
Somatomedin-Cautocrine mitogenic stimulation
lung cancer cells, 3716Soma)ostatili analogues
oncological applications, 6977Sorcin
purificationmultidrug resistance, monoclonal anti
bodies, 3173Soybean agglutinin
binding cellslymphatic metastasis, mammary ade
nocarcinoma, 1451removal of breast cancer cells
model for purging human marrow,4573
Spermatogenesisprocarbazine-induced germinal cell apla
siapartial prevention by testosterone,
4354Spermatogonial cells
assessment of cell cycle durationsister chromatid exchange, 5953
Spermidinemetabolism and interconversion
NIH 3T3 cells, ras transfection, 3336Spheroids
diffusion and bindingantitumor antibodies, 4032
multicellularglucose diffusivity, 3905growth saturation, role of necrosis,
2432uptake kinetics of inAb. human malig
nant melanoma, 1856Spirohydantoin mustard
pediatrie Phase I and pharmacokineticstudy, 2292
SpleenT helper cells and accessory cells
tumor-specific CTL generation, 1422Sqiiamous SQCC/Y1 cells
differentiationchanges in glycosphingolipids, 2121
SR 4233metabolism by Chinese hamster ovary
cells, 5947Stature
adultrisk of cancer, 1658
breast cancer risk assessmentsanthropometry, 5363
Staurosporinecontrasting actions
neutrophils, epidermal cells, 4646Sterigmatocystin
effect on glucocorticoid receptorst>rosine aminotransferase, Reuber
hepatoma cells, 5188Steroids
dehydroepiandrosteroneinduction of ovarian granulosa cell tu
mors, 2788diabetes and
insulin receptor kinase, mammary ade
nocarcinoma, 3742effects of phenol red
breast cancer cell growth, 3693hepatic effects
structure-activity studies, 2462insensitivity
breast cancer cells, 4340peptide growth factors and
c-fos expression, breast cancer cells,802
risk of colorectal cancer, 4399Sterol
alteration of cholesterol biosyntheticpathways
polycyclic aromatic hydrocarbons,2555
Stomachbiomarkers of increased susceptibility
gastrointestinal neoplasms, cancer prevention, 235
carcinogenesisphenolic antioxidants, 5310
gastric carcinogenesiscaerulein enhancement, 6332
hydroxy metabolites of methyl-n-amylni-trosamine, 5663
Stomach neoplasmsanti-ros p21 monoclonal antibodies,
5503high risk of
diet, case-control study in China, 3518loss of chromosomal heterozygosity,
2988Streptomyces mediocidicus
teleocidins A and Btumor-promoting activity, 4211
Streptozotocindrug sensitivity assay
monolayer culture, colon carcinomas,3236
Stromafibrin-fibronectin degradation
ovarian carcinoma, 3507Strontium phosphate
human bronchial epithelial cellsT-antigen transformation, 1904
Subendothelial matrixinteraction of intravascular tumor cells
endothelial cells, 4065Substrates
effects of deoxycytidinethymidine kinase deficiency, deoxyri-
bonucleosides, 3681yV-Succinimidyl3-(tri-n-butylstan-
nyl)benzoate intermediateradiohalogenation of monoclonal anti
body, 1446Sudan III
mechanism of induced preventionchemical carcinogenesis in rats, 254
Sulfatideslaminin-dependent and -independent
adhesionmelanoma cells, 3367
Superoxide dismutaseeffect on Adriamycin tolerance
Chinese hamster ovary cells, 4493erythroleukemia maturation, 6674
Suppressor cellstumor-induced myelopoiesis
prostaglandin K•¿�regulation, Lewislung carcinoma, 6826
Surface markersphenotype and growth of melanomas
serum-free medium, 686Surgery
chemotherapy andtiming of, osteosarcoma model, 5533
Swainsonineaugmentation of murine natural killer
cells, 1410Sweetners, artificial
squamouse cell carcinomabladder adenocarcinoma, 3853
Taiwanseroepidemiology of HTLV-1, 5042
Tamoxifendisparate actions
breast tumor growth, athymic mouse,812
endocrinologypremenopausal node-positive breast
cancer, 1026estrogen receptor and hormone respon
sivenessmedullary thyroid carcinoma, 2760
estrogens as cause of human cancer, 2464-hydroxy-A'-desmethyltamoxifen metab
olitehuman bile, 2304
inhibition of estrogen-induced renal carcinogenesis
DNA adduci levels, 779specific and direct binding
protein kinase C, 3626-stimulated growth of MCF-7 tumors
long-term antiestrogen administration,5183
vs. estradici effectsnormal breast cells, 7193
Tannic acidprotection against skin tumorigenesis,
2361Taxol
microtubule changes and cytotoxicityleukemic cell lines, 4093
T-cellsCD8+ depressed responses, 6992denaturation and renal unit ion of len-
tinan, 671early acting delayed-type hypersensitivity
effector cells, tumor rejection, 5922elimination of suppressor activity by
bleomycintumor-bearing rats, 6658
endocytosis and degradationanti-human CD3 mAb, 2249
helperrejection, ultraviolet-induced skin can
cers, 2325immune system of cancer patients
low dose cyclophosphamide, 1671inhibition of tumor growth
TlOl-ricin A-chain, athymic mousemodel, 4862
intervention in transportationmouse mammary tumor virus, mam
mary gland cells, 6555Lyt-2+
importance in tumor rejection, 4834polyclonal lymphocytosis
human T-cell leukemia virus I, 2585production of suppressor lymphokine
syngeneic mammary adenocarcinoma,943
spontaneous resetting
7449
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
molecular pathways of adhesion,Hodgkin's cell line, 37
tyrosine kinase YT16 expression, 8563T3 cells
disorganizing-overstabilizing drugscell proliferation, microtubules, 4892
Teleocidins A and Btumor-promoting activity, 4211
Icstii ulur neoplasmsdifferential repair of platinum-DNA ad-
ducts, 3019Testis
cadmium carcinogenesisdose-response, 4656
stage migrationgerm cell neoplasms, 3524
Testis neoplasmsestrogens as cause of human cancer, 246
Testosteronearomatization
epithelial tumor cells, ovarian carcinoma, 6491
imidazole-induced tyrosinase expressionB16 melnoma cell culture, 3586
increase in 5«-dihydrotestosteroneandrogen-independent prostate carci
noma, 609partial prevention
germinal cell aplasia, procarbazine-in-duced, 4354
2,3,7,8-Tetrachlorodibenzo-y>-dioxinAh receptor analysis
A431 squamous cell carcinoma, 2388Tetrachloro(</,/-frai»)l,2-diaminocyclohex-
ane platinum (IV)therapeutic and pharmacological studies,
1745l2-O-Tetradecanoylphorbol-13-acetate
alteration of cholesterol biosyntheticpathways
polycyclic aromatic hydrocarbons,2555
alterations in epidermal polyamine levelsDNA synthesis, chrysarobin, 6390
antitumor actionoleanane-type triterpenoid compounds,
5210biphasic effects on keratinocytes
down regulation, protein kinase C, 964calmidazolium and
differentiation modulation, coloniecancer cells, 6173
clonogenic keratinocytestwo-stage carcinogenesis, 6285
i,-a-dioctanoylglyceroltumor promoter in mouse skin, 1736
duration of exposurerequirement for transformation, 7126
effect on cAMP-dependent protein kin-ases
teratocarcinoma cells, retinoic acid,3993
-induced ( •¿�delaytime lapse photography, HeLa cells,
1759-induced synthesis of ornithine decarbox-
ylase mRNAretinoic acid inhibition, 2168
induction of 8-lipoxygenasecomparison in SENCAR and C57BL/
6J mice. 658inhibition of chemotactic signals
intracellular calcium, HL-60 cells,2707
inhibition of induced tumor promotioncurcumin, mouse skin, 5941
inhibition of MCF-7 cell growthprotein kinase C activity, 6943
molecular mechanisms of carcinogenesiscancer prevention and treatment, 4135
nerve growth factor receptorschromatin, melanoma cells, 7200
ornithine decarboxylase activitymicrowave fields, 4222
retinoic acid and/ormodulation of transglutaminases, 74
reversible induction of anchorage-independent growth
normal mouse keratinocytes, 1566role of oxygen radicals
squamous differentiation, bronchialepithelial cells, 822
seed oil of Jatropha curcasnew tumor promoter, 5800
transfer of promotion sensitivitypro gene, 1195
Tetragastrininfluence of cimetidine on anticarcino-
genic effectAr-methyl-Ar-nitro-/V-nitrosoguanidine,
1591Tetrahydrofolates
characterizationxenografts of colon adenocarcinoma,
3062Tetrahydrouridine
clinical pharmacologyl-/3-D-arabinofuranosylcytosine, 1337
Tetraplatin: see Tetrachloro(i/,/-frfli«)l,2-diaminocyclohexane platinum (IV)
Texas Gulf Coastoccupational risk factors, laryngeal can
cer, 1960T helper cells
accessory cells andtumor-specific CTL generation, 1422
ThermoresistanceRIF tumor cell strains
isolation, initial characterization, 1803Thermosensitivity
heat-induced vascular damage andmurine tumors, 7226
Thermotolerancedevelopment in Chinese hamster ovary
cellsglutathione depletion, heat shock pro
tein synthesis, 7033effect of hyperthermia
glycosyltransferases, Chinese hamsterovary cells, 5717
protein synthesisbone marrow progenitors, 3630
Thioether phospholipideffects on protein kinase C
HL-60 cell differentiation, 66696-Thioguanine
enhanced cytotoxicityADP-ribosyltransferase inhibitors,
5650HL-60 cells
mitogenic responsiveness to GM-CSF,2683
modulation of activity by guanine,3648
Thiolsexposure to A'-2-acetylaminofluorene
depletion of adenosine diphosphate-ri-bosyl transferase activity, 3581
rescue agentsLLC-Pk, cells as model, cisplatin
nephrotoxicity, 6017Thiotepa
antitumor effects of pentoxifyllinehuman cancer cells, 4375
Thrombospondininteractions with sulfated glycolipids and
proteoglycanshuman melanoma cells, 6785
laminin-dependent and -independentadhesion
sulfatides, melanoma cells, 3367Thromboxane
evidence for biosynthesislung adenocarcinomas, 2674
prostacyclin andincreased synthesis, ovarian malig
nancy, 2396Thymic neoplasms
immunohistological analysisPE-35 monoclonal antibody, 1896
Thymidineeffect on nitrosourea activity, 4272incorportion in hepatoma
linoleic acid, arachidonic acid, 3106increased levels of DNA lesions
leucovorin-5-fluoropyrimidine, colonadenocarcinoma, 4153
inhibition of uptakeLHRH agonist, 7252
Thymidine kinaseactivity of cytosolic isozyme
malignancy, lung tumors, 5001deficiency
substrate cycles, deoxyribonucleosides,3681
Thymidylateantifolate drug interactions, 2421synthesis inhibition
methotrexate effects on methylenete-trahydrofolate, LI210 cells, 3398
Thymidylate synthasedetection of drug resistance
enzymatic amplification, human tumors, 5775
mechanisms of innate resistance5-fluorouracil, 5894
proliferation-dependent cytotoxicitymethotrexate, leukemia, 5638
Thymidylate synthetaseinterferon interactions
halogenated pyrimidine antimetabo-lites, HL-60 cells, 4868
Thymomaimmunochemotherapy
use of idarubicin mAb conjugates, 926Thymosin fraction V
combined modality treatmentsmall cell lung cancer, 1663
Thymusglucocorticoid receptor at protein level,
2636Thyroid
carcinogenesiscytochrome P-450 induction, hydan-
toins, 2492C-cells
N-myc expression, neoplasia, 4073Thyroid cells
neoplasticepidermal growth factor receptor,
3652Thyroid neoplasms
7450
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
activated ras oncogenes, 4459anli-ru,v p2l monoclonal antibodies,
5503Tiazofurin
effects on protooncogene expressionHL-60 cell differentiation, 5965
T-lymphocytes: see T-cellsT-lymphoma cells
normal T-cell proliferationtransferrin-like autocrine growth fac
tor, 3425Tn antigen
IgG3 monoclonal antibodyblood group A antigen, 4361
Tobaccoeffects of timing and type
cigarette-induced bladder cancer, 3849esophageal carcinoma, 3843long-lasting effects of smoking
pulmonary drug-metabolizing enzymes, lung cancer, 4695
Toluidine blue Opyronin Y and
photosensitizing effects, 1295Topoisomerase I
camptothecin-resistant CHO cell mutants, 6404
mammaliandrug target, camptothecin, 1722
Topoisomerase IIantitumor inhibitors
sister chromatid exchanges, Chinesehamster cells, 512
effect of inhibitorshyperthermic cytotoxicity, 3932
effects of antileukemia agentsnuclear matrix-bound DNA replica
tion, CCRF-CEM leukemia cells,1850
etoposide-resistant human KB cell linescombined modalities of resistance,
5956-interactive antitumor drugs
estrogen and DNA damage, breastcancer cells, 297
phorbol ester-induced changesDNA cleavage, leukemia cells, 6625
production of protein-associated DNAbreaks
PZE, LI210 cells, 1404resistance of noncycling cells to anisa
crine, 310TPA: see 12-O-Tetradecanoylphorbol-13-
acetateTrachea) epithelial cells
cytogenetic changesearly stages, carcinogen-induced neo-
plastic progression, 702induction of ornithine decarboxylase ac
tivityasbestiform minerals, 709
Tranquilizersrisk of colorectal cancer, 4399
Transferringrowth requirements of colon carcinoma
monolayer and soft agarose, 2469-like autocrine growth factor
T-lymphoma cells, normal T-cell proliferation, 3425
phenotype and growth of melanomasserum-free medium, 686
Transformantsspontaneous
uniqueness, clone of BALB/c 3T3
cells, 2512Transformation
-associated cell surface antigenidentification, fetus-derived fibroblast,
2798characterization of chromium effects
liver epithelial cell lines, 6484gap-junctional intercellular communica
tionBALB/c 3T3 cells, 3490
normal homologous cellsHa-rfli oncogene, 3470
pro-l and pro-2 transfectantstumor promoters and antipromoters,
mouse cells, 6076requirement
duration of TPA exposure, 7126simian virus 40
intercellular gap junctional communication, fibroblasts, 3485
spontaneousC3H 10T'/2 cells, 5969A'-methyl-Ar'-nitro-Ar-nitrosoguanidine,
C3H 10T'/2 cells, 5977target
differentiation-induced Mil cells,4389
Transformed cellsselective killing
intercellular communication, therapeutic applications, 3203
Transformed growth-inhibiting factorlatency
human malignant effusions, 418Transforming growth factor-«
autocrine growth factorresponse, lung carcinoma cell line,
4976effusions from cancer patients
marker of tumor burden and prognosis, 5023
expression of mRNAsglioma cell lines, 3910
transformed hamster oral keratinocytes,3130
Transforming growth factor-/?biological activity
estrogen receptor-negative breast cancer cells, 3898
characterization of resistant subclonescolon carcinoma, 7120
enhancement of cell transformation,2832
induction of carcinoembryonic antigensecretion
fibronectin expression in colon carcinoma, 4059
modulation of plasminogen activator activity
endometrial adenocarcinoma cells,6384
regulatory effects of cell density, 4266stimulation
metastatic fibrosarcoma, 6999Transforming growth factors
growth modulation of mouse keratinocytes, 1596
4-as-hydroxy-L-prolinegrowth sensitivity of transformed ro
dent cell lines, 2483liver epithelial cells, 850multiplicity
human malignant effusions, 1792oncogene expression and
mammary epithelial cells, 7041therapy by directing differentiation of
carcinoma, 1996Transglutaminascs
tissue and epidermalmodulation, TPA and/or retinoic acid,
74Transplantation
fetal forebrain,/V-nitrosoethylurea induction, oligo-
dendrogliomas, 2871murine and human tumors into brain
subcutaneous tissues of mice, 6510non-T-leukemia cells
tumor regression, immunotoxins, 4673orthotopic implantation of colorectal
carcinoma, 6863progressive growth of fish tumors
thymic-aplastic mice, 741purging regimens
clonogenic assays in mice, 3394quantitative assays
spontaneous tumors in C3H mouse,4525
renal carcinomaerythropoietin-induced polycythemia,
3430studies of putative lymphosarcoma
Xenopus, 954Transplantation antigens
cyclophosphamide andinterleukin 2, active specific chemoim-
munotherapy, 101Trichothiodystrophy
DNA repair defectcellular response, ultraviolet light,
6090/V,/V',A'"-Triethylenethiophosphoramide
cyclophosphamide andcombination in vitro and in vivo, 94
I rifui ium pratenseassay for detection of anticarcinogens
natural products, 6257Trifluoperazine
ATPase activity of P-glycoproteinsmultidrug resistance, K562/ADM
cells, 49264,5',8-Trimethylpsoralen
repair of DNA damagenormal and Fanconi's anemia, 2015
Trimetrexateantifolate drug interactions, 2421characterization of transport
lymphoblastoid cells, lipophilic anti-folates, 6986
Phase I study, 5029Triphenylethylene
specific and direct bindingprotein kinase C, tamoxifen analogue,
3626Triterpenoid compounds
oleanane-type12-O-tetradecanoylphorboI-13-acetate,
antitumor action, 5210Tryptophan
concentration in culture mediaantiproliferative activity, 7-interferon,
346TSP-180
quantitation in normal and tumor tissue,816
Tubercidinmodulation of antibody response
natural killer cell activity, purine mi
7451
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
cleoside analogues, 4799Tuberculosis
risk factors for lung adenocarcinomapersonal and family history, 7279
Tumor-associated antigensATM-1
T-cell clone, sera of cancer patients,4848
autologous cytotoxic T-cell clonecharacterization, n-butyl alcohol, 3892
comparison of sialylated Le" antigens
human colon and pancreas, 3834Ewing's sarcoma
endocrine tissue, 6127gastrointestinal tumor-associated glyco-
proteinCA 19-9 expression, 1505
glycoprotein 72second generation monoclonal anti
bodies, 4588IgGj monoclonal antibody
( ÃŒM. lactone immunization, inhibitedmelanoma growth, 5680
monoclonal antibodyneuraminidase-treated cancer cells,
412monoclonal antibody with restricted
specificityprostate and breast carcinoma, 4543
Tumor-associated glycoproteinTAG-72
purification, monoclonal antibodies,6811
Tumor bed strinilaeffect of radiation-induced injury
metastatic spread, sarcomas and carcinomas, 2116
Tumor burdenprognosis and
transforming growth factor-a, cancereffusions, 5023
Tumor cellsantibody-mediated killing
attached effector cells, 624antiproliferative activity
ether lipid analogues, DNA-interactiveagents, 1788
autologous cytotoxic T-cell clonetumor antigen characterization, n-bu-
tyl alcohol, 3892blood How, 2641brain
sister chromai id exchange, alkylatingagents, 3100
cell growth and drug sensitivitysoluble tetrazolium/formazan assay,
4827collagenolytic activity
macrophage and lymphocyte potentia-tion, 6832
cytoskeletonplatelet adhesion role, platelet aggre
gation, 3787doxorubicin resistance
differing mechanisms, 2793drug-resistant
flow cytometric enumeration, 6037lysis by activated lymphocytes, 2372
effect of bleomycinelevated temperatures, two pH values,
615endothelial cell-derived interleukin 1
chemotactic activity, 7041extracellular matrix invasion assay
protein gels, 6933-fibroblast interaction
enhancement of metastatic capacity,1456
growth stimulationmononuclear cell-derived factor, 5411
humanprostaglandin biosynthesis, 4770
identification of platelet-aggregating factor
monoclonal antibodies, colon adenocarcinoma, 6411
interaction of melanoma with murinemesentery, 5296
intravascularinteraction with endothelial cells, sub-
endothelial matrix, 4065invasion
collagenase secretion blockade, estra-mustine, 6262
MDAY-D2collagen-binding glycoproteins, 4743
Mer" and Mer+ cellsmixed-function drugs, aerobic and hy-
poxic toxicity, 798mixed heterogeneous
dominance, tumor subpopulation,5747
MOPC-315tumor rejection, Lyt-2+ T-cells, 4834
murineantitumor activity, MX2, 6653
mutagen-treated murineexpression of gp70, 1137
nitrosourea-resistant Mer*
thermal sensitization, 1086patterns of methionine dependence, 6775protection against cytotoxic cells
fibrin coagulation, 5216rhabdomyosarcoma
terminal differentiation, retinoic acid,5264
RIFthermoresistance, isolation and char
acterization, 1803rodent and human
glutathione, various cell cycle phases,3661
glutathione levels, 3657synergistic cytotoxicity and DNA strand
break formationbromodeoxyuridine, bleomycin, 4244
tissue inhibitor of metalloproteinasesmelanoma cells, 5539
tumor necrosis factorlymphotoxin gene expression, 5417
viability and inoculum densitygrowth in agar, 3944
Tumor growthbreast
disparate actions, tamoxifen, 812Gompertzian model, 7067
delay with trimodality therapyFSalIC fibrosarcoma, 2693
effect of interferon-aA/D, 2366inhibition of T-cell line
T101-ricin A-chain, athymic mousemodel, 4862
mammarymast cells, prolactin binding and local
ization, 3765polyamines, progesterone, 3058reconstitution of site preference, 3698
restriction
sodium-deficient diet, 3445v-/ms-induced
inhibition by castanospermine, 1091I unioni ¡ilalactivity
induction in alveolar macrophagesmonocytes, lung cancer, 3949
motility andinterleukin-2-stimulated lymphocytes,
3374Tumorigenesis
colonie cell proliferationstructural requirements, oxidized fatty
acids, 1771A'-ethyl-A'-nitrosourea-induced
major histocompatability complex(H-2), 6634
gene for granulosa cell tumors, 5092genetic convergence and divergence
tumor progression, 5911mammary
adrenal regulation, 3801dietary fat and caloric restriction, exer
cise, 4276influence of caffeine, unsaturated fat,
2074influence of caffeine, coffee consump
tion, 2068hyperplastic alveolar nodules, trans
plantation, 3197skin
protection by tannic acid, 2361Tumorigenicity
cytoplasmic suppressionreconstructed mouse cells, 830
dedifferentiated rat hepatoma line, 3258murine lymphomas
fluorescence-detected natural antibodybinding, 270
oncogene expression andpediatrie cancer, 2715S49 wild type and cyc~ lymphoma
adenylate cyclase, 641Tumor models
treatment-induced changesdrug sensitivity, 2749
xenogeneicradioiodine-labeled monoclonal anti
bodies, B-cell lymphoma, 2475Tumor necrosis factor
anticellular and DNA fragmenting activities
correlation, 6006antitumor effect of immunoconjugates,
3607breast cancer survival model, 5565circulating cytokines in metastatic cancer
patientsinterleukin 2, LAK cells, 5864
distinction from natural killer cell cytotoxic factor
recombinant human lymphotoxin, 891human macrophage function, 5604hyperthermia and
synergistic effect, 650, 654immunomodulatory properties, 544interleukin 2 and
activation, cytotoxic lymphocytes, 788lymphotoxin gene expression
human tumor cell lines, 5417mediator of cancer anorexia, 4567production in nude mice
muramyl peptides, bacterial vaccines,5766
role in macrophage activation
7452
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
tumoricidal activity, 5427self-induction of synthesis
human and murine cell lines, 5407synergy with -y-interferon and interleukin
2successful therapy, pulmonary métas
tases, 2245toxic effect
tumor vasai hiturc in mice, 2179Tumor necrosis factor-a
antitumor effectsrole of serotonin, 4250
effects of hematopoietic suppressor molecules
granulocyte-macrophage progenitorcells, 1548
interleukin 2 andsynergistic antitumor effects, 4011
species preferencehuman and murine, 920
Tumor progressiongenetic convergence and divergence,
5911glioma malignancy stages
clonal genomic alterations, 5546Kirsten rov oncogene
clonal diversity, 4941phenotypic changes in neoplastic cells
5-aza-2'-deoxycytidine, hydroxyurea,
2440retrovirus-associated antigen
modulation of melanoma cells, 4954SENCAR mouse skin
initiator dose, 7048Tumor promoters
antipromoters andpro-l and pro-2 transfectants, mouse
cells, 6076cytochrome P-450 induction
hydantoins, liver and thyroid carcino-genesis, 2492
L-a-dioctanoylglycerolmouse skin, 1736
duration of TPA exposurerequirement for transformation, 7126
-induced nuclear associationprotein kinase C, 1910
liverepidermal growth factor receptors,
modulation, 1162oxidation of retino! to retinoic acid
epidermis, 7038p32 cDNA clone isolation, 4795phorbol ester
comparison, SENCAR and C57BL/6Jmice, 658
ornithine decarboxylase activity, microwave fields, 4222
protein kinase C as receptor, 1phosphorylation of M, 34,000 to 40,000
proteinsprotein kinase C, epidermis, 4018
seed oil ofJatropha curcas, 5800teleocidins A and B
carcinogenesis, 4211transfer of pro gene transfection
JB6 cells, 1195transforming growth factor-/3, 2832
Tumorsaneuploid and diploid
tumor spread and DNA content, renalcell carcinoma, 3165
artificial heterogeneouscompositional stability, mitomycin C
as probe, 2669concomitant immunity
effector mechanism, murine plasmacy-toma, 1398
host effectors, isolation and reactivity,1153
detection of drug resistanceenzymatic amplification, 5775
detection of necrotic lesionsnovel method, human cancers, 5842
detection with monoclonal antibodiescolorectal cancer, 4348
endocrine and nonendocrineneuroendocrine markers, 4078
incidence and nature•¿�y-irradiation,Sprague-Dawley rats,
2451interstitial pressure
heterogeneous distribution, monoclonal antibodies, 7022
malignantnuclear preparations, lectin-binding
proteins, 551predictive value
MIvitro clonogenic assays, 5447primary
selection and overgrowth, genetics,6109
rat brainblood-brain barrier disruption, metho-
trexate, 694solid
antitumor activity, interleukin la,6011
CDS* tumor-infiltrating lymphocytes,
depressed responses, 6992chromosomes, 104910-ethyl-lO-deazaaminopterin, Phase I
trial, 5573glucose diffusivity in spheroids, 3905pathophysiology, cyclophosphamide
effect, 4206Ar-(phosphonacetyl)-i.-aspartate, bio
chemistry, 4434therapeutic attack of hypoxic cells,
775tobacco-related
lung and pancreas of rats, 6912transplan table
biological effects, phthalocyanine dyes,3040
vasculaturethermosensitivity, 7226
Tumor-specific antigensbutano! extraction
fibrosarcoma, ultraviolet light-induced,7004
lyrosinaseeffects of estradici
estrogen and progesterone receptors,melanoma, 3720
imidazole-induced expressiontestosterone effect, B16 melanoma,
3586influence of organ microenvironment
pigmentation, metastatic murine melanoma, 2258
Tyrosine aminotransferasemodulation of hormonal induction
glucocorticoid receptors, Reuber hepa-toma cells, 5188
rat ductular oval cellspromotion of growth, primary culture,
368
Tyrosine kinasealteration in phosphorylation
granulocytic maturation, HL-60 cells,52
human T-cell-specific YT16 expression,856
phosphotyrosine phosphatase activitiesand
biochemical characterization, HL-60cells, 4299
protein activitypp60""irrexpression, flow cytometry,
4633
U
U-71,I84CC-1065 analogues
cell survival and cycle, Chinese hamster ovary cells, 109
U937 cellsdifferentiation-associated changes
chondroitin sulfate proteoglycan, 6103effect on differentiation
endogenous and exogenous interferons, 82
enhancement of Adriamycin antitumoractivity
polymethacr> late nanospheres, 1835phorbol ester-induced adhesion and
translocationprotein kinase C, 3168
phorbol ester-stimulated differentiationretinoic acid, protein kinase C, 5779
Ultraviolet Beffect of radiation on growth
melanoma cells, 4007Ultraviolet irradiation
antioxidant enzymesxeroderma pigmentosum fibroblasts,
2132detection of activated oncogenes
human skin cancers, 3341DNA damage
benoxaprofen and phagocytes, 3094DNA repair defect
trichothiodystrophy, 6090incidence of cutaneous melanoma
histology, 5036-induced fibrosarcoma
butano! extraction, tumor-specific antigens, 7004
-induced murine skin cancersrejection, role of helper T-cells, 2325
systemic effectsenhancement, chemical carcinogenesis,
620United States
comparative epidemiology of cancer,7285
incidence of cutaneous melanomahistology, 5036
Uric acidserum levels
cancer risk in humans, 2916Urinary bladder
carcinogeneffect of peroxidase inhibitors, 304
epithelial cellsDNA repair, arylamine metabolites,
4227papillary and nodular transitional cell
carcinoma, 2299Urinary bladder neoplasms
blood group-related antigens, 4113
7453
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
A'-nitrosobutyl-(4-hydroxybutyl)aminepharmacokinetic profile, 3666
Urinedeficient carboxyphosphamide excretion
cyclophosphamide administration,cancer patients, 5167
increased levelsfibroblast growth factor-like activity,
bladder or kidney cancer, 2083levels of A'-nitrosothioproline
ingestion of cod with vegetables, 4049plasma and
5-fluorouracil metabolites, 1680Uroepithelial cells
SV40-transformedcytogenetic instability, chromosome
changes, 3215Urokinase
determination of levelscolon carcinoma cell lines, 3112
modulation of metastatic potentialmurine melanoma cells, 1270
Urotheliumdifferential regulation of plasminogen ac
tivatorsepidermal growth factor, 5552
humanblood group-related antigens, 4113
normal and malignantglycosyltransferases, 4427response to blockade, polyamine syn
thesis and interconversion, 357Uterine cervix
carcinomahuman papillomavirus types, 993
Uterine corpusreproductive factors
risk of cancer, 6217Uterine curettage
risk of colorectal cancer, 4399Uterus
mAb reactive with human cervical ade-nocarcinoma
immunodiagnostic potential, 6565
Vascularityeffect of cyclophosphamide
pathophysiology, solid tumors, 4206Vascular leak syndrome
antitumor and antiviral natural immunity
interleukin 2, immunodeficiencystates, 6081
Vasculaturetumor
toxic effect, tumor necrosis factor,2179
Vasoactive intestinal peptidecellular processing
colonie carcinoma cells, 6201receptors
breast cancer cells, 5079V79 cells
bacteria andmutagenicity, CC-1065 and analogues,
32low-molecular-weight growth inhibitor
characterization, 3737mutagenicity
5-hydroxymethy 1-2' -deoxyuridine,
5466polyadenosine diphosphoribose stimula
tion
sodium chromate-induced DNA lesions, 1100
uptake of WR-2721 derivativestransported form of drug, 3634
Verapamilantiproliferative effect
brain tumor cells, 3617ATPase activity of P-glycoproteins
multidrug resistance, K562/ADMcells, 4926
-hypersensitive Chinese hamster ovarycells
properties of, 4477intrinsic drug resistance
possible link, detoxification mechanism, 3025
reversal of doxorubicin resistancemultidrug-resistant myeloma cells,
6365Vimentin
diagnostic and therapeutic monoclonalantibodies
mesothelioma cell lines, 5228Vinblastine
effect on microtubulescell proiferation, 3T3 cells, 4892
Vinca alkaloidssnail neurons as model
testing, neurotoxic side-effects, 7184Vincristine
etoposide-resistant human KB cell linescombined modalities of resistance,
5956mechanisms of multidrug resistance
H L-60 cells, 3959methotrexate combination
other agents, acute lymphoblastic leukemia, 351
methotrexate transport in LI210 cells,5995
reversal of resistancequinacrine, P388 leukemia, 2064
verapamil-hypersensitive Chinese hamster ovary cells
properties of, 4477Vinculin
phosphorylationprotein kinase C role, HL-60 cells,
3324Virus
incidence and nature of tumors•¿�»•-irradiation,Sprague-Dawley rats,
2451rare events as clues to cancer etiology,
3544tumor
DNA, oncogenes, 493Vitamin A
dietary /3-carotenecancer of the prostate in Japan, 1331
oxidation to retinoic acidepidermis, 7038
Vitamin I!,,metabolism in McA-RH7777 cells, 1080
Vitamin Cdiet and high risk of stomach cancer in
China, 3518risk of colorectal cancer, 4399vitamin E and
prevention of recurrence, colorectalpolyps, 4701
Vitamin I>,chondroitin sulfate proteoglycan
differentiation-associated changes.
U937 cells, 6103Vitamin K
-dependent protein deficient serumfactor X activator capabilities, Lewis
lung carcinoma, 6504Vitamins
diet and mesotheliomacase-control study in Louisiana, 2911
intervention trial in Chinaprecancerous lesions of the esophagus,
2280Voronoi's method
proliferating area of human gliomaintercapillary distance, 2938
VP-16: see EtoposideVulvar neoplasms
human chorionic gonadotropinnew marker, 1356
VX-2 tumortissue-specific pharmacodynamics
5-bromo-2 '-deoxyuridine incorpora
tion, 6900
W
Walker 256 carcinomablood flow and venous pH
hyperglycemia, 1201effect of galactose on systemic hemody-
namicsblood flow rate, normal and tumor tis
sues, 1476Wheat germ agglutinin
-resistant human melanoma mutantsmetastatic profiles, nude mice, 665
White blood cellspolycyclic aromatic hydrocarbon-DNA
adductsfoundry workers, 2288
\\ ilins' tumor
age distribution, 1653cancer families
susceptibility to neoplasia, 5381WR2721
derivativesuptake by cells in culture, 3634
influence on DNA cross-linkingnitrogen mustard, bone marrow and
leukemia cells, 6002radioprotection of cells, 3641
Xanthine oxidaserole in interferon-mediated depression
hepatic cytochrome P-450 system inmice, 2107
Xenograftscarcinoma
radioimmunolocalization, second generation monoclonal antibodies, 4597
characterization of colon cancer mucin,6678
Clouser and renal cellmonoclonal antibody uptake, blood
flow, 188colon adenocarcinoma
folate pools, 3062colon cancer
radioimmunotherapy, carcinoem-bryonic antigen, 3270
tumor targeting, second antibody,2005
gastric adenocarcinoma growtha-difluoromethylornithine, 3265
human
7454
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
SUBJECT INDEX TO VOLUME 48
cu-diamminedichloroplatinum(II)andmitomycin C, interferon action, 64
human breast cancermetabolism in vivo, 7264
human gliomaamplification, epidermal growth factor
receptor gene, 2231treatment, radioimmunotherapy, 2904
human glioma modelantiglioma monoclonal antibody, ther
apeutic efficacy, 559human tumor in nude mice
metalloporphyrin enhancement, magnetic resonance imaging, 4604
medulloblastomaenhanced melphalan cytotoxicity, glu-
tathione depletion, 2764rodent and human tumor cells
glutathione levels, 3657transplantable
chemotherapy, bifunctional alkylatingagents, 4189
tumor transplantabilitymyc family gene abnormality, lung
cancers, 6025quantitative studies in mice, 6510
variant forms of rat epidermal growthfactor
presence in urine of rats bearing human tumors, 1428
Xenopusmycobacterium-induced infectious granu
loma, 958putative lymphosarcoma
transplantation studies, 954Xeroderma pigmentosum
cancer in homozygotes and hétérozygotes in Britain, 2929
domain-oriented repair synthesis, 844fibroblasts
antioxidant enzymes, 2132formation and repair of cisplatin-DNA
adductsfibroblasts, 6058
inducible repairherpes simplex virus, 6054
ultraviolet light responseDNA repair defect, trichothiodystro-
phy, 6090X-ray
f;s-diamminedichloroplatinum(II) cross-resistance
human tumor cell lines, 5133recurrent tumor sensitivity
rat model, mammary tumors, 4549
Yeastinternucleosomal cleavage
bleomycin, phleomycin, 6837
Zincmetabolism in Ehrlich cells, 3381vitamin intervention
precancerous lesions of esophagus inChina, 2280
7455
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from
1988;48:7401-7455. Cancer Res Subject Index
Updated version
http://cancerres.aacrjournals.org/content/48/24_Part_2/7401.citation
Access the most recent version of this article at:
E-mail alerts related to this article or journal.Sign up to receive free email-alerts
Subscriptions
Reprints and
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://cancerres.aacrjournals.org/content/48/24_Part_2/7401.citationTo request permission to re-use all or part of this article, use this link
Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from